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This work examines the use of a small number of naturally-derived materials as 
scaffolds, specifically for bone tissue engineering. Damaged bone is typically replaced with 
grafts, and second only to blood, bone is the most transplanted tissue [1]. The ability to 
produce autologous grafts from patients’ own cells using an engineered scaffold would 
therefore be extremely valuable. This thesis reports the design and use of microparticle cell 
carriers for bone tissue engineering applications, as potential injectable or mouldable units. 
The suitability of silk fibroin (SF) and gelatin (G) blends as biomaterials was tested 
in two-dimensional cultures, using 3T3 fibroblasts and rat MSCs (rMSCs). The blends 
(25:75, 50:50 and 75:25) were shown to be biocompatible and with appropriate mechanical 
properties for bone tissue engineering with Young’s moduli between 36 and 59 MPa. The 
SF/G blends supported the osteodifferentiation of rMSCs at levels equivalent to tissue 
culture plastic. Although SF alone did not strongly support cell attachment, the cells that did 
adhere showed high levels of osteodifferentiation, measured by osteopontin expression. 
The inclusion of gelatin significantly improved cell attachment while retaining the ability of 
the SF/G blends to support osteodifferentiation. Novel microparticles were created from the 
same SF/G blends in a reproducible, controllable manner using a flow focussing device 
assembled from commercially available fittings. Cell behaviour on the 3D scaffolds 
mimicked the results observed on 2D films: cell adhesion was significantly improved by the 
addition of gelatin with the seeding efficiency of 3T3 fibroblasts increasing from 25% on SF 
microparticles to 69 – 81% on the blended microparticles. Osteogenic differentiation of 
rMSCs was observed on SF/G 25:75 microparticles in both basal and osteogenic medium, 
and osteopontin expression was shown to be slightly higher than for rMSCs grown on 
commercially available Cultispher-S microparticles. Although attempts were made to mould 
the particles into larger 3D structure, successful preliminary results could not be repeated.  
Adapting the flow focussing device from liquid-liquid to a liquid-air system allowed 
the rapid production of oxidised alginate microparticles, blended with extracellular matrix 
proteins, and with encapsulated cells. These microparticle scaffolds were also shown to 
support cell viability (75% of rMSCs were viable after 7 days) and osteogenic differentiation. 
With the potential to easily encapsulate different proteins or ECM extracts, alginate-blended 
microparticles are potentially useful tools for culture of different cell types. Finally, the 
culture of microparticles within a hollow fibre bioreactor, with the hollow fibre mimicking 
blood capillaries, was shown to improve cell viability compared to a non-perfused control: 
20 times more 3T3 fibroblasts were harvested from the bioreactor than from the control. 
This showed the potential for using the hollow fibre bioreactor to rapidly produce large, 
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Within the field of tissue engineering, there is a lack of consensus about which materials 
are the most appropriate for cell scaffolds. In reality, since there is a wide range of target 
organs for tissue engineering products, it is unlikely that one material could fulfil all the 
requirements for all potential applications and thus investigation into a range of materials is 
justified. One of the primary decisions to make in choosing a scaffold material is between 
the use of synthetic and naturally-derived materials. It is now widely understood that cells 
grown in two-dimensional systems differ in morphology and behaviour to their in vivo 
counterparts. Investigation into three-dimensional scaffolds is therefore timely and 
important to produce physiologically relevant tissue engineering products. 
While the composition of synthetic polymers can be finely controlled, materials of this type 
typically lack innate cell recognition sites which leads to poor cell attachment. On the other 
hand, naturally-derived polymers such as collagen are rich in cell attachment sites. Rather 
than attempting to best mimic the natural extracellular matrix (ECM) using synthetic 
materials, it seems logical to use materials that actually form the ECM in the first place, or 
at least those that closely resemble them. For example, collagen makes up 25% of the 
protein mass of most mammals, while alginate is a hydrophobic polysaccharide resembling 
hyaluronic acid (an important ECM glycosaminoglycan) in structure [2].  
A second key decision is the design and construction of the scaffold itself. While it is 
possible to create scaffolds in a particular shape or of a specific size from the start, a more 
flexible approach is to build scaffolds from the bottom up, using small units such as 
microparticles. This allows for different scaffold materials or cell types to be built into the 
final product, mimicking the heterogeneity of endogenous tissues. Small scaffold units also 
have potential for use as injectable scaffolds, which could be delivered without the need for 
invasive surgery. 
 
 Thesis outline 
Chapter 2 is a literature review of research into the requirements of scaffolds for use in 
tissue engineering and candidate materials for scaffold production. It covers scaffold design, 
cell sources, the formation of tissue engineering constructs, and the use of biomaterial 
scaffolds for the delivery of growth factors or other relevant biochemical signalling 
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molecules. At the end of this chapter, the aims and objectives of this thesis are set out. The 
third chapter reports the materials and methods used in the research carried out in this 
project. 
The following chapters report results from the research performed. Chapter 4 describes the 
characterisation of silk fibroin and silk fibroin/gelatin blends as osteodifferentiation-
supporting biomaterials, while Chapter 5 describes the translation of this work into a three-
dimensional context. The work exploring decellularised materials and their use with alginate 
is reported in Chapter 6. The final results chapter, Chapter 7, describes the design and use 
of a custom hollow fibre bioreactor for the culture of cell laden microparticles and the 
production of a viable tissue construct. 
Chapter 8, the final chapter, draws conclusions from the results described within this thesis, 






Tissue engineering: natural materials, microparticles and bioreactors for the 
bottom up development of tissue constructs 
Tissue engineering is a multidisciplinary field that combines biological and engineering 
perspectives to create functional substitutes for diseased or damaged tissue, or model 
tissues for in vitro testing. The field of regenerative medicine is more focussed on 
harnessing the body’s ability to heal itself, with the help of therapeutic cells or growth factors 
where appropriate. The main focus of these fields are diseases or injuries where often the 
only treatment is whole organ transplant. 
Organ transplants are overwhelmingly successful (97% of living donor kidney transplants 
function well after 1 year [3]) but problems arise when suitable donor organs are not 
available, which is a frequent issue. Additionally, the use of allograft organs always carries 
the risk of immune rejection. Tissue engineering aims to overcome these problems by 
building new organs or tissues essentially from scratch, using the patient’s own cells and 
therefore removing both the need for a suitable donor and the use of immunosuppressant 
therapies post-transplant. 
Figure 2.01 illustrates the simplified stages in this process. The first step consists of cell 
harvest though the cell type will vary with the intended product. The next stage is the 
expansion of cells in culture to produce a therapeutically relevant quantity, though again 
this is application dependent. For cells that are capable of significant proliferation in vivo, 
106-107 cells may be sufficient, but for fully differentiated cells, or to produce a construct 
with a cell density equivalent to native tissue (~108 cells/cm3) the number may easily reach 
1010 [4, 5]. These numbers render traditional two-dimensional flask-based culture deeply 
impractical both in terms of the space the flasks would require and the time it would take to 
manually culture them. Alternative cell expansion systems such as stirred tank bioreactors 
or packed bed systems must therefore be considered. Once a suitable number of cells is 
obtained, the cells are seeded onto or encapsulated within a scaffold. The scaffold must be 
appropriate to the target tissue in terms of its structure, strength, flexibility and 
biodegradability.  
This review will focus on ideal scaffold properties and candidate materials, with particular 
reference to microparticle scaffolds. Other key considerations of the tissue engineering 





Figure 2.01: Schematic of the key stages necessary to create an autologous transplant. Cells 
are harvested from a patient, isolated and expanded in culture before maturation on an appropriate 
scaffold, primed with chemical and mechanical stimuli. The tissue or organ construct is implanted 
into the patient to repair their damaged or diseased tissue. © HIA/ Wikimedia Commons [6]. 
 
 Cell sources for bone tissue engineering  
The choice of cell for a given tissue engineering application is determined primarily by the 
target tissue, followed by the availability of each cell type. These criteria also affect the 
choice between autologous or allogeneic cells. The cells chosen must be available in a 
sufficient quantity or capable of substantial proliferation while maintaining their phenotype. 
The cells must remain biologically functional, and be able to lay down new extracellular 
matrix and interact with the scaffold and neighbouring cells through the release of cytokines 
or growth factors [7].  
While the use of mature primary cells may seem an attractive prospect for autologous 
transplant, primary cells often de-differentiate ex vivo and have limited potential for 
proliferation. For example, articular chondrocytes have a tendency to produce fibrocartilage 
instead of hyaline cartilage during cultivation [8]. There are also cell types, such as spinal 
cord neurons, which are not suitable for patient harvest due to the loss of function at the 
donor site. Autologous bone grafts are possible but limited by the amount or volume of bone 
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that can be removed from a donor site (e.g. the iliac crest). Primary cells therefore have 
limited use in tissue engineering. 
Immortalized cell lines typically have much greater proliferative potential than primary cells 
and are useful tools for in vitro experiments and investigations. However, their proliferative 
nature is often due to the fact they are derived from tumours, or have been genetically 
modified to allow their continued proliferation. They are unsuitable for transplantation into 
patients but remain a valuable resource for research. 
Embryonic stem cells (ESCs), derived from the inner cell mass of blastocysts, are a 
pluripotent cell source, capable of differentiation to all mature cell types. Cultured in vitro, 
hESCs were traditionally grown on top of a feeder layer of mouse fibroblasts to maintain 
their capacity for self-renewal, but it was found cells cultured in this way expressed a non-
human protein [9]. These cells would therefore be susceptible to immunogenic attack after 
implantation. Animal-product or xeno- free conditions have since been established for the 
culture of hESCs [10, 11]. The ESCs would need to be matched to individual patients to 
avoid immunogenic rejection and differentiation tightly controlled to prevent the formation 
of teratocarcinomas. However, it is the moral and ethical debate on the destruction of 
embryos to produce ESCs that is most likely to hinder their use as a potential cell source 
for therapeutic applications [7, 12]. 
A more promising candidate cell type for bone tissue engineering is the adult mesenchymal 
stem cell (MSC). These cells are found in many adult tissues, where they exist in an 
undifferentiated state, capable of undergoing multi-lineage differentiation in order to repair 
damaged and aging tissues. They may differentiate into connective tissue cells, including 
bone, cartilage, muscle and fat [13]. Bone marrow was the first known source of MSCs, 
though obtaining bone marrow samples for clinical use necessitates an invasive procedure 
performed under general anaesthetic [14]. In the case of an autologous transplant, this 
results in further pain for the patient with the risk of donor site morbidity. Cell numbers 
obtained from bone marrow may also be low, and so other cell sources were investigated. 
Of particular interest are adipose-derived stem cells, which are harvested from lipoaspirate 
(which would normally be discarded after liposuction surgery) [15]. Like bone marrow 
derived MSCs, adipose-derived stem cells may undergo osteogenic, adipogenic, myogenic 
or chondrogenic differentiation in response to appropriate culture conditions. Adipose-
derived stem cells show huge potential within the field of tissue engineering, and have been 
shown to form greater numbers of colonies and have higher proliferative capacities than 
bone marrow-derived MSCs [14-16]. 
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 Scaffolds in tissue engineering  
Key among the challenges of tissue engineering are the problems of finding an appropriate 
cell scaffold, and also of vascularisation – how to engineer an artificial blood supply within 
a tissue construct to supply cells with nutrients and oxygen. In vivo the maximum distance 
between capillaries is 200 µm (correlating to the diffusion limit of oxygen), and so 
engineered tissues must contain a network equivalent to this in order to maintain cell viability 
and prevent necrosis [17].  
In order to create a viable tissue construct in the first place, cells must be provided with a 
suitable scaffold to mimic the in vivo three-dimensional extracellular matrix (ECM). The 
ECM provides physical support for cell attachment as well as influencing cell migration, 
proliferation, differentiation, and cell-cell communication [18]. Composed of collagens, 
proteoglycans and glycoproteins, the ECM also acts as a reservoir for growth factors and 
cytokines [19]. As the cells can receive signals and biological cues from the ECM, they can 
also rearrange and remodel the ECM around themselves. In bone, osteoblasts create the 
ECM which is composed largely of dense type 1 collagen mineralised with hydroxyapatite 
as well as proteins such as osteopontin, a calcium-binding protein, and osteonectin, which 
anchors hydroxyapatite to collagen fibres [20]. 
For the development of an artificial scaffold, Agrawal et al. identified ten key properties it 
should possess [21]: 
“1. The scaffold should be biocompatible. 
2. It should be biodegradable or capable of being remodelled. 
3. It should biodegrade in tune with the repair or regeneration process. 
4. It should be very porous. 
5. It should be highly permeable to allow for proper diffusion. 
6. It should have the correct pore size for the candidate cells. 
7. It should possess adequate mechanical properties to provide the correct 
microstress environment for cells. 
8. It should provide a surface conducive for cell attachment. 
9. It should encourage the formation of ECM by promoting cellular functions. 




While biocompatibility is a property intrinsic to a material, many of the other properties listed 
here will depend on the processing steps and final form of the scaffold itself. Thus in 
choosing a potential scaffold material, biocompatibility should be assessed primarily, and 
design of the scaffold optimised to fit as many of these ideal criteria as possible. 
 
2.2.1. Promoting cell adhesion & encapsulation 
While an advantage of using naturally-derived materials over synthetic polymers is that they 
are often cell adhesive, this is not always the case. For example, although alginate is 
biocompatible, it does not support cell attachment and must be modified in order to facilitate 
this [22]. As stated previously, an ideal cell scaffold would be capable of promoting cell 
adhesion, possibly with the ability to recruit specific cell types.  
If the material is not naturally cell adhesive, cell attachment can be improved through 
surface modification of the scaffold, for example with the amino acid sequence arginine - 
glycine - aspartic acid (RGD) [23]. Integrins are cell surface proteins that mediate cell 
adherence to the ECM, and the RGD sequence is a key component of the integrin-binding 
protein. This sequence accounts for the high level of cell adhesion to materials such as 
collagen and gelatin [24].  
There are cell-specific peptide motifs that can be used to target a particular cell type, such 
as the arginine-glutamic acid-aspartic acid-valine (REDV) sequence, which endothelial cells 
selectively adhere to [25]. Alternatively the use of bound antibodies targeting specific cell 
surface markers can be used to selectively bind a certain cell type to the scaffold [26]. 
Directing specific cell adhesion in this way could allow for the development of highly 
organised cell/scaffold constructs. However, it would be preferable to work with a material 
requiring minimal improvements, especially to avoid expensive antibody modifications. 
A simple alternative to chemically modifying a non-adhesive material is to blend it with a 
material that does promote cell adhesion. To use the same examples, alginate can be 
blended with collagen to produce a scaffold that combines the properties of both [27-29]. 
While alginate allows for the rapid formation of a stable hydrogel in a non-temperature 
dependent manner, collagen supports cell adhesion and growth. 
An alternative approach to create a more homogenous cell distribution is to encapsulate 
cells within the scaffold itself. Initially investigated as an immunoprotective barrier for 
transplanted cells producing therapeutic proteins, cell encapsulation has since been 
recognised as a useful method for tissue regeneration applications [22]. Cells encapsulated 
 8 
 
in gels are considered to be in a more realistic 3D environment and show improved 
functional behaviour [30, 31]. This is in comparison to cells grown on sponge-like scaffolds, 
where the cells are in three dimensions with respect to each other but are only attached to 
the scaffold in a two-dimensional manner [22]. Hydrogels (e.g. collagen, gelatin, alginate) 
are particularly well suited for cell encapsulation as they provide a highly hydrated tissue-
like environment, are easily handled, and can form in mild, biologically-compatible 
conditions [32].  
 
2.2.2. Scaffold strength & biodegradability 
The mechanical properties of the scaffold are important and the elasticity, toughness and 
strength of a scaffold should match that of the target tissue. A scaffold designed to replace 
or repair injured bone must obviously be strong enough to bear the same loads as the native 
tissue, whereas a soft tissue scaffold does not have the same mechanical requirements. 
The strength of a scaffold can be affected by its structure and processing – a highly cross-
linked structure will be stronger than a less cross-linked version. Scaffold elasticity is also 
relevant at a cellular level – this property can strongly influence cell behaviour. Engler et al. 
showed that MSCs grown on substrates with different elastic constants differentiated to 
distinct lineages. MSCs cultured on gels with a stiffness of 25-40 kPa, designed to mimic 
the stiffness of osteoids, were shown to develop an osteoblastic phenotype, while MSCs 
grown on substrates with a softer elasticity of 10 kPa favoured a myogenic pathway. The 
ability of cells to sense the stiffness of their microenvironment is thought to be mediated by 
non-muscle myosin II isoforms, which apply tension to cortical actin structures linked to 
focal adhesions [33]. 
The biodegradability of a scaffold is also an important consideration. Within tissue 
engineering, most scaffolds are created with the intention of allowing cells to lay down and 
remodel native matrix to replace the artificial scaffold over time. The implanted scaffold 
should support initial cell growth and provide structural support, but degrade at a rate 
equivalent to the production of new ECM. The products of biodegradation should be 
carefully considered, since the release of any toxic or harmful moieties will obviously prove 
detrimental to the healing and recovery process. While naturally-derived materials are 
generally subject to enzymatic biodegradation in vivo (collagen is susceptible to the action 
of matrix metalloproteinases [34]), many synthetic materials will not degrade under 
physiological conditions, or if they do, may release acidic breakdown products which 
negatively affect biocompatibility [35, 36]. 
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In bone, degradation of a substitute matrix occurs by both physicochemical degradation and 
osteoclast-mediated resorption Osteoclasts play a role in natural bone remodelling, through 
acidification and proteolysis of the bone ECM. Their effects on biomaterial degradation is 
strongly influenced by the biomaterial composition, and to a lesser extent, properties such 
as crystallinity, density and surface topography [37, 38]. 
 
2.2.3. Growth factor release and delivery 
As well as supporting long term cell growth, the potential of a scaffold to deliver relevant 
proteins, growth factors or even drug compounds would prove useful [39]. Growth factors 
can be incorporated into scaffolds to direct cell differentiation or growth [23, 40]. The scaffold 
can act as a reservoir for the compound in question, to provide steady release over a period 
of time throughout the entire structure [41]. Combining a scaffold with drug delivery 
functionality could prove a highly efficient approach to improve scaffold integration in vivo 
by directing cells to angiogenesis or by attracting resident cell populations to the site of the 
implant. 
  
2.2.4. Scaffold structure design 
Scaffolds used for adherent cell culture traditionally consist of a relatively large porous 
structure, designed in a particular shape or configuration. However, it can be difficult to 
ensure cells are distributed evenly throughout the scaffold and to maintain viability in order 
to produce a cell-dense, mature tissue [42]. Without perfusion of media, scaffolds of this 
type can frequently develop necrotic central regions as cells seeded within the inner areas 
are starved of oxygen and nutrients while waste products accumulate. 
In recent years, modular or ‘bottom up’ approaches have emerged as a viable alternative 
to these ‘top down’ preformed scaffolds. Starting with small units of scaffold, cells can either 
be evenly seeded on the surface of the material or encapsulated within it. Most tissues 
consist of small, repeating functional units organised in three dimensions. Microparticle cell 
carriers, previously used for scaling up the production of anchorage-dependent cells are an 
example of an alternative scaffold structure that can mimic this arrangement. Once seeded, 
cell-laden microparticles can be physically moulded into a larger, complex structure with 
cells evenly spread throughout the entire volume. Using small building blocks theoretically 
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allows for precise control of combinations of different cell types or even scaffold types, in 
order to replicate native tissue architectures.  
Constructs created in this manner still suffer from the lack of defined vasculature, meaning 
that over time central areas will become necrotic. An ideal system would be a construct 
created with an integrated pseudo-vasculature to allow the perfusion of media through the 
structure, maintaining cell viability during cell proliferation and construct maturation. Once 
implanted in vivo this pseudo-vasculature could undergo anastomosis with the host 
vasculature to integrate with the native tissue.  
 
2.2.5. Microparticle cell carriers as scaffolds 
As discussed, microparticle cell carriers provide an alternative to the more traditional top 
down scaffold-based approach to tissue fabrication. Cells can be encapsulated within 
carriers, seeded on them after formation, or indeed both. A bottom up approach can be 
used to assemble the particles into larger, more complex structures, with cells distributed 
evenly throughout. 
Both biopolymers and synthetic polymers have been used to create bead-like microparticles 
[30, 43]. Growing cells on microparticles, either as a monolayer on the surface or as 
multilayers within a porous structure, allows high yields of up to 2 million cells per millilitre 
[44]. A microparticle system may therefore allow both the expansion of cells to a 
therapeutically relevant quantity, and the creation of a tissue construct. Minimising the 
number of steps in the overall process could prove highly beneficial, especially if it removes 
the need to detach and re-attach cells to different matrices. 
The term ‘microparticle’ is typically used to describe particles of 100-500 μm (commercial 
microparticles are in the range of approximately 100-300 µm). The smaller the 
microparticles, the larger the surface area for a given volume, therefore increasing the area 
available for cell adhesion. Microparticles are typically used in stirred suspension cultures, 
while for fluidised and fixed bed bioreactors, larger particles (0.6-5 mm) are more commonly 
used due to their higher sedimentation rate. Particularly in fixed bed reactors, larger 
particles are preferred as they give larger channels for media delivery between individual 
particles that are less likely to become blocked by cell growth [45]. 
A narrow size distribution of carriers is desirable to maximise homogeneity of culture 
conditions. This ensures cells are experiencing the same environment, which could 
otherwise vary dramatically between different sized carriers as a result of surface curvature. 
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The size of polylactide-co-glycolide (PLGA) microparticles has been shown to affect the 
proliferation and differentiation of rabbit MSCs [46]. However, commercially available 
carriers often show significant variation in particle size: Cultispher-S carriers (Percell) are 
described as ranging from 130 – 380 µm [47]. 
 
Cell expansion on microparticles 
Cells are seeded onto microparticles in suspension cultures, often in spinner flasks [48]. 
Alternative systems include rotating wall vessel bioreactors and perfusion cultures. Rotating 
wall systems have been shown to provide a low fluid shear environment which allows cell 
aggregates to form based on natural cell affinities, producing differentiated tissues [49], 
though more specific equipment is required for this system. Other systems for the culture 
of cell-laden microparticles include packed beds, though these may suffer from poor oxygen 
transfer, and fluidized beds, with improved oxygen transfer, but both of these approaches 
are more suitable for the manufacture of a secreted product than for cell expansion. 
Macroporous beads allow the cells to attach within the bead itself. These cells are shielded 
from the shear stresses that externally seeded cells are exposed to in suspension cultures. 
Macroporous beads can deliver higher cell densities than solid beads. The average cell has 
a diameter of 10 μm and pores larger than this allow for cell invasion into the particle interior. 
Microparticles may also be meso- or microporous (pores less than 50 nm), meaning that 
molecules and media can diffuse through the particles themselves. 
For scaling up cell numbers, it is easiest to grow the cells on the surface of the beads so 
they are easier to harvest. However, for tissue engineering applications it might be desirable 
to encapsulate cells within the beads as well as on the surface to produce a more 
homogenous cell distribution.  
 
Production of microparticles 
Different methods of producing microparticles exist and the most appropriate will depend 
on the material used as well as the desired properties (e.g. size, porosity) [50]. The 
advantages and disadvantages of several possible methods are described below.  
One method of microparticle production is the emulsion of two immiscible solutions. 
Commonly a hydrogel precursor would be in an aqueous solution, and stirring or 
homogenisation causes this to emulsify within a hydrophobic oil phase, producing a 
suspension of hydrogel microparticles. Depending on the material, the microparticles may 
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stabilise into solid structures as a result of temperature change or chemical cross-linking. 
Size control of the particles is achieved by altering the viscosity of the solutions and the 
stirring rate (i.e. shear rate), though control is limited. This approach can be easily scaled 
up but the particles produced in this way have a wide size distribution [50].  
Unlike emulsification, photolithography provides a high degree of control over the size and 
shape of the final microparticles. In this system, a hydrogel precursor is mixed with a photo-
initiator. Upon exposure to ultraviolet light, the photo-initiator catalyses cross-linking of the 
hydrogel to produce a solid structure. To create microparticles in this way, Dendukuri et al. 
generated a system in which their polymer/photo-initiator solution flowed through a 
microfluidic channel fitted with a photo-mask with cut-outs in the shape of the desired 
particles. Ultraviolet light was shone through the mask to produce hydrogels in a variety of 
shapes and sizes in a continuous flow process [51]. Though this is a highly controllable 
method, photo-initiators are often cytotoxic, limiting the use of this technique for cell 
encapsulation, and are more typically run as batch processes. 
While techniques such as spray-drying and emulsification are effective methods for particle 
production, the size distribution of the resultant particles is often large [52]. Microfluidic 
approaches, however, have been shown to generate particles with a much narrower 
distribution [53]. Systems of this sort consist of two immiscible co-flowing streams, and 
utilise the predictable break-up of these streams to produce homogenous, discrete droplets. 
Using a polymer solution as the disperse phase allows the production of microparticles. 
Alternatively, an air flow can be used to disrupt the disperse phase instead of a secondary 
liquid. 
In a typical flow-focussing system, the continuous flow consists of an oil, while the disperse 
flow is an aqueous (bio-) polymer solution. The polymer solution is directed into the faster 
flowing oil phase, causing the shear forces of the oil flow to pull out droplets of the polymer 
from its source. The flow rates are adjusted to a level and ratio at which the inner fluid forms 
droplets, rather than a jet of fluid. Drop formation is a balance between the viscous drag of 
the outer fluid pulling on the nascent droplet and surface tension [54]. Cross-linking the 
droplets produces solid microparticle spheres. The size of the particles can be altered with 
the flow rate ratio of the two phases allowing easy control over particle diameter in a 






Microparticles as building blocks for tissue engineering 
The use of microparticles to expand cell populations produces ready-made building blocks 
for a bottom up approach to tissue construct fabrication, and removes the need to harvest 
cells from the microparticles before further processing. Cell-laden microparticles may form 
aggregates in suspension cultures through cell-cell, cell-ECM or cell-scaffold interactions, 
but to create larger macroscopic constructs moulds are frequently employed. This process 
is summarised in Figure 2.02. This approach has been used by Matsunaga et al. to create 
a macroscopic tissue construct from atelocollagen microparticles in a custom mould. 
Though the resultant construct was only several millimetres in size, this demonstrated the 
flexibility of the approach and the ability to incorporate different cell types as co-cultures 
within the structure [30]. Taking the process another step further, Twal et al. moulded cell-
laden Cultispher-G microparticles into small ring structures which were then stacked to 
produce a tube. Cellular bridges fused the component rings together [56]. 
 
 
Figure 2.02: Assembling cell-laden microparticles into a 3D tissue. (A) Cells are seeded onto, 
or encapsulated within, hydrogel beads. (B) The cell carriers are assembled within a small mould, 
and (C) cells on adjacent beads form cell-cell attachments, creating a homogenous tissue construct. 
(D) The three-dimensional construct can be released from the mould whilst retaining its shape. Figure 
reproduced from Matsunaga et al. [30], © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. 




While the constructs above were simply incubated in static conditions following formation, 
Chen et al. packed gelatin Cultispher-S particles, seeded with human amniotic MSCs, into 
a perfusion culture system [57]. This produced a centimetre-sized bone construct, but the 
osteogenic differentiation of the cells within the construct was affected by the relative 
stresses experienced in different regions of the perfused chamber. In long term cultures 
however, the same group observed cell death in the inner regions of the construct. This is 
likely due to a dense cell layer on the outer surface of the structure preventing efficient 
oxygen perfusion. To overcome this, the perfusion chamber, acting as a mould, was fitted 
with glass rods (1 mm diameter) which were removed after the construct formation to leave 
microchannels through the structure. This allowed for better nutrient/oxygen delivery to 
central regions of the construct. However, this was a proof of concept for cell viability using 
Cytopore-2 carriers and fibroblasts, so the ability of this scaffold format to support 
differentiation or the culture of a clinically relevant cell type was not investigated [58]. In 
addition, the use of commercially available microparticles, though convenient, raises 
questions about the production and cross-linking protocol used, proprietary information 
which would be valuable in establishing the suitability of these scaffolds for in vivo use. 
Commonly used gelatin cross-linking agents like glutaraldehyde are toxic, and can leach 
out from scaffolds during degradation [59].  
 
 Material choices 
Naturally-derived biopolymers have found widespread use as scaffolds for cell culture. 
Commonly used biopolymers include collagen and hyaluronic acid, which are natural 
components of the ECM, as well as agarose, alginate, fibrin and gelatin. Silk fibroin is 
another naturally-derived polymer that is suitable for use in cell scaffolds [60, 61]. Generally, 
natural materials of this type have high biocompatibility and bioactivity. Their mechanical 
properties and biodegradation rates can be tuned through varying concentrations and levels 
of cross-linking. These materials are generally processed using environmentally-friendly 
aqueous-based protocols, and their degradation products are not cytotoxic [62]. 
Though synthetic polymers, such as polylactic acid (PLA) and polyglycolic acid (PGA), are 
also biocompatible, these materials are not generally as cell adhesive as naturally-derived 
materials and require modification to correct this. Though they can be fabricated into 
different architectures, synthetic materials generally form stiff structures which may be 
useful for load-bearing applications but less so for soft tissue engineering [63]. In addition, 
the synthesis of these materials can require extensive processing using organic solvents, 
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which can negatively impact biocompatibility if not fully removed. For these reasons, this 
section will concentrate on a small selection of naturally-derived materials. 
 
2.3.1. Mulberry silk fibroin 
Silk fibres have a long history of use in biomedical applications: for hundreds of years silk 
was used as suture thread. As a material, it is lightweight, elastic and thermally stable, as 
well as biocompatible [61]. Silk is produced on a large scale by the textile industry, so there 
are many sources available at a reasonable cost, and as it is insect-derived, it avoids the 
bioburdens potentially associated with mammalian-derived materials. 
Mulberry silk, collected from the cocoon of Bombyx mori, the domesticated silkworm, 
accounts for 90% of international silk production [64]. Tussah silk, eri silk, and muga silk 
are also widely produced, and are collected from different species of silkworm, summarised 
in Table 2.01.  
 
Table 2.01: Summary of silkworm species and silk types produced [64]. 
Silkworm species Silk produced Country of origin 
Bombyx mori Mulberry China 
Nangnoi srisaket Mulberry Thailand 
Antheraea yamamai Tussah Japan 
Antheraea pernyi Tussah China 
Philisamia ricini Eri China, Korea 
Antheraea assamensis Muga India 
 
 
These different silks have different amino acid sequences: Bombyx mori SF has a higher 
proportion of glycine, while Antheraea pernyi SF has more acidic and basic amino acid 
residues. These differences can result in varied levels of biocompatibility, biodegradability 
and solubility [65, 66]. Most investigations of silk as a biomaterial have used Bombyx mori-
derived silk, and unless otherwise specified, references to silk or SF within this thesis denote 
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Bombyx mori products. However, it is estimated there are more than 3,000 different strains 
of Bombyx mori alone [67]. It is possible that silks collected from different strains could have 
variations in their properties as a result of amino acid sequence deviations. 
Native silkworm silk consists of two fibroin brins encased in a coat of glue-like sericin 
proteins, as shown in Figure 2.03. A number of studies have identified sericin as being 
responsible for adverse hypersensitivity reactions to silk, and so it must be removed from 
the fibroin before use as a biomaterial [68]. To remove immunogenic sericin, native silk is 
‘de-gummed’ by boiling in sodium carbonate, then washed. The regenerated SF may be 
further processed into hydrogels, non-woven micro-fibrous nets, mats or membranes, 
sponges, tubes, microspheres, and fibres. This wide range of potential formats means silk 
can be used for a variety of applications [69]. SF is characterised as a natural block 
copolymer, consisting of ordered hydrophobic blocks which tend to form β-sheets or 
crystals, combined with less ordered hydrophilic blocks [61]. In Bombyx mori SF, the β-
sheet regions are composed of glycine-alanine repeats, while in Antheraea pernyi they are 
primarily alanine repeats [65]. The high glycine content allows for tight β-sheet packing, 
which in turn provides a rigid structure to the material [70]. 
  
Figure 2.03: SEM image of an untreated silk fibre. The fibroin forms two filaments, held together 
by the gummy sericin. A Bombyx mori silk fibre is typically triangular in shape. The mean of the base 
and height of the triangle is reported to be 12.9 µm [71]. Image reproduced from [72]. Scale bar 
represents 10 μm. 
 
The biocompatibility of silk films is comparable to that of collagen films and smaller 
inflammatory responses have been observed for implanted silk films than collagen or PLA 
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in vivo [68, 73]. Coating polymer scaffolds with SF, and incorporating SF within a scaffold, 
have been shown to improve cell-scaffold interactions [61, 74]. The carboxy-terminal region 
of Bombyx mori SF is basic and arginine-rich, and hence positively charged. This results in 
favourable electrostatic interactions with cells (negatively charged due to sialic acid 
residues on the cell surface) [75]. The variety of processing techniques can result in SF 
scaffolds with a range of mechanical properties, appropriate to different applications. SF 
scaffolds have been used for both ligament engineering, as silk fibre cords, and for soft 
tissue engineering, as freeze-gelled scaffolds [76, 77]. Meinel et al. demonstrated that 
human MSCs (hMSCs) on salt-leeched porous 3D silk scaffolds showed higher levels of 
attachment, proliferation and metabolic activity than those on equivalent collagen scaffolds. 
The extent of chondrogenesis (measured by the deposition of sulphated 
glycosaminoglycans) in this model was greater on the silk scaffolds over the 4 week 
investigation, possibly due to the slower degradation rate of the silk relative to the collagen 
[78]. 
SF degrades slowly, and although silk sutures are defined as non-degradable by the US 
Pharmacopeia, they are actually proteolytically degraded over months and years due to a 
foreign body response. They are susceptible to macrophage-produced chymotrypsin and 
protease cocktails. SF is degraded to its component peptides and amino acids which can 
be metabolised in vivo, such that the products of degradation cause no toxicity [79]. The 
rate of absorption of sutures depends on a range of variables, including the health of the 
patient and alterations to the silk protein structure as a result of processing [68]. The β-
sheet content of the processed silk affects the rate of degradation so that the higher the 
content, the slower the degradation. It has been shown that the rate of silk scaffold 
degradation affected the metabolism of hMSCs and the rate of osteogenesis in vitro, such 
that more rapid degradation supported increased osteogenesis [80].  
The properties of SF can also be modified by combination with other materials, such as 
starch, chitosan and synthetic polymers [74, 81-83]. This can improve the stability, 
biocompatibility and cell adhesion to the resultant material, producing a final material with 
better characteristics than each component part [65]. Mixing SF with collagen or gelatin has 
been shown to produce final scaffolds with higher compressive moduli than the pure protein 
controls: in the case of freeze-dried sponges this has been attributed to thicker pore walls 
and a more homogenous pore distribution [84, 85]. Collagen and gelatin are also strongly 
cell adhesive and therefore their inclusion can improve this property of SF blended materials 
[84, 86, 87]. For example, Moisenovich et al. proposed a SF/hydroxyapatite/gelatin blend 
as a bone tissue engineering scaffold, having observed higher fibroblast proliferation on 
these scaffolds compared to SF alone. Similarly, the polysaccharide chitosan has been 
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blended with SF to provide scaffolds more cell adhesive than SF alone, and with improved 
osteoinductive properties as shown by the enhanced osteodifferentiation of bone marrow 
MSCs [88, 89]. 
By the criteria listed in Section 2.2, SF shows a great deal of potential as a scaffold material 
it is biocompatible, biodegradable, cell-adhesive, and its mechanical properties can be 
varied by its final format, of which a variety are possible. 
 
2.3.2. Alginate 
Alginate is a polysaccharide isolated from brown algae, and is composed of a mixture of β-
D-mannuronic acid and α-L-guluronic acid residues, though the ratio between the two can 
vary. Alginate forms a hydrocolloid in an aqueous medium, and gelation is induced by the 
presence of divalent cations (e.g. Ca2+, Ba2+). The cations form an electrostatic interaction 
between the guluronic carboxylic acid residues. Alginate is not cell adhesive but 
modification with RGD residues, or blending with cell-adhesive materials, can improve this 
[22]. Alginate has been widely used for cell encapsulation, and stem cell encapsulation in 
strontium cross-linked alginate has been investigated as a short term alternative to 
cryopreservation [90]. 
Traditionally divalent calcium ions have been used to cross-link alginate into a hydrogel for 
biological purposes but the resultant gels are susceptible to attack by chelating agents, 
including phosphate. On top of this, non-gelling ions like sodium will exchange with the 
calcium ions in physiological solutions, causing calcium alginate gels to swell, destabilise 
and rupture. To overcome this, gels can be formed using barium ions instead. Barium ions 
have a higher affinity towards alginate so should therefore give stronger, more stable gels, 
though in reality this is dependent on the ratio of mannuronic acid to guluronic acid in the 
alginate. A further consideration is that barium can inhibit membrane potassium channels 
at concentrations of 5-10 mM and so its concentration should be kept as low as possible 
[91]. 
The loss of divalent cations from alginate hydrogel in vivo results in slow and uncontrolled 
degradation, producing high and low molecular weight alginate units, as well as free calcium 
ions which are reported to inhibit cell growth at high concentrations [92]. Periodate oxidation 
of alginate produces a dialdehyde derivative, which is much more susceptible to 
biodegradation via hydrolysis. This results in more rapid biodegradation which may be 
useful for tissue engineering applications such as cell delivery [93, 94]. Oxidation has also 
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been show to produce more porous gels, as a result of changes in gel mass, with positive 
effects on cell viability. The oxidised alginate gels are also less stiff than their unmodified 
counterparts [95]. 
 
2.3.3. Collagen & gelatin 
Collagen is a fibrous ECM protein with key structural roles in tissues. It is the most abundant 
protein in the human body, and has 29 recognised forms. Type I collagen, the most 
common, has a triple helix structure, and self-assembles to a fibrillar structure under 
physiological conditions. It is, unsurprisingly, cell adhesive. However, collagen hydrogels 
are weak, and as a result contract greatly when encapsulating cells, due to cells exerting 
forces on fibres within the collagen [22]. Cross-linking collagen with a chemical agent such 
as glutaraldehyde improves gel strength and stability though milder cross-linking agents are 
necessary for biological applications to prevent accidental fixation of the cells themselves 
[96]. Collagen has been used to produce a variety of scaffold types, including microparticles 
[97]. However, collagen gel formation is temperature, pH and ionic strength dependent, and 
these particular conditions can limit the ease of handling, which is why it has also been used 
in combination with materials such as alginate and fibrin [27-29, 98, 99]. 
The hydrolysis of collagen is achieved by acid or alkali treatment, yielding Type A or Type 
B gelatin respectively. These differ in their isoelectric points and their net charges at 
physiological pH. Gelation is achieved by dissolving gelatin in aqueous solutions at 
approximately 60°C before allowing the solution to cool to room temperature [100]. It is 
biodegradable, and is used for culinary, pharmaceutical and medical applications [22]. It is 
more cheaply available, and its gel formation is less sensitive to environmental factors than 
collagen. Gelatin retains the crucial RGD motif from collagen, facilitating high levels of cell 
adhesion [101, 102]. However, when reheated to physiological temperatures or higher, 
gelatin hydrogels will melt and therefore must be cross-linked to improve their stability under 
these conditions. A number of cross-linking substances have been used for this purpose, 
including glutaraldehyde, genipin, and EDC [59, 100, 103]. EDC is a zero length cross-
linking agent, and does not become incorporated into the final structure, unlike aldehyde or 
isocyanate cross-linkers, but is instead lost as a water soluble urea derivative. The degree 
of cross-linking, which influences the final stiffness of the gel, can be controlled by altering 




2.3.4. Decellularised tissue materials 
Whole decellularised organs have been used as tissue engineering scaffolds, and a number 
of decellularised tissue products are commercially available [104]. Decellularisation leaves 
behind the ECM components of the tissue (such as collagen, glycoproteins, and fibronectin) 
that are ideal scaffolds for cell reseeding, and materials of this sort have been shown to 
exert angiogenic and chemoattractant effects [105]. ECM components can be harvested 
from a variety of tissues including the small intestine, skin, and liver [18, 106]. One example 
is small intestine submucosa (SIS), a resorpable collagen-based matrix that is used 
clinically to reinforce and strengthen soft tissue remodelling [107, 108]. Once decellularised, 
the organ scaffold can be reseeded with the patient’s own cells and implanted once mature 
[109]. Although this approach removes much of the risk of immune rejection of the ‘new’ 
organ, it still requires a donor in the first place. Although the availability of donor organs 
would increase for a given patient once immunocompatibility is no longer an issue, there is 
still a dependence on consenting donors and thus this approach is unlikely to ever be 
suitable as an ‘off-the-shelf’ solution. The applications of these scaffolds can also be limited 
by their shape or geometry.  
To overcome this, it is possible to process the decellularised matrix into an injectable form, 
which would increase the possible applications for a scaffold of this type [110]. An injectable 
scaffold can be implanted in a minimally-invasive process, which reduces patient 
discomfort, infection risk, and cost compared to open surgical procedures. Additionally, 
injectable scaffolds have advantages over pre-formed implantable scaffolds when the 
defect to be repaired is of an irregular or unknown size [111, 112]. Injectable powders, 
produced using waste material from liposuction procedures, have been shown to support 
the development of highly vascularised grafts in vivo [113]. 
Several groups have also used ECM products as microparticle scaffolds, by encapsulating 
the decellularised product within alginate beads [114, 115]. In the case of Mazzitelli et al., 
the alginate acts as an immunoprotective barrier for the encapsulated cells during transplant 
[55]. Alternatively, injectable hydrogels can be created directly from decellularised ECM 
materials, solubilising ECM products by digestion. The resultant products contain a high 
proportion of collagen, allowing the formation of hydrogels under physiological conditions 






Methods of decellularisation  
The removal of cellular antigens is an essential step for the production of decellularised 
ECM materials, as otherwise the presence of antigens may induce an inflammatory and 
immune response [118, 119]. The removal of cellular components can be achieved through 
three main approaches: chemical, enzyme-based, or physical. 
Physical methods include mechanical agitation, freeze/thaw cycles and sonication, while 
enzymatic treatments can include the use of trypsin, and endo- and exonucleases. 
Chemical methods are more varied, and can involve the use of acid or alkali solutions, hypo- 
and hypertonic solutions, and ionic, non-ionic and zwitterionic detergents such as Triton X-
100, SDS and CHAPS respectively [120]. A combination of these approaches is likely to be 
most effective. A variety of factors such as tissue type, tissue density and the desired end 
product affect the choice of methodology. 
Crapo et al. define the following criteria as requirements for successful decellularisation 
[46]: 
1. The material should contain less than 50 ng dsDNA per milligram of dry 
ECM. 
2. DNA fragments should be less than 200 base pairs in length. 
3. No nuclear material is visible in tissue sections stained with H&E or DAPI. 
Although the focus here is on DNA content, this is logical given that DNA levels are 
proportional to adverse host reactions, and DNA can act as an indicator for other cell 
residues remaining within the ECM [104]. Fulfilling these criteria imparts confidence in the 
safety of the material for in vivo use, having removed immunogenic stimuli. 
 
Skeletal muscle-derived substrates 
As the ECM varies with tissue type, it has been assumed that the best matrix for a particular 
cell type will be the one that most closely resembles its natural in vivo environment. For 
example, for myoblast expansion, rat skeletal muscle was processed by decellularisation, 
lyophilisation and milling into a powdered form. The extract was re-dissolved for use as a 
coating material for tissue culture plastic, which resulted in enhanced proliferation and 
differentiation of myogenic cells relative to uncoated/collagen-coated surfaces [121]. Cell-
type specific coatings can be created in this way, useful for in vitro culture or possibly for 
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coating medical devices in vivo [122, 123]. For three-dimensional culture, a gel or similar 
structure would be required. 
 
Adipose-derived substrates 
Adipose-derived scaffolds have been investigated due to the wide availability of human 
adipose tissue, a waste product from liposuction surgeries [124]. Human ECM powders can 
be generated from adipose tissue by homogenising the blood- and oil-free tissue, followed 
by freeze-drying and milling. Such powders support human adipose-derived stem cell (ASC) 
adhesion and proliferation in vitro. Seeded powders injected into nude mice supported 
adipogenesis and new blood vessel formation, as opposed to untreated adipose tissue or 
unseeded ECM powders [111]. Though powders alone do not confer much in the way of 
structure, hydrogels have been created in a similar way. Decellularised, lipase-treated 
adipose samples were solubilised with pepsin and upon exposure to physiological 
temperature and pH, self-assembled to form a hydrogel with a nanofibrous structure. This 
matrix supported normal human ASC growth and proliferation and could prove useful for 
soft tissue regeneration applications [105]. 
 
 Bioreactors for tissue-engineered constructs 
The culture and scale-up of three-dimensional tissue constructs requires the development 
of bioreactor systems which can support cell growth and tissue maturation. This may be 
simply through the provision of oxygen and nutrients, or in more complex designs, the 
generation of mechanical stimuli designed to aid cell differentiation. Statically cultured tissue 
constructs as small as 1 cm3 can develop central necrotic regions, as internally seeded cells 
exist in an oxygen and nutrient depleted environment, while those on the periphery maintain 
their viability [125]. In order to overcome this, and so that tissue constructs can be made 
sufficiently large to be clinically relevant, dynamic bioreactor cultures can be used to 
improve mass transfer. In short, bioreactors are systems in which certain parameters are 
controlled to maintain stable environments throughout a culture. Commonly controlled 
conditions for cell culture applications include temperature, pH, oxygen and nutrient supply, 
in addition to the removal of waste products such as lactic acid [126]. 
There are a variety of bioreactor types and the choice of bioreactor will depend on the size, 
shape and design of each tissue construct. Some bioreactor designs, such as stirred tanks, 
can be used both for initial cell seeding of a scaffold as well as for its long term culture, 
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while other systems would require a separate cell seeding or encapsulation method. Some 
of the most commonly used bioreactors are discussed in more detail below, though for a 
given application each bioreactor design can be modified and optimised. 
 
2.4.1. Spinner flasks 
Spinner flasks are the simplest form of bioreactor, and can be used to culture either cell-
laden microparticles, freely suspended, or larger scaffolds suspended by wire into the 
vessel. These systems are easy to assemble and use, and rMSCs cultured on PLGA 
scaffolds for 21 days in a spinner flask showed improved proliferation, alkaline phosphatase 
activity, osteocalcin expression and calcium deposition over statically cultured controls 
[127]. However, the size of constructs that can be grown in spinner flasks is limited. 
Increasingly large constructs require increased rotation rates to deliver nutrients to core 
regions, producing higher shear stresses on the outer regions of the structure which leads 
to cell death [125]. 
 
2.4.2. Perfusion systems 
Perfusion bioreactors can overcome the size limitations of spinner flasks by continuously 
pumping media through a porous scaffold (or packed microparticles, in the case of Chen et 
al.) [57]. Care must be taken to ensure the media flows through the scaffold, rather than 
around it, but when correctly assembled, nutrient transport is improved to central scaffold 
regions [128]. Perfusion systems can also be used to seed cells onto porous scaffolds, 
which for top down scaffolds encourages a more homogenous cell distribution than passive 
seeding, by transporting cells directly into internal pores [129]. 
Improved osteogenic outcomes have been observed for structures cultured in perfusion 
bioreactors, compared to static and spinner flask systems, possibly due to the action of 
flow-mediated stresses, which are known to upregulate osteogenic differentiation and 
mineralisation [130, 131]. However, the same shear stresses provided by continuous 
perfusion can be responsible for ‘washing out’ newly formed ECM, delaying or inhibiting 




2.4.3. Hollow fibre bioreactors  
Hollow fibre membrane bioreactors separate mass transfer from shear stresses. Cells are 
typically cultured on the exterior of hollow fibres, packed within a cartridge. Media is fed 
through the fibres, and while nutrients and oxygen diffuse through the membrane towards 
the cells, waste products travel the opposite way, in accordance with concentration 
gradients. Hollow fibre bioreactors provide high surface areas for cell attachment and cells 
are protected from shear stresses. Alternative arrangements are possible – for example 
cells could be grown inside the fibres or encapsulated in scaffolds around them [132]. 
However, hollow fibre bioreactors have primarily been investigated as a method of cell 
expansion rather than for the development of tissue constructs [133, 134].  
 
2.4.4. Stimuli-providing bioreactors  
Mechanical conditioning of tissue engineered constructs has been shown to improve the 
final properties of the product over a range of applications. For example, mechanical 
stretching has been shown to enhance the proliferation of cardiomyocytes on gelatin 
scaffolds, as well as the deposition and organisation of ECM by the cells [135]. Similarly, 
the application of pulsatile radial stress to tubular smooth muscle cell-seeded scaffolds 
improved the rupture strength of the resultant construct [136]. In a sense, most bioreactors 
provide some mechanical stimuli if only through the application of shear stress. However, 
for bone tissue engineering, bioreactors have been developed in order to replicate some of 
the mechanical stimuli bone and cartilage experience in vivo, such as compression, bending 
and tension. An example of this is the perfusion compression bioreactor. Osteosarcoma 
MG63 cells cultured in this system showed significantly higher levels of osteogenic markers 
compared to cells cultured under perfusion conditions only [125].  
The use of mechanical cues is crucial in conditioning tissue engineered constructs but the 
processes by which this can be achieved are varied. Problems include how best to deliver 
force into a bioreactor, as well as choosing a scaffold material that can withstand the force 





While the steps necessary to create a functional tissue construct are relatively well-defined, 
there is a lack of consensus about the most appropriate scaffold design approach, and 
indeed the scaffold material itself.  
For bone tissue engineering, the most suitable cell type for autologous or allogenic 
transplants is the mesenchymal stem cell, which is capable of osteodifferentiation as well 
as adipogenic and chondrogenic differentiation. The conditions required to induce each of 
these pathways are generally well-understood. As adult MSCs can be harvested from a 
number of tissues including bone marrow, adipose tissue, or peripheral blood, for research 
purposes the most appropriate source is likely to be determined by the resources or donors 
available. For preliminary experiments however it may be more convenient and rapid to use 
immortalised cell lines. 
It can be difficult to evenly seed cells throughout a traditional top down scaffold and specific 
arrangements of different cell types is also hard to achieve. In comparison, taking a bottom 
up approach to scaffold building allows for the even distribution of cells and a degree of 
control over cell type placement: seeding different cells types on different scaffold units can 
provide the ability to physically build in layers of complexity and hierarchy as the structure 
is assembled. Microparticles are ideally suited for use as the scaffold units of building blocks 
in this approach: cell culture on and in microparticles is well-established as a method of 
adherent cell expansion in stirred tank bioreactors, and these small spheres can be 
produced rapidly and easily. 
However, the choice of scaffold material will affect the specific processing techniques 
required for microparticle productions. Naturally-derived materials, such as SF, gelatin, 
collagen and alginate, are biocompatible and their degradation products are non-toxic. The 
mechanical properties can be finely tuned through different processing steps, and the 
environment they provide can closely mimic the natural ECM. By blending these different 
materials together, their beneficial attributes can be combined, and the resultant products 
can be developed to give a range of scaffolds. In particular, blends of SF and gelatin show 
promise as cell adhesive, osteogenic materials. 
However, the limiting factor in the development of engineering tissues and organ is the need 
for cells to be within 200 μm of an oxygen supply. Without a local oxygen supply, central 
construct regions will necrose rapidly. This can be overcome through the use of bioreactors 
to provide perfused media flow through a scaffold, or through the design of a pseudo-
vasculature within the construct itself. There is potential for these approaches to be 
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combined in the development of a hollow fibre bioreactor, in which the fibres themselves 
are integrated within the construct.  
 
 Aims & Objectives 
The aim of the work is to use blends of naturally-derived biomaterial microparticles, for use 
as cell-bearing scaffolds in bone tissue engineering applications. The materials in question 
are SF, alginate and ECM proteins. Microparticle scaffolds are proposed due to their 
suitability as cell carriers and the ability to mould individual scaffolds together into a 
macroscopic tissue-like construct. The eventual aim of producing such a construct would 
be for its use in replacing damaged tissues in vivo, or for use in in vitro studies to minimise 
animal use for research. As the viability of tissue constructs is dependent on the proximity 
of cells to a source of nutrients and oxygen, a final target of this work is to create a pseudo-
vasculature within the structure by moulding particles around hollow fibres. The objectives 
of this work are therefore as follows: 
 Investigate the biocompatibility, and characterise the physical properties, of blends 
of SF, alginate, and ECM protein materials in two and three dimensional systems.  
 Determine the best method for the production of gel-forming decellularised ECM 
materials. 
 Establish methods for the production of monodisperse microparticles for various 
material blends. 
 Isolate and culture rMSCs and investigate their osteodifferentiation on the materials 
in question. 
 Establish protocols for seeding or encapsulating cells within the microparticles to 
maintain cell viability.  
 Mould cell-laden microparticles into a macroscopic tissue construct, and 
characterise cell viability, distribution and construct strength. 
 Design a hollow fibre bioreactor system for moulding cell-laden microparticles into a 
tissue construct with integrated pseudo-vasculature, and use for the creation of a 




Materials & Methods 
This chapter includes the experimental procedures, material sources and analysis methods 
used throughout this thesis. Unless otherwise specified, materials were obtained from 
Sigma-Aldrich. 
 Experimental methods 
 
3.1.1. Cell culture 
All cell culture work was carried out under sterile conditions in a class II biological safety 
cabinet. Cells were maintained at 37 °C, at saturation humidity and 5% CO2. Cells were 
passaged regularly, at approximately 80% confluence, by trypsinisation. Trypsin was used 
at 0.25%, supplemented with 0.02% ethylenediaminetetraacetic acid (EDTA), in phosphate-
buffered saline (PBS; Oxoid). 
Where it was necessary to culture cells outside of the atmosphere-controlled incubator, 
CO2-independent medium (Gibco) was used to ensure the pH remained constant. The basal 
medium was supplemented with 10% v/v foetal bovine serum (FBS; Gibco), 4 mM L-
glutamine (Gibco), 100 U/mL penicillin and 100 µg/mL streptomycin. Cell lines were adapted 
to this medium by initially introducing 25% v/v of CO2-independent medium into the normal 
cell line media, and increasing the proportion to 50%, 75% and finally 100% v/v over a week 
of culture. 
 
Culture of 3T3 fibroblasts 
NIH 3T3 fibroblast cells (93061524; Health Protection Agency) were cultured in complete 
Dulbecco’s Modified Eagle’s Medium (DMEM; D5796) with 10% v/v FBS (Gibco), 100 
U/mL penicillin and 100 µg/mL streptomycin. 3T3 fibroblasts were used as they were 
routinely cultured in the laboratory.  
 
Isolation & culture of rat mesenchymal stem cells (rMSCs) 
rMSCs were extracted from the bone marrow of juvenile Wistar rats as described by Zhang 
and Chan [137]. Cells were selected by adherence to tissue culture plastic (TCP), followed 
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by fluorescence-activated cell sorting (FACS) analysis, using the antibodies listed in Table 
3.01. Cells were trypsinised and counted, then divided into microcentrifuge tubes containing 
between 105 and 106 cells per sample (one for each isotype control and antibody, as well 
as a tri-labelled sample for sorting). Samples were pelleted by centrifugation (300 x g, 5 
minutes) and washed in cold FACS buffer consisting of PBS with 1% v/v FBS before 30 
minutes incubation on ice. Samples were again pelleted then re-suspended in 50 μL of 
FACS buffer. The antibodies and isotype controls were added to each sample as 
appropriate, in the dilutions listed in Table 3.01. The samples were incubated for 1 hour on 
ice, protected from light. Finally, the samples were washed twice by pelleting and re-
suspending in FACS buffer, then re-suspended in 500 μL of PBS, at which point FACS was 
carried out using a Becton Dickinson FACS Aria III. 
 
Table 3.01: List of antibodies and isotype controls used for the identification of rMSCs by 
FACS. 
Antibody Conjugate Dilution used  






MACS Miltenyi Biotech 
Mouse anti-rat 
CD54 
FITC 1:3.5  
FAB5831F;  
R&D Systems 









MACS Miltenyi Biotech 
Isotype control 
mouse IgG2b 
FITC 1:3.5  
130-099-119;  







The population positively labelled for CD90.1 and CD54 and negative for CD45 was 
reserved. These cells were cultured in Minimum Essential Medium Eagle’s, alpha 
modification (αMEM, M8042) with 10% v/v FBS (Gibco), 2 mM L-glutamine (Gibco), 100 
U/mL penicillin and 100 µg/mL streptomycin. This is referred to hereafter as basal medium. 
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Cells were discarded after passage 8, as older cells lose activity, proliferative capacity and 
ability to differentiate [138]. 
 
Tri-lineage differentiation assays 
Adipogenic induction medium consisted of basal medium, supplemented with 1 μM 
dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 100 μM indomethacin and 10 
μg/mL of insulin. Adipogenic maintenance medium consisted of basal medium 
supplemented with 10 μg/mL of insulin only. rMSCs were seeded at 1.1 – 1.5 x 104 cells/cm2 
in basal medium and grown to 100% confluence before switching to differentiation media 
[139]. Confluent cell monolayers underwent media changes according to the following 
protocol: 
Days 1, 3, 5, = adipogenic induction medium 
Day 7 = adipogenic maintenance medium 
Days 9, 11, 13 = adipogenic induction medium 
Day 15 = adipogenic maintenance medium 
Days 17, 19, 21 = adipogenic induction medium  
Chondrogenic differentiation medium consisted of DMEM High Glucose (4.5 g/L) 
supplemented with 10% v/v ITS+1 Premix Tissue Culture Supplement (insulin-transferrin-
sodium selenite, linoleic-bovine serum albumin), 0.1 μM dexamethasone, 1 μM ascorbate-
2-phosphate, 1 mM sodium pyruvate (Invitrogen), and 10 ng/ml transforming growth factor-
beta 1 (TGF-β1, Invitrogen). Chondrogenesis was induced by means of pellet culture. 8 x 
105 cells were centrifuged in a 15 mL polypropylene tube at 450 x g for 10 minutes. The 
resulting pellet was then cultured in chondrogenic medium for 21 days, with medium 
changes 3 times per week [140].  
For osteogenic differentiation assays, rMSCs were seeded at 1.1 – 1.5 x 104 cells/cm2 in 
basal medium and grown to 100% confluence before switching to differentiation media. 
Osteogenic differentiation medium (ODM) consisted of basal medium supplemented with 
0.1 μM dexamethasone, 0.2 mM ascorbic acid 2-phosphate and 10 mM glycerol-2-
phosphate [141]. Cells were cultured in ODM for up to 28 days with medium changes 3 
times per week. 
Analysis of rMSC differentiation can be found in Section 3.2.3. 
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Seeding microparticles with cells 
To prevent cells preferentially adhering to TCP over microparticles, multiwell plates were 
coated with 1% w/v agarose in DMEM. The solution was heated until the agarose dissolved, 
then sufficient volume to cover the base of the wells was added to each. The agarose was 
allowed to cool and set before the plates were used. 
In a total volume of 500 μL, 3.75 x 105 cells/mL were seeded onto microparticles (4 x 103 
/mL) in an agarose-coated 24 well plate. The plate was incubated under normal cell culture 
conditions on a plate rocker. After 24 hours, the suspension was filtered through a 70 μm 
cell strainer to separate unattached cells, which were manually counted to calculate seeding 
efficiency: 
Where 𝓍 is the concentration of unattached cells in the filtrate: 
 
Seeding efficiency = 100 x (3.75 x 105 –𝓍)/3.75 x 105   (Equation 3.01) 
 
Where required, gelatin Cultispher-S microparticles (Percell Biolytica) were reconstituted as 
per the manufacturer’s directions, by autoclaving and washing in PBS (Oxoid), followed by 
washing in culture media. 
 
Cell encapsulation in alginate/collagen microparticles 
Cells (either 3T3 fibroblasts or rMSCs) were trypsinised, pelleted, and re-suspended in 3 
mg/mL rat tail collagen I solution (Invitrogen) at a concentration of 2 x 106 cells/mL. The 
collagen cell suspension was then mixed in a 1:1 ratio with 2.5%-oxidised medium viscosity 
(MV) alginate solution at a concentration of 10% w/v (with a final cell concentration of 1 x 
106 cells/mL). Alginate oxidation is described in Section 3.1.5. 1 M sodium hydroxide was 
added at 2.5% of the volume of collagen used, in order to neutralise the collagen and allow 
gel formation. The mixed cell suspension was aspirated into a sterile syringe which was 
then attached to the air flow focussing system (see Section 3.1.9). The resulting cell-laden 





3.1.2. Moulding cell-laden microparticles into larger constructs 
Cell-laden microparticles were moulded using a re-purposed cloning cylinder and non-
adhesive agarose-coated plates. Cylinders were secured in wells by pushing them firmly 
into the agarose gel layer. Cell-laden microparticles were gently pipetted into the mould 
created by the cylinder, with media filling the entire well over the height of the cylinder to 
ensure the sample did not dry out, as shown in Figure 3.01. After 7 days, the mould was 
removed with a pair of forceps. If successful, the microparticles held the shape of the mould 
independently, and the structure was stable to manual manipulation. 
 
 
Figure 3.01: Schematic of system for moulding microparticles together. (A) Cross-section; & 
(B) top view of a media filled 24-well plate well coated with an agarose layer, fitted with a cloning 
cylinder filled with microparticles. Not drawn to scale.  
 
3.1.3. Bioreactor design and assembly 
A custom bioreactor was created from commercially available parts and fittings. A diagram 
is shown in Figure 7.01. The body of the chamber was made from a Thermo Scientific Pierce 
Spin Column (Part no. 69705), with a length of polyvinylidene fluoride (PVDF) hollow fibre 
(KrosFlo® Implant Membrane, Spectrum Laboratories) fixed through the centre. A filter disc 
from the spin column set was pierced to produce a ring-shaped polyethylene frit that was 
pushed down around the hollow fibre to provide a flat surface at the bottom of the chamber. 
At this stage the hollow fibre was primed by 30 minutes soaking in 100% ethanol. The 
system was then sterilised by a further 30 minute soak in 70% ethanol, followed by washing 
in autoclaved distilled water. Peristaltic pump tubing (PharMed® BPT tubing 14; Cole-
Parmer) was connected in line with silicone tubing to create a closed system around the 
hollow fibre chamber.  
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Protein diffusion into the chamber 
For investigating protein diffusion through the hollow fibre into the spin column chamber, 
the top of the chamber was sealed with the ‘screw top to Luer’ cap provided, which was in 
turn connected to a Y-shaped 3 barb connector. The hollow fibre was threaded through, 
and sealed where it exited the connector, to prevent backflow. Tubing was fitted over the 
barb/hollow fibre. The third outlet was sealed with a removable cap, to allow for sampling 
of the chamber fluid at defined time points. 
A solution of 0.4 mg/mL bovine serum albumin (BSA) in PBS was pumped through the 
system at 10 mL/minute. The chamber was initially filled with PBS alone. At various time 
points over 2 days, 50 μL of the solution from inside the chamber was sampled. Protein 
concentration was determined using the Pierce™ BCA protein assay (Life Technologies). 
 
Cell culture in the bioreactor 
The chamber was seeded with 2 x 103 cell-laden microparticles before the Luer fitting on 
the screw cap was attached directly to a Luer-to-barb connector, which in turn connected 
directly with the tubing. The space between the hollow fibre and barb fitting was sealed to 
prevent medium falling back into the chamber from the end of the hollow fibre and ensure 
medium travelled in one direction only. The medium reservoir was kept at 37°C in a water 
bath, as was the bioreactor chamber. Cells cultured in the bioreactor were adapted to CO2-
independent medium to allow growth outside the normal incubator environment (see 
Section 3.1.1). The flow rate was set to 10 mL/minute. Where medium samples were 
collected for analysis, these were drawn from within the chamber itself. 
Control samples were cultured in a static, non-perfused environment (a sealed Eppendorf 
tube) for the same length of time, in the same volume of media as the bioreactor chamber 
held (2 x 103 cell-laden microparticles/0.5 mL). 
 
3.1.4. Processing silk fibroin (SF) and gelatin (G)  
In order to purify SF from raw silk, Bombyx mori cocoons (Homecrafts Direct) were first 
boiled in 0.2 M sodium carbonate in distilled water for 1 hour to remove sericin proteins. 
The silk was then washed 5 times in distilled water and air-dried. Once dry, the SF was 
dissolved in 9 M lithium bromide at 15% w/v, at 60°C for 4 to 5 hours before the solution 
was dialysed against regularly changed distilled water for approximately 2 days, or until the 
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conductivity of the water stopped increasing. The concentration of the aqueous SF solution 
was determined by drying a known volume of the solution. It was stored at 4 °C, and used 
at a concentration of 5% w/v unless stated otherwise. Solid SF was obtained by lyophilising 
the solution (using a Thermo Savant MicroModulyo bench top freeze-dryer). 
Type A porcine gelatin was dissolved in distilled water at approximately 60 °C, at a 
concentration of 5% w/v, immediately before use. 
 
Coating plates with SF and SF/G blends 
SF and gelatin were adsorbed onto TCP to investigate their effects on cell adhesion. Silk 
fibroin, gelatin and silk fibroin/gelatin blends (SF/G 75:25, 50:50, 25:75) were each diluted 
to 50 µg/mL in 0.02 M acetic acid, and added to a 96 well plate at 5 µg/cm2. The plate was 
incubated at room temperature for at least 1 hour, before the solutions were aspirated from 
the wells. The wells were washed 3 times with PBS to remove any remaining acid. Plates 
were either seeded immediately with 3T3 fibroblasts at 1.25 x 104 cells/cm2, or air-dried and 
stored at 4 °C. 
To create thin films of SF, gelatin and SF/G blends, SF and gelatin were dissolved in 
hexafluoroisopropanol (HFIP, Alfa Aesar) at 2% w/v. SF and gelatin were blended in ratios 
of 75:25, 50:50 and 25:75, and films were cast by allowing the solution to evaporate to 
dryness (20 μL/well in a 96 well plate, 200 μL/well in a 24 well plate). Once dry, films were 
cross-linked by exposure to 50 mM 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC, 
Alfa Aesar) in methanol for 24 hours at 4°C before washing three times with distilled water. 
Dry plates were sterilised by exposure to UV light for 30 minutes (253.7 nm, 0.115 kW, 
Bioquell), and then stored at 4°C until use. 
 
Samples for determination of Young’s Modulus 
To produce films for use in tensile testing, 2% w/v solutions of SF, SF/G blends and gelatin 
in HFIP were cast into silicone moulds. Films were cross-linked using 50 mM EDC in 
methanol for 24 hours, washed three times with distilled water and air dried. The films were 
peeled off the silicone mould and trimmed to size (10 x 20 mm). 
To produce solid discs for compression testing of SF/G materials, 1.5 mL of 5% w/v 
solutions were added to wells of a 12 well plate. Plates were cooled to 4°C to set the discs, 
which were then treated with 50 mM EDC in methanol for 24 hours, and finally washed three 
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times in PBS. Once removed from the plates, discs were punched out of the solid materials 
using a cork borer. This produced uniform discs of 13.5 mm diameter, and 3-4 mm height. 
 
Mineralisation of SF/G films 
SF, SF/G blends and gelatin films were cast onto glass coverslips, and cross-linked with 
EDC as previously described. Once dry, the film-coated coverslips were weighed and 
individual masses were recorded. The coverslips were then incubated in a modified 
simulated body fluid (MSBF) as described by Murphy and Mooney, consisting of 141 mM 
NaCl, 4 mM KCl, 0.5 mM MgSO4, 1 mM MgCl2, 4.2 mM NaHCO3, 5 mM CaCl2 and 1 mM 
KH2PO4 [142]. The films were incubated in the solution (at pH 6.8) for 7 days at 37 °C, then 
washed, dried, and weighed again. Control samples were treated identically but incubated 
in distilled water rather than MSBF. 
 
3.1.5. Production of oxidised alginate 
Oxidised alginate was produced by treatment with sodium periodate [93]. 100 mL of 1% w/v 
sodium alginate solution was reacted with 0.25 M sodium periodate for 24 hours, protected 
from light. The volume of sodium periodate was adjusted to provide a certain number of 
molar equivalents to the sodium alginate to produce the desired level of oxidation. For 
example, to produce 5% oxidation, 0.05 molar equivalents of sodium periodate were added. 
The reaction was stopped by the addition of 1 mL ethylene glycol, and 2.5 g sodium chloride 
was added. 200 mL of ethanol was added to the solution in order to precipitate the product, 
which was collected by centrifugation (910 x g, 10 minutes). The precipitated product was 
re-dissolved in 100 mL of distilled water, and re-precipitated with 200 mL ethanol. The 
precipitate was collected and lyophilised (using a Thermo Savant MicroModulyo bench top 
freeze-dryer).  
To investigate the level of oxidation, the remaining sodium periodate in the solution was 
quantified as described elsewhere [95, 143]. Before the reaction was quenched, 120 μL 
aliquots of the reaction mixture were collected, and mixed with 80 μL of an indicator solution 
consisting of 0.75% w/w starch and 15% w/v potassium iodide. The absorbance of the 
solution at 486 nm (due to the presence of tri-iodide starch complexes) was measured using 
a BMG Labtech FLUOstar Omega plate reader. The periodate concentration was calculated 
using a standard curve. The difference between the initial periodate and final amount in the 
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sample corresponds to the number of glycol groups oxidised to aldehyde groups, and 
therefore the level of oxidation [143]. 
 
3.1.6. Production of fine calcium carbonate particles 
Calcium carbonate particles were produced from calcium chloride and sodium carbonate. 
2.5 mL of 1 M sodium carbonate was added to 650 µL of 5 M calcium chloride and stirred 
vigorously for 10 minutes. After this time, 5 mL of distilled water was added and any large 
calcium carbonate particles (that precipitated without centrifugation) were discarded. The 
calcium carbonate was collected by centrifugation (581 x g, 5 minutes), and the supernatant 
was discarded. The product was lyophilised using a Thermo Savant MicroModulyo bench 
top freeze-dryer [144]. 
 
3.1.7. Decellularising porcine skeletal muscle  
SDS decellularisation 
Adipose tissue was removed from a 5-10 g sample of porcine skeletal muscle (PSM; F. 
Griffiths & Sons, Ashcott), which was then finely sliced. The samples were washed in 
distilled water for 30 minutes, and then stirred in 1% w/v sodium dodecyl sulphate (SDS) in 
PBS for 48-50 hours, until all colour had faded and the samples became ‘feathery’ in 
appearance. The samples were then rinsed in distilled water for approximately 6 hours, with 
the water changed several times. Decellularisation was assessed at this stage (see Section 
3.2.7). Finally the decellularised PSM was lyophilised (Thermo Savant MicroModulyo bench 
top freeze-dryer) and ground into a powder.  
The ground powder was digested with 1 mg/mL of pepsin in 0.1 M hydrochloric acid, at a 
concentration of 10 mg of decellularised PSM per 1 mL of hydrochloric acid. After 
approximately 60 hours, or when no particles were visible in the solution, the mixture was 
neutralised to pH7.4 with sodium hydroxide and PBS. The solution of solubilised ECM was 






Triton X-100/EDTA decellularisation   
Tissue samples were decellularised as described by Stern et al. [121]. Briefly, samples were 
sliced thinly, and washed in distilled water for 2 days, before treatment with 0.05% trypsin 
with0.02% EDTA for 1 hour. All solutions were used at a ratio of 1 L per 40 g of starting 
material. To neutralise the trypsin the samples were placed in DMEM with 10% v/v FBS 
overnight. The samples were then exposed to 1% v/v Triton X-100 for 5 days, and finally 
washed for 2 days in distilled water and 1 day in PBS. Decellularisation was assessed at 
this stage (Section 3.2.7). 
 
Homogenisation and solubilisation 
PSM was decellularised using a method described by Abberton et al. [145]. Samples of 
PSM were weighed, then washed, finely sliced, and homogenised three times in ice-cold 
3.4 M sodium chloride buffer, containing 0.5 mM phenylmethylsulfonyl fluoride, 2 mM EDTA, 
0.1 M 6-aminocaproic acid, and 2 mM N-ethylmaleimide. After each homogenisation, the 
samples were centrifuged at 1780 x g for 5 minutes, and the supernatant was discarded. 
The samples were then homogenised again with fresh buffer. The total volume of buffer 
used was equal to three times the initial mass of the sample.  
The samples were then treated with 2 M urea in 0.05 M Tris/0.15 M sodium chloride (TBS) 
buffer, overnight at 4 °C, in a volume equal to the initial sample mass. Following this, the 
samples were centrifuged (10,000 x g, 30 minutes) and the supernatant reserved. The 
pellets were re-homogenised in 2 M urea/TBS and left overnight again at 4 °C. The 
supernatant was collected. The combined supernatants were dialysed against 0.5% v/v 
chloroform in TBS for 1 day, then against several changes of TBS, and finally against 
DMEM. The product was stored at 4 °C. Protein concentration was determined by the 
Pierce™ BCA protein assay (Life Technologies).  
 
3.1.8. SF and SF/G microparticle production 
Emulsions 
Initially SF particles were formed using an emulsification method. Approximately 80 mL of 
corn oil was mixed using an IKA DI 18 homogeniser. 500 μL of aqueous SF solution was 
added to the beaker and homogenised until the SF droplets appeared evenly distributed 
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throughout the oil phase. 0.8 mL Tween 20 was then added to the emulsion to give a 
concentration of approximately 1% v/v, followed by approximately 8 mL of methanol (1/10th 
of the initial volume of corn oil). The solution was centrifuged (327 x g, 4 minutes) and the 
aqueous top layer, containing the particles, was collected. The particles were incubated in 
fresh methanol overnight, then washed 3 times in PBS. 
 
Axisymmetric microfluidic flow focussing 
A schematic of the axisymmetric focussing device constructed in this work is shown in 
Figure 3.02. The main casing consisted of a T-junction piece (Tee LP PEEK 1/4-28 1/16" 
0.040" Thru Hole, Kinesis), fitted with a glass capillary (Hollow Round Glass Capillaries ID 
0.50mm OD 0.70mm, CM Scientific) running centrally through the junction. The outer 
diameter of the capillary measured 0.7 mm while the diameter of the lumen is slightly larger 
(1 mm), allowing the continuous phase to flow evenly between the capillary and the lumen 
wall. The inner and outer phases were fed into the T-junction through PEEK tubing (Tubing 
PEEK 1/16" OD x 0.03" (0.75mm), Kinesis) and the output travelled through the same tubing 
with a smaller inner diameter (Tubing PEEK 1/16" OD x 0.02" (0.50mm), Kinesis). The input 
tubing pieces were connected to Luer lock syringes via tubing-to-cone and cone-to-Luer 
fittings (Fingertight fitting two-piece PEEK 10-32 Long, Adaptor female Luer to 10-32 female 
PEEK, both Kinesis). The parts described are shown in Figure 3.03.  
 
 
Figure 3.02: Schematic of the axisymmetric focussing device used to produce microparticles. 
The outer phase is shown in dark grey, while the inner phase is shown in light grey. The inner phase 





Figure 3.03: Component parts of the axisymmetric flow focussing device. The glass capillary 
in shown in the left hand image. In the right hand image, the capillary has been threaded through the 
central lumen of the T-junction. Scale bars represent 5 cm. 
 
The outer continuous phase flowed in an L-shape through a port at a right angle to the 
capillary. The third port acted as the output. The two phases were controlled by separate 
syringe drivers (Harvard Pump 11 plus/Cole Parmer single syringe infusion pump). The 
inner phase consisted of the aqueous protein solution while the outer phase was oil-based. 
The outer phase consisted of oleic acid (Alfa Aesar), methanol and Span 80, in the volume 
ratio of 73:25:2 [55]. The inner flow rate was set to 0.36 mL/hour while the outer flow rate 
was set to 7.2 mL/hour. The output was collected into a 1:1 mixture of excess outer solution 
and methanol. Microparticles were then soaked in methanol, and gelatin-containing 
particles were cross-linked using 50 mM EDC for 24 hours. After this, the microparticles 
were washed once in a 1% v/v Tween 20 solution then three times in PBS. Microparticles 




Porous particle production 
To create SF microparticles with large interconnected pores, the use of porogens was 
investigated. SF solution was blended with 1% or 10% w/v sodium chloride, 10% w/v 
polyethylene glycol (PEG), or 5%, 10% or 20% w/v calcium carbonate, and microparticles 
were created as described above. To leach out sodium chloride and PEG, the microparticles 
were soaked in distilled water overnight. To dissolve calcium carbonate, the microparticles 
were incubated in acidified methanol (1.5 mM hydrochloric acid in methanol) overnight 
before washing with distilled water. 
 
3.1.9. Alginate and alginate/ECM microparticle production 
Axisymmetric microfluidic focussing 
Alginate particles were produced in the flow focussing device described earlier in Section 
3.1.8. For this application, the inner phase consisted of a slurry of 2% w/v insoluble calcium 
carbonate particles in alginate solution. The outer phase consisted of corn oil with 1% v/v 
Tween 20, acidified with 5% v/v acetic acid. The inner flow rate was set to 0.36 mL/hour 
while the outer flow rate was set to 7.2 mL/hour. The alginate microparticles were collected 
into an excess of the outer solution and allowed to settle before the majority of the oil was 
aspirated away. Hexane was added to dissolve the remaining oil and as much as possible 
was aspirated. Particles were washed in a calcium chloride washing buffer (80 mM CaCl2 
with 0.1% v/v Tween 20) before microscopy analysis. 
Air flow focussing  
An air flow focussing device was set up to rapidly produce alginate or oxidised alginate 
particles (from 1-10% w/v, MV or LV). A schematic of the system is shown in Figure 3.04. 
The flow of alginate solution from the end of a fine stainless steel capillary was evenly 
broken up by a coaxial flow of nitrogen gas, controlled by a regulator. Parts used included 
the Tee LP PEEK 1/4-28 1/16" 0.040" Thru Hole, flangeless fittings for 1/16” OD tubing, 
PEEK bulkhead union 1/4-28 flat-bottom, and stainless steel capillary tubing 1/32” OD 
0.010” ID (all Kinesis). The droplets were collected in a bath of 135 mM (1.5% w/v) calcium 
chloride or 10 mM (0.208% w/v) barium chloride which cause rapid gelation of the alginate 
producing microparticles. The solution flow was controlled by a syringe pump (Cole Parmer 
single syringe infusion pump).  
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10% w/v 2.5%-oxidised MV alginate solution was blended with the decellularised 
homogenised/solubilised PSM extract (7-11.4 mg/mL), or 3 mg/mL collagen (Invitrogen) to 
create alginate-protein particles. The air flow rate was set at 0.5 bar and the alginate solution 




Figure 3.04: Schematic and photo of air flow focussing set up. The nitrogen air flow pulls drops 
off the end of the capillary tube and propels them into the collection bath. The alginate solution input 
was controlled by a syringe driver. The nitrogen flow was controlled by an inline regulator. Schematic 
not drawn to scale. 
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 Analytical methods 
 
3.2.1. Measuring cell number, metabolism & proliferation  
Cell metabolism was assessed using the CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (MTS, Promega) according to manufacturer’s instructions. Unless 
otherwise specified, three days after seeding cells, 20 μL of MTS reagent per 100 μL media 
was added to each well. After 2 hours incubation the absorbance of the plate was read at 
490 nm using a BMG Labtech FLUOstar Omega plate reader. 
Cell proliferation was alternatively measured using the reduction of resazurin solution. A 
0.15 mg/mL solution of resazurin in PBS, pH 7.4, was added to cells (in freshly replaced 
media) at 20% v/v and incubated at 37 °C. After 2 hours, the fluorescence of the media was 
measured at Ex/Em 560/590 nm, again using a BMG Labtech FLUOstar Omega plate 
reader. 
Cell numbers in microparticle cultures were analysed using fluorescent measurements of 
Hoechst-stained cell lysate [146]. Briefly, media was removed from the samples, which were 
frozen at -80 °C, then thawed at 37 °C. Distilled H2O was added to each sample before 
sonicating for 15 minutes (VWR Ultrasonic Cleaner USC300TH) and then re-freezing. 
Samples were again thawed at 37 °C, and sample supernatants were added to an equal 
volume of 20 μg/mL Hoechst 33342 in TNE buffer (10 mM Tris-HCl, 1 mM EDTA, 2 M NaCl; 
pH 7.4). A standard curve was constructed using samples with known cell numbers. 
Fluorescence was read at 350/460 nm (BMG Labtech FLUOstar). 
 
3.2.2. Analysis of cell viability by fluorescent staining 
Samples were stained with LIVE/DEAD ®, consisting of calcein AM (2 μM) and ethidium 
homodimer 1 (2 μM) in PBS. Cells were washed with PBS, then incubated in the 
LIVE/DEAD solution in the dark for 30-40 minutes at room temperature, or for 20 minutes 
at 37 °C. Samples were then viewed under fluorescent light (Ex/Em calcein = 494/517 nm; 
Ex/Em DNA-bound ethidium homodimer 1 = 528/617 nm) (Leica DMI4000B). 





3.2.3. Analysis of rMSC differentiation 
Adipogenesis  
To confirm adipogenic differentiation, cultured cells were stained with Oil Red O. Cells were 
fixed with 4% w/v paraformaldehyde for 30 minutes, and then washed 3 times with PBS for 
5 minutes each. Two rinses with distilled water followed this, before the cells were treated 
with Oil Red O solution. The solution was prepared by diluting a 0.5% w/v stock solution of 
Oil Red O in 2-propanol with distilled water in a ratio of 3:2. The diluted solution was filtered 
and used immediately. Samples were incubated for 50 minutes at room temperature in this 
solution, after which time it was aspirated, and the samples were washed 3 times with 
distilled water. A positive result was indicated by the presence of red-stained lipid droplets 
within the cells. 
 
Chondrogenesis  
Chondrogenic cell pellets were fixed in 4% w/v paraformaldehyde, dehydrated and 
embedded in paraffin wax. 5 μm slices were sectioned using a microtome (Leica RM2125), 
and de-waxed using HistoChoice® Clearing Agent (2 x 2 minute washes). Samples were 
re-hydrated in a series of ethanol solutions (100%, 95%, 90%, 70%, 50%; 1 minute in each), 
then in distilled water for 1 minute. This was followed by staining with Toluidine Blue (1% 
w/v in distilled water) for 1 minute. Samples were then washed 3 times in distilled water, 
dehydrated and mounted using DPX Mountant. A purple stain indicated the presence of 
cartilaginous extracellular matrix, while blue staining showed undifferentiated tissue. 
 
Osteogenesis – alkaline phosphatase activity  
To confirm osteogenic differentiation, alkaline phosphatase (ALP) activity was assayed. 
Media was aspirated from the cell cultures, which were then carefully washed in PBS. The 
cells were exposed to 4% w/v paraformaldehyde for 60 seconds, then washed in washing 
buffer (PBS + 0.05% Tween 20). The cells were then covered in BCIP®/NBT Liquid 
Substrate System (5-bromo-4-chloro-3'-indolyphosphate p-toluidine salt/nitro-blue 
tetrazolium chloride) and incubated at room temperature for 10 minutes. The samples were 
then rinsed again in washing buffer before PBS was added. A positive result was indicated 




Osteogenesis – mineral staining 
Von Kossa stain was used to investigate the presence of calcium deposits. Samples were 
washed three times in distilled water, then incubated in 1% w/v silver nitrate under an 
ultraviolet light for 20-30 minutes before washing again in distilled water. To remove 
unreacted silver, samples were treated with 5% w/v sodium thiosulphate for 5 minutes, then 
washed again. Samples were counterstained with 0.1% nuclear fast red solution for 5 
minutes and washed in distilled water. Calcium salts are stained black or very dark brown 
by the Von Kossa stain, and nuclei are stained red by nuclear fast red. 
Alizarin Red was also used to stain calcium deposits. Cell culture samples were washed in 
PBS (Ca2+ and Mg2+ free) and fixed with 4% w/v paraformaldehyde for 30 minutes. Following 
fixation, samples were incubated in Alizarin Red solution (2% w/v, pH 4.1-4.3, filtered) for 
45 minutes at room temperature, protected from light, and then washed with distilled water 
four times. Mineralised deposits are stained bright red by Alizarin Red. 
 
Osteogenesis – protein expression 
Expression of osteocalcin was determined using the LI-COR Biosciences In Cell Western 
Assay. Cells grown in 96 well plates were washed in PBS, then fixed for 10 minutes in 4% 
w/v paraformaldehyde, before again washing in PBS. Cells were permeabilised by washing 
5 times in PBS + 0.1% Triton X-100, and then blocked by 30-90 minutes exposure to 
Odyssey Blocking Buffer (LI-COR Biosciences). Cells were then labelled with a 1:50 dilution 
of primary antibody, rabbit anti-mouse osteocalcin (sc-30045, Santa Cruz Biotechnology 
Inc.) overnight at 4 °C, before washing 5 times in PBS + 0.1% Tween 20. The antibody was 
reported to have rat reactivity. The secondary antibody (goat anti-rabbit IRDye 800CW; 925-
32211, LI-COR Biosciences) was added to the plates for 1 hour at a 1:800 dilution, protected 
from light at room temperature. The plates were finally washed 5 times with PBS + 0.1% 
Tween 20 before reading on the LI-COR Odyssey CLx infrared imaging system. The data 
was normalised by cell number, ascertained by counts of Hoechst-stained nuclei. Samples 
were stained by incubation with 5 μg/mL Hoechst 33342 in PBS, and images of stained 
nuclei were recorded and quantified using ImageJ software (NIH, Bethesda, MD, USA; 
http://imagej.nih.gov/ij). 
Osteopontin levels were quantified from cell culture media supernatants using a 
commercially available enzyme-linked immunosorbent assay (Mouse/Rat Osteopontin 
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Quantikine ELISA Kit, R&D systems). This data was normalised by cell number, determined 
by Hoechst staining of lysed cells. 
 
3.2.4. Determination of Young’s modulus values 
Uniaxial, unconfined compression measurements were performed on SF, SF/G blends and 
gelatin discs using an Instron 5965 testing machine at room temperature. All samples were 
measured under a loading rate of 0.2 mm/minute. Samples were measured for 6 minutes.  
Unidirectional tensile tests were carried out on SF, SF/G blend and gelatin films. The 
thicknesses of the dry films, trimmed to 10 mm x 20 mm, were measured using a micrometer 
screw gauge. Films were fixed into cardboard holders, which were in turn clamped into the 
Instron 5965 with an initial distance of 10 mm between vices, and tension was applied at a 
rate of 0.5 mm/minute until material failure.  
Young’s modulus values were calculated from linear regions of the stress-strain curve using 
the following equation:  
Young’s modulus = (load/initial cross-sectional surface area) / (extension/initial length) 
(Equation 3.02) 
 
3.2.5. Scanning electron microscopy and energy-dispersive X-ray spectroscopy 
Samples were examined by scanning electron microscopy (JEOL JSM6480LV).  
Cell-free samples were lyophilised (Thermo Savant MicroModulyo bench top freeze-dryer) 
before sputter coating with gold (Edwards Sputter Coater 5150B). Cell-laden samples were 
prepared by fixation in 2.5% glutaraldehyde in DMEM with 1% w/v potassium ferrocyanide, 
for 2 hours at 37 °C. After washing with DMEM, the samples were post-fixed in 1% aqueous 
osmium tetroxide with 1% w/v potassium ferrocyanide for 1 hour at room temperature. 
Samples were then washed twice with distilled water over 10 minutes, and stained with 2% 
aqueous uranyl acetate for 1 hour, in the dark, at room temperature. Finally samples were 
dehydrated in a graded series of aqueous acetone solutions (50, 70, 90, 100% acetone) 
followed by 1:1 acetone:hexamethyldisilazane (HMDS) and 100% HMDS. Once the majority 
of the HMDS had been aspirated, samples were left for 1-2 hours for the remaining solvent 
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to evaporate. Once dry, samples were sputter coated with gold before SEM images were 
recorded.  
For energy-dispersive X-ray spectroscopy (EDX), samples were sputter coated with 
chromium. EDX was carried out in combination with SEM, using an Oxford ISIS X-ray 
analyser. 
 
3.2.6. Microparticle size analysis 
Bright field images of microparticles were captured using a Leica digital microscope (Leica 
DMI4000B). Image J software was used to calculate the Feret’s diameter (the maximum 
measured diameter) of the microparticles within each image. 
 
3.2.7. Confirming and quantifying decellularisation 
Decellularisation was confirmed with Haematoxylin & Eosin (H&E) staining, Hoechst 33342 
staining and DNA content quantification, measured by the Quant-iT™ PicoGreen ® dsDNA 
assay (Life Technologies).  
For H&E staining, samples were fixed in 4% w/v paraformaldehyde, embedded in wax and 
sectioned. Sections were de-waxed in HistoChoice® Clearing Agent (2 x 2 minute washes), 
then re-hydrated in a series of ethanol solutions (100%, 95%, 90%, 70%, 50%; 1 minute in 
each), then in distilled water for 1 minute. Sections were stained with filtered Harris 
Haematoxylin (0.7% w/v) for 3 minutes, washed gently with running tap water for a further 
3 minutes then placed in concentrated hydrochloric acid in 70% ethanol for 30 seconds. 
The sections were then placed in 1% ammonia in 70% ethanol for 1 minute and washed in 
70% ethanol for 30 seconds. Eosin staining was then achieved by placing the sections in 
filtered Eosin Y (0.25% w/v) for 1 minute, then very briefly washing in 70% ethanol (3 
seconds maximum), 95% ethanol (5 seconds) and 100% ethanol (5 seconds). The sections 
were finally washed again twice in HistoChoice® Clearing Agent and mounted under 
coverslips using DPX Mountant. 
For nucleic acid staining with Hoechst 33342, samples were fixed in 4% w/v 
paraformaldehyde, embedded in wax and sectioned. Sections were de-waxed in 
HistoChoice® Clearing Agent (2 x 2 minute washes), then re-hydrated in a series of ethanol 
solutions (100%, 95%, 90%, 70%, 50%; 1 minute in each), then in distilled water for 1 
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minute. Protected from light, sections were incubated in Hoechst solution (2 μg/mL) for 10 
minutes at room temperature, before rinsing briefly with PBS and mounting. Samples were 
kept protected from light and fluorescent images were recorded immediately (Leica 
DMI4000B).  
For quantification, DNA was extracted from lyophilised, ground samples. Weighed samples 
(10-30 mg) were suspended in 0.5 mL of extraction buffer (0.1 M NaCl, 10 mM Tris, 1 mM 
EDTA pH 8.0, 1% SDS) with 5 µL of 10 mg/mL Proteinase K, and incubated at 50°C for 24 
hours. To extract nucleic acids from proteins, the samples were shaken with 0.75 mL 
phenol/chloroform/isoamyl alcohol (25:24:1 v/v) and centrifuged (12,000 x g, 15 minutes). 
The upper aqueous phase, containing the nucleic acids, was retained. The extraction was 
repeated. To precipitate DNA from the solution, 2 volumes of 100% ethanol and 0.1 volume 
of 3 M sodium acetate (pH 5) were added to each sample. The samples were incubated at 
-20 °C for 3 hours, and then centrifuged (12,000 x g, 15 minutes) to collect each DNA pellet, 
which was washed in 70% ethanol and air-dried. The pellets were re-suspended in 1 mL 
TE buffer (10 mM Tris, 1 mM EDTA pH 8.0) and stored at 4 °C before use in the PicoGreen 
assay. 
 
3.2.8. Gel electrophoresis of homogenised/solubilised muscle extract 
Samples were analysed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis as 
described by Abberton et al. [145]. Briefly, samples were mixed in a 1:1 ratio with 2x 
concentrated Laemmli solution (4% w/v SDS, 20% v/v glycerol, 10% v/v 2-mercaptoethanol, 
0.004% w/v bromophenol blue and 0.125 M Tris HCl, pH 6.8) to give a final sample 
concentration of 1 mg/mL, and heated at 90 °C for 5 minutes. 20 μL of each sample, and 5 
μL of a molecular ladder solution were loaded onto the stacking gel, and separated in 10% 
polyacrylamide resolving gels for 45 minutes at 200 V. After this, the gel was removed from 
its frame, rinsed with distilled water and stained with SimplyBlue SafeStain™ (Invitrogen) 
for 1 hour at room temperature to identify separated protein bands. 
 
3.2.9. Histology of three-dimensional samples 
Samples were fixed in 4% paraformaldehyde for 24 hours and embedded in wax before 
microtome slicing. Sections were de-waxed in HistoChoice® Clearing Agent (2 x 2 minute 
washes), then re-hydrated in a series of ethanol solutions (100%, 95%, 90%, 70%, 50%; 1 
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minute in each), then in distilled water for 1 minute. Samples were stained with H&E to 
identify cell cytoplasm and nuclei within the construct, as described in Section 3.2.7. 
 
3.2.10. Measuring viscosity 
Viscosity measurements were obtained using a Bohlin C-VOR rheometer under dynamic 
conditions at 25 °C. Samples were placed between a flat plate and PU40 cone (40 mm 
diameter cone with 4° angle) and measurements were obtained using a stepped shear 
stress test (10 steps between 2 and 13 Pa). Each sample type was measured three times 
(using fresh solution each time) and the viscosity was calculated from the mean average of 
all measurements. 
 
3.2.11. Statistical analysis 
Statistical analysis was performed with one-way analysis of variance (ANOVA) with Tukey’s 
honest significant difference post-hoc test using R software (R Foundation for Statistical 







 Silk fibroin & gelatin blends as biomaterials 
 Introduction  
Silk as a biomaterial 
As discussed in Section 2.3.1, silk fibroin (SF) has been highlighted as a promising 
biomaterial due to its mechanical and biological properties. Native silk fibres are produced 
with a core of fibroin coated in glue-like sericin. Though sericin can promote cell proliferation 
when added as a supplement to culture media, it has also been found responsible for 
adverse immunogenic reactions in vivo [68, 147]. Sericin must therefore be removed from 
silk before use in tissue engineering or other biological applications. Fortunately this is an 
easy process, as boiling native silk in sodium carbonate removes sericin proteins from the 
fibroin core [148]. Regenerated SF has been shown to have both good biocompatibility at 
levels equivalent to other commonly used biomaterials, including collagen, Teflon and poly-
glycolic acid [68, 73, 149]. Indeed, the extensive use of silk sutures means that the reaction 
of the body to the introduction of SF is well-characterised. Although traditionally defined as 
non-degradable, there is evidence that SF breaks down over time as a result of proteolytic 
degradation [150-152]. SF is a thermally stable material, and can be sterilised by 
autoclaving without compromising structural integrity [80].  
SF has been investigated as a scaffold for osteogenic and chondrogenic tissue engineering 
in a variety of formats, including films. A number of cell lines, including fibroblasts and colon 
adenocarcinoma cells, were shown to have equivalent growth rates on SF films compared 
to collagen films [153, 154]. Human MSCs have been successfully differentiated down 
osteogenic, chondrogenic and ligament lineage routes on SF scaffolds [76, 155, 156]. Saos-
2 osteoblast-like cells were shown to have undergone bone formation on RGD (arginine - 
glycine - aspartic acid)-modified SF films, as RGD residues provide attachment sites for cell 
integrin receptors, facilitating cell adhesion [102]. 
 
Silk fibroin/gelatin scaffolds 
While there are many reports of successful cell adhesion and proliferation on SF materials, 
there are a number of instances where SF has been blended with other biopolymers such 
as collagen, gelatin and cellulose to improve its properties [84, 157].  
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Gelatin is a product of collagen hydrolysis, and the two materials share many 
characteristics. Gelatin forms a temperature-dependent hydrogel in aqueous solutions, and 
is strongly cell-adhesive as a result of RGD residues within its structure [101, 102]. Where 
SF has been reported have low cell adhesion, this has been significantly improved by the 
inclusion of even small proportions of gelatin. Yang et al. found that including 1.2% gelatin 
in SF films improved the attachment of 3T3 fibroblasts, and that blended films containing 
10-20% gelatin supported higher proliferation than either SF or gelatin alone. A summary 
of papers reporting improved biological and physical properties from blended SF/gelatin 
(SF/G) materials is shown in Table 4.01.  
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 Aims & Objectives  
As described, SF is an attractive scaffold material for tissue engineering. The decision was 
therefore taken to investigate SF as a scaffold for osteogenic cell culture, initially in two-
dimensional formats. Given reports of variable levels of cell adhesion to SF materials, 
investigation into the effects of blending SF with gelatin was proposed as a method to 
improve cell attachment. 
 
The aim of the work in this chapter is to investigate SF based scaffolds for use as osteogenic 
biomaterials: 
 Investigate the properties of SF and SF/G materials.  
 Confirm the biocompatibility of SF and SF/G blends, and investigate their ability to 
support cell growth. 
 Isolate and characterise rat mesenchymal stem cells (rMSCs), and explore 
whether SF and SF/G materials support osteodifferentiation. 
 
 
 Results & Discussion 
 
4.3.1. Topography of SF & SF/G films 
When examined by scanning electron microscopy (SEM), films of SF and SF/G blended 
materials appeared flat and even, with no pores or holes revealing the surface underneath. 
This confirms that when cells are seeded onto these films, they are interacting with the film 
rather than the material underneath. Examples of these films are shown in Figure 4.01. The 
film of SF/G 50:50 was typical of all blends of SF/G. While all films completely covered the 
surface with no visible gaps, the SF and SF-containing films appeared smoother than those 
composed entirely of gelatin. This is similar to effects observed for films composed of blends 










4.3.2. Mineralisation of SF & SF/G films 
To investigate whether the SF/G materials would be suitable as scaffolds for bone tissue 
engineering applications, their ability to support mineralisation was investigated. The 
predominant mineral component of human bone is carbonated hydroxyapatite. If a material 
has the appropriate surface properties, it can become mineralised which is highly desirable, 
as coating polymeric materials with hydroxyapatite improves their integration with native 
bone, increases cell adhesion and supports the osteodifferentiation of stem cells [162, 163]. 
In vivo mineralisation of extracellular matrix proteins requires a high degree of control over 
the physical processes related to mineral growth. This is initially mediated by the 
organisation of collagen fibrils into parallel sheets around anionic spaces, rich in phospho- 
and glycoproteins, which attract calcium-rich mineral nuclei leading to mineral growth [142, 
164].  
Films of SF, SF/G 50:50 and gelatin were incubated in a modified simulated body fluid 
(MSBF) described by Murphy and Moody [142]. Simulated body fluid (SBF) is designed to 
contain ion concentrations very close to those of human plasma, and the presence of 
calcium and phosphate ions allows for the spontaneous growth of apatite on bioactive 
materials incubated in the solution. The development of apatite layers on materials in SBF 
is an accurate predictor of in vivo bone bioactivity [165]. Typical SBF experiments can be 
time-consuming but by increasing the concentration of calcium and phosphate to produce 
the MSBF, the apatite coating process is accelerated. 
As can be observed in Figure 4.02, the films incubated in MSBF increased in mass while 
those incubated in dH2O showed smaller increases or slight decreases. The mass increase 
indicates a deposition of mineral crystals, also evidenced by the crystals observed on the 
films in Figure 4.03. The loss of mass in dH2O-treated samples is likely due to slight damage 
to the films, especially at the edges, during washing steps.  
 53 
 
Figure 4.02: Change in dry mass of films incubated in MSBF or dH2O for 7 days. The average 
initial mass of the films + coverslips is 41.1 mg. Three films were weighed for each sample type 
(n=3). 
 
The films were examined by energy dispersive X-ray spectroscopy, and deposits on the 
MSBF-treated film surfaces gave elemental signals typical of calcium hydroxyapatite, for 
example calcium, phosphorous and oxygen (Figures 4.03, 4.04 and 4.05). Films incubated 
in water did not show signals typical of calcium phosphates. The silicon signals in Figure 
4.03 spectrum 2, Figure 4.04 spectrum 2 and Figure 4.05 spectrum 1 are likely due to the 
penetration of x-rays into the glass coverslip underneath the film, while the iron signal in 
Figure 4.04 spectrum 1 can be attributed to the contaminant particle visible on the film 
surface, most likely accidentally incorporated during processing for SEM. The SF, SF/G 
50:50 and gelatin films all behaved equivalently in this context. 
It was reported by Choi et al. that SF particles (of a 1-10 μm diameter) supported the 
generation of calcium-deficient hydroxyapatite crystals, mediated by negative charges 
caused by the deprotonation of functional groups on the particle surfaces [166]. It is likely a 
similar interaction occurs in the SF and SF/G materials described in this thesis. This group 
also described the effect of pH on mineral deposition, with high pH solutions producing 
smaller, finer plate-like crystals and lower pH solutions producing larger crystals that were 
sparsely distributed. The experiment described in this work was carried out using MSBF at 
pH 6.8, as described by Murphy and Mooney, to prevent the homogenous precipitation of 
calcium phosphide phases, so the process could be optimised by altering the pH of the 
solution or even the constituents of it to produce different crystal formations [142]. 
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This experiment shows that SF and SF/G materials are suitable substrates for 
mineralisation. In vitro apatite formation on a material corresponds directly to apatite 
formation on the same material in vivo, and thus accurately predicts the ability of the 
material to bind to and become integrated with living bone. Materials that do not mineralise 
may instead become encapsulated in fibrous tissue, isolated from bone [165]. These results 
therefore strongly suggest that all the materials examined, SF, SF/G 50:50 and gelatin, are 
suitable for bone tissue engineering applications. The ability of these materials to develop 
an apatite coating could also be utilised by creating a highly osteo-inductive surface before 
seeding with osteo-progenitor cells to encourage differentiation. 
 
 
Figure 4.03: Representative SEM images coupled with energy dispersive X-ray spectra of 




Figure 4.04: Representative SEM images coupled with energy dispersive X-ray spectra of 




Figure 4.05: Representative SEM images coupled with energy dispersive X-ray spectra of 
mineral deposits on MSBF- and dH2O-treated gelatin films. Scale bars represent 20 μm. 
 
4.3.3. Young’s modulus of SF, SF/G & gelatin films 
The Young’s modulus of a material can have a profound effect on the behaviour of the cells 
grown on it [33, 167, 168]. By matching the Young’s modulus of a proposed scaffold to that 
of the target tissue, the cell response can be optimised by encouraging appropriate 
differentiation. It has been observed that stiffer cell culture substrates favour osteogenic 
differentiation of MSCs as the culture environment more closely mimics the bone niche in 
vivo. A Young’s modulus of in the region of 30 kPa has been shown to sufficiently rigid as 
to induce osteogenic differentiation, with increasing rigidities resulting in more advanced 




Figure 4.06: Young’s modulus of SF, SF/G and gelatin films (10 x 20 mm) determined by tensile 
testing. Data shown represents mean + standard error (n=3). 
 
SF/G materials were analysed by tensile testing, wherein films cast from SF, SF/G blends 
and gelatin were clamped between two vices and uniaxial force was applied to stretch the 
films until failure. The results are shown in Figure 4.06. Unexpectedly, SF films gave the 
lowest values of Young’s modulus at 19.8 MPa, suggesting these are the least rigid of the 
materials tested. The value observed for SF is consistent with previously reported values: 
SF films cast from 5% w/v solutions (in formic acid) were found to have Young’s modulus 
values of ~35 MPa [170]. Although no statistical significance was observed, a trend of 
increasing rigidity with increasing proportion of gelatin is apparent.  
The value obtained for gelatin is difficult to compare to literature values, since different 
cross-linking protocols result in different stiffnesses. Cross-linked gelatin films have 
variously been reported as having Young’s moduli of 2.7-4.9 GPa [158], 10-30 MPa [171], 
4 MPa [101] and 20 kPa – 1MPa [172]. The value of 94 MPa measured here is within this 
wide range of values. It is also potentially useful to be able to control the stiffness of gelatin 
across such a wide range by altering the cross-linking protocol.  
The stiffness of human cortical bone is reported as ranging between 10 MPa and 40 GPa 
[167, 173]. The results obtained here put all of the SF/G materials within this range, 
confirming the potential of SF/G blends as scaffolds for osteogenic tissue engineering. 
However, these data relate to SF/G films and not any other form of scaffold, which should 
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be tested independently. It is also important to note that due to practical limitations, the films 
were dry when tested, but for biological applications are likely to be wet. Literature evidence 
suggests that for SF and similar materials, such as spider dragline silk and keratin, 
mechanical properties, such as Young’s modulus, are reduced when wet [174, 175]. It has 
been observed than SF scaffolds have lower compressive moduli when wet compared to 
their dry state, and wet regenerated SF fibres tested by Plaza et al. also showed a 
significance decrease in stiffness and tensile strength from the values measured for their 
dry counterparts [176, 177]. It is therefore likely that the values obtained in Figure 4.06 
would decrease for the same materials in wet conditions. 
 
4.3.4. Seeding fibroblasts on SF- & SF/G-coated tissue culture plastic 
To confirm the biocompatibility of SF materials, 3T3 fibroblasts were seeded onto SF and 
gelatin coated surfaces. 3T3 fibroblasts proliferate more rapidly than harvested rMSCs, and 
can be used to a higher passage number [178, 179]. They are therefore a useful tool for 
preliminary experiments of this sort. In this experiment, the protein solutions of SF, SF/G 
and gelatin were adsorbed onto tissue culture plastic (TCP). Cells were seeded and after 
three days, cell metabolic activity was measured using the MTS assay as a measure of 
relative cell number. The results were confirmed visually. 
The data shown in Figure 4.07 suggests that SF itself does not strongly support the 
adhesion or proliferation of 3T3 fibroblasts, contrary to many reports in the literature. Many 
groups have reported good cell attachment to a variety of reconstituted Bombyx mori SF 
scaffolds, with cells ranging from fibroblasts to bone marrow-derived MSCs [77, 153, 156]. 
This quality has been attributed to the presence of positively charged amino acid residues 
in the SF sequence which interact favourably with the negatively charged surface of 
mammalian cells [75]. One reason for this discrepancy could be the variety in sources of 
silk cocoons, as there are reportedly over 3,000 different strains of Bombyx mori and the 
exact strain used is not frequently known [67]. Indeed, there is evidence to suggest that 
different Bombyx mori strains produce silks with different compositions, affecting both cell 
adhesion and differentiation [66].  
However, it was found that by mixing SF solution with gelatin, cell adhesion was significantly 
increased. This is most likely due to the presence of the RGD tripeptide in gelatin which is 
recognised by cell integrin receptors and implicated in cell attachment [101, 102]. SF and 
gelatin were blended in three different ratios (SF:G 75:25, 50:50, and 25:75) and these were 
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shown to be equivalent to gelatin alone in terms of cell attachment. The blends 
outperformed TCP, suggesting that these materials were a suitable candidate for tissue 
engineering scaffold materials, at least in terms of their biocompatibility and cell adhesion 
properties.  
Figure 4.07: 3T3 fibroblast metabolism assessed 3 days after seeding. Values are expressed 
as a percentage of the signal obtained for the control (untreated TCP). Higher values suggest higher 
cell viability on the substrate in question. Data shown represents mean + standard error (n=4). *** 
p<0.001 w.r.t SF alone. ## p<0.01 w.r.t untreated TCP. 
 
4.3.5. MSC harvest and identification 
MSCs were harvested from rat bone marrow by their selective adhesion to tissue culture 
plastic [180]. After one passage, cells underwent fluorescence-activated cell sorting (FACS) 
analysis to collect a population positive for the MSC markers CD90 and CD54, and negative 
for the leukocyte marker CD45 [137]. Extracting MSCs from bone marrow means there is a 
high risk of haematopoietic cells contaminating the culture, but by excluding CD45-positive 
cells this can be avoided. By selecting cells positive for MSC markers, the identity of the 
cell type is confirmed. In this case, cells were labelled for the intercellular adhesion molecule 
CD54 (or ICAM-1) and the extracellular CD90 (or Thy-1) protein. The population identified 
as dual positive for CD90 and CD54, population ‘Q2’ as shown in Figure 4.08, was collected 
and cultured. In the example shown, the ‘Q2’ dual positive population made up 94.3% of 
the total cell number, showing that simply selecting MSCs by their adhesion to TCP provides 
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an efficient method for collecting these cells. The average dual positive proportion of the 














All events 10,000 n/a 2,281 5,563 811 
Q2 9,426 94.3 2,254 5,835 711 
 
Figure 4.08: rMSCs sorted by the presence of the MSC markers CD54 and CD90.1. Anti-CD54 
was conjugated to FITC; anti-CD90.1 was conjugated to Vioblue. The table shows the number and 
proportion of cells sorted into population Q2 and the relative signals obtained for each fluorescently 
labelled antibody. 
 
The multipotent properties of the collected cells were confirmed through standard tri-lineage 
differentiation assays. Cells were cultured in adipogenic, chondrogenic or osteogenic 
conditions and analysed by staining with Oil Red O for intracellular lipid droplets, Toluidine 
Blue for cartilage and Alizarin Red for mineralisation respectively. The results are shown in 
Figure 4.09 and demonstrate that the putative rMSCs were capable of differentiation down 
adipogenic, chondrogenic and osteogenic pathways. The cells grown under adipogenic 
conditions show the presence of intracellular lipid droplets typical of adipocytes, while cells 
grown under osteogenic conditions have organised themselves into discreet, mineralised 
nodules typical of osteoblasts. The small purple region in the Toluidine Blue-stained image 
indicates the presence of proteoglycans, a major component of cartilage. Although this a 
small proportion of the visible section, this could be a result of the culture conditions: while 
the adipogenic and osteogenic cultures were grown in monolayers, the chondrogenic 
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differentiation assay requires cells are grown in a pellet. The pellet must then be fixed, 
embedded in wax and sliced before staining. It is therefore possible the proteoglycan 
positive region extended in a direction perpendicular to the slice. It is also possible that the 
pellet had not been cultured long enough to fully differentiate or for the cells to deposit 
chondrogenic extracellular matrix. It could be a result of bone marrow-derived MSCs having 
poorer chondrogenic potential compared to MSCs from other sources, such as synovium 
[181]. The results observed are nonetheless sufficient to confirm the identity of the 
harvested cells as MSCs.  
 
 
Figure 4.09: rMSCs differentiated down three distinct pathways. (A) rMSCs that underwent the 
adipogenic differentiation protocol stained with Oil Red O. (B) rMSCs treated with osteogenic media 
stained with Alizarin Red. (C) rMSCs treated according to the chondrogenic differentiation protocol 
stained with Toluidine Blue. Scale bar in (A) represents 100 μm; scale bars in (B) and (C) represent 
200 μm. 
 
4.3.6. Adhesion of rMSCs to films of SF & SF/G materials 
After the preliminary results using fibroblasts were obtained, the adhesion experiment was 
repeated using rMSCs seeded onto SF/G films cast from 2% HFIP solutions (examples of 
which are shown in Figure 4.01). Whereas the initial experiment using adsorbed protein 
was sufficient to test biocompatibility of the materials in question, the films were used to 
examine the behaviour of cells on SF/G materials fully in contact with these materials. The 
results are shown in Figure 4.10, and confirm that rMSCs remain viable when seeded onto 
SF/G material blends. As observed with 3T3 fibroblasts (Figure 4.07), the cells show very 
low metabolism on SF films. This could be due to their initial poor adhesion to the surface, 
resulting in lower numbers of cells in the SF samples. Unexpectedly, the rMSCs also 
showed relatively low metabolism in the wells coated with gelatin. Gelatin is sometimes 
adsorbed onto plasticware to increase cell adhesion and so it would be expected that cells 
would adhere well and show higher metabolism on gelatin films. The low level observed 
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here could be a result of the thin films of gelatin absorbing a large volume of media and thus 
becoming very soft. 
 
 
Figure 4.10: rMSC metabolism assessed 3 days after seeding. Values are expressed as a 
percentage of the signal obtained for the control (untreated TCP). Higher values suggest higher cell 
adhesion to the substrate in question. Data shown represents mean + standard error (n=4). * p<0.05 
w.r.t SF alone. ** p<0.01 w.r.t SF alone. 
 
Swelling of gelatin in physiological conditions is well documented and the level of hydration 
affects its physical properties [182]. The more liquid it absorbs, the softer the structure. 
Cross-linking can decrease swelling by reducing the number of hydrophilic groups in the 
structure (EDC cross-linking consumes amino groups), but cross-linked gelatin is still prone 
to swelling [183, 184]. SF has a more hydrophobic character and thus is less likely to absorb 
liquid from aqueous solutions [185]. This behaviour does not reflect the results obtained 
from tensile testing (Fig. 4.06), wherein gelatin appeared to be the most rigid of the materials 
in question. However, as described previously, that data was collected using non-hydrated 
films. To measure the hydrated stiffness of these materials a different method would be 
required, such as indentation atomic force microscopy.  
In Figure 4.10, the blends of SF/G all show improved cell viability at the day 3 time point 
over SF and gelatin alone. For the SF/G blends, there does appear to be a slight trend of 
improved cell viability with increasing proportion of SF, despite the very low metabolism 
observed for SF alone. This could be the effect of a balance between the availability of RGD 
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residues provided by gelatin and the beneficial effects of SF on the mechanical properties 
of the films themselves. In the absence of RGD, the rMSCs may struggle to adhere to the 
material surface, resulting in the very low values seen for SF. However, blends with high 
proportions of gelatin could suffer from reduced mechanical properties, hindering cell 
proliferation. 
Nonetheless, the results shown here continue to support the use of SF/G blends as scaffold 
materials, as they allow for greater cell adhesion and viability than either SF or gelatin alone 
in this case. Cells grown on SF/G films show a similar level of cell metabolism to those on 
TCP. These results are consistent with literature reports of SF and gelatin blended 
scaffolds, in which the blended materials show improved biological properties over SF alone 
(Table 4.01).  
 
4.3.7. Proliferation of rMSCs on SF, SF/G & gelatin films 
Having established that rMSCs would adhere to and remain viable on SF/G materials, cell 
proliferation was investigated over a 7 day period. Again, rMSCs were seeded onto films of 
SF, SF/G and gelatin, but on this occasion were cultured for 7 days and assayed using 
resazurin at days 1, 4 and 7. The results are shown in Figure 4.11. 
  
Figure 4.11: Proliferation of rMSCs on films of SF/G blends, measured by reduction of 
resazurin. Data is presented as the percentage of signal compared to that of TCP at day 1. Data 
shown represents the mean value (n=3). 
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Mirroring the previous results, the rMSCs showed consistent proliferation over 7 days when 
grown on films composed of SF/G blends at a level almost equivalent to those grown on 
TCP. Predictably, rMSCs grown on SF films did not show an increase in cell number, 
confirming yet again that SF alone is not a good candidate for a scaffold material. However, 
rMSCs on gelatin films also showed a low level of proliferation. Gelatin is known to support 
cell growth and proliferation, and so these results are unexpected, but consistent with the 
results observed in Figure 4.10. Again, a possible explanation is that the gelatin films absorb 
more liquid than SF/G films, and thus become very soft, inhibiting cell proliferation. 
However, it is encouraging that the blended SF/G films all show better properties than SF 
or gelatin alone. There was not a significant difference in performance between the three 
blends of SF/G; they all supported cell proliferation at a level equivalent to the TCP control, 
and greater than SF or gelatin alone. Again, this is likely due to the benefit of combining the 
materials: while gelatin provides cell adhesion sequences, SF prevents excessive hydration 
and softening of the film. 
 
4.3.8. Osteodifferentiation of rMSCs on SF, SF/G & gelatin films 
The ability of the SF/G materials to support osteodifferentiation was investigated by 
culturing rMSCs, seeded on SF/G films, in osteogenic differentiation media (ODM).  
Normally osteogenesis is assessed by staining for mineralisation of cell cultures, for 
example with Alizarin Red or Von Kossa. However, this was not appropriate in these 
experiments due to the high level of background staining that the SF/G films developed in 
the absence of cells. It was therefore necessary to use other methods to analyse 
osteodifferentiation.  
Alkaline phosphatase (ALP) is an enzyme that is present in most cells of the body but is 
particularly elevated in certain cell types, particularly osteoblasts [186]. ALP activity is 
commonly used to show evidence of osteodifferentiation in MSC cultures and it has been 
reported for mouse MSCs that ALP-2 protein is expressed continuously over 28 days of 
osteodifferentiation [187]. In the NBT/BCIP (nitro-blue tetrazolium chloride/5-bromo-4-
chloro-3'-indolyphosphate p-toluidine salt) assay, the action of ALP results in the production 
of an insoluble blue precipitate from the initial pale yellow solution.  
rMSCs seeded onto SF/G films in 96 well plates were cultured for 14, 21 and 28 days in 
either ODM or unsupplemented basal media, and after each of these time points cultures 
were assayed for ALP activity. A set of typical results from one of these assays in shown in 
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Figure 4.12. Although there is evidence of ALP activity in cells grown on SF/G materials, 
those cultured in basal media appear to have produced more of the blue formazan product 
than those cultured in ODM. However, this is not a quantitative assay so reading too much 
into the relative levels of ‘blueness’ is to be avoided. One possible explanation for the results 
observed is that the cells cultured in basal media undergo spontaneous low-level 
differentiation causing the cells to produce ALP. Meanwhile, the cells in ODM are prompted 
to full differentiation by the presence of the osteogenic supplements in the media, and 
differentiate fully, rearranging themselves into dense bone nodules, where ALP activity in 
the well is focussed. This causes small dark blue regions, as observable for SF/G materials 
in ODM, day 28, in Figure 4.12, rather than the widespread blue colouring observed for the 
less fully differentiated rMSCs in basal media. 
 
 
Figure 4.12: rMSCs cultured on SF/G materials for 14, 21 and 28 days stained for alkaline 
phosphatase activity. ALP activity is indicated by the presence of insoluble blue deposits. 
 
An alternative, and preferably quantitative, method of analysis for osteogenesis was sought. 
The In Cell Western Assay was chosen as it would allow for the quantification of osteocalcin, 
with the ability to normalise data by relative cell number. Osteocalcin (sometimes called 
bone gamma-carboxyglutamic acid-containing protein) is a well-defined marker of 
osteogenic maturation, as it is produced solely by osteoblasts [188]. rMSCs were again 
cultured on SF/G films for 14, 21, and 28 days in either basal media or ODM before fixation, 
permeabilisation, and labelling with anti-osteocalcin antibody. The results of these 
experiments are shown in Figures 4.13 and 4.14. The results for cells grown on SF or gelatin 
coatings are not included in the data below, since their poor capacity to support cell 




Figure 4.13: Relative expression of osteocalcin in rMSCs grown on SF/G materials over 28 
days, cultured either in basal media or ODM. The data shown is normalised by relative cell number 
and expressed as a percentage of the signal observed for rMSCs on TCP at day 14 in basal media. 
Data represents mean + standard error (n=3). 
 
The levels of osteocalcin expression would be expected to be highest in cultures grown in 
ODM, and to increase with time, since the cells would have had longer to deposit 
osteocalcin alongside other extracellular matrix proteins.  
The results in Figures 4.12 and 4.13 are consistent to a certain degree. It appears in both 
cases that there is a higher level of differentiation in the rMSCs cultured in basal media, 
rather than ODM, indicated by the ‘bluer’ colour caused by higher ALP activity in Figure 
4.12 and the higher osteocalcin expression in Figure 4.13. This counters the earlier 
suggestion that the increased deposition of the ALP reaction product from rMSCs in basal 
media could be due to widespread, low level differentiation, compared to controlled, specific 
differentiation of rMSCs grown in ODM. If it were the case that the cells in ODM had 
undergone more advanced osteogenic differentiation, it would be expected that the levels 
of osteocalcin, a late differentiation marker, would be much higher in these cultures than 
those in basal media. However, this is not the case. It is worth noting that the differences in 




The osteogenic differentiation of MSCs can typically be divided into three stages. The first 
stage, typically between days 0 and 4, consists primarily of cell expansion and cell numbers 
peak during this time. The second stage, days 5 to 14, involves early cell differentiation and 
is typified by high ALP expression which reaches a peak during this phase, and then begins 
to decline. The final stage, from day 15 onwards, consists of terminal differentiation and 
matrix maturation. The main markers of this stage are osteocalcin, osteopontin and mineral 
deposition [187, 189].  
For rMSCs grown on SF/G 50:50 and 25:75, osteocalcin expression does seem to increase 
slowly over time, but for the cells cultured on TCP and SF/G 75:25, osteocalcin expression 
unexpectedly peaks at day 21. This is mirrored in the observed ALP activity, at least for the 
cells grown in basal media. However, to gain a better understanding of ALP activity within 
these cultures, the experiments should be repeated using a quantitative method of 
detection, such as colorimetric hydrolysis of p-nitrophenyl phosphate to p-nitrophenol or 
reverse transcription PCR. 
Expression of osteocalcin appears fairly low across all materials. Nonetheless, it is 
encouraging that the SF/G 25:75 cultured cells show higher osteocalcin expression than 
TCP particularly at day 28, in both ODM and basal media. This is shown in Figure 4.14, 
which shows only the data from the cells grown in ODM. 
 
Figure 4.14: Relative expression of osteocalcin in rMSCs grown on SF/G blended films in ODM 
for 14, 21 and 28 days. The data is expressed as a percentage of the expression in rMSCs grown 
on TCP in basal media at day 14. Data shown represents mean + standard error (n=3). 
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Since this data appeared to contradict the well-established understanding that ODM should 
increase osteogenic differentiation relative to unsupplemented basal media, a third method 
of analysis was pursued to confirm the osteogenic differentiation of rMSCs on SF/G 
materials.  
A third marker of osteogenesis is osteopontin (or bone sialoprotein I), an osteoblast-
secreted protein with roles in biomineralisation and bone remodelling. Levels of osteopontin 
in culture media were measured using an ELISA and normalised by cell number. Due to 
time and cost constraints, these cultures were analysed at day 14 only. The results are 
shown in Figure 4.15. As discussed, this is a relatively early time point for a mature marker 
of osteodifferentiation and it is possible that higher levels of osteopontin expression would 
have been observed at later time points.  
Figure 4.15: Expression of osteopontin from rMSCs grown on SF/G films for 14 days. The data 
shown represents mean + standard error (n=3). ** represents p<0.001, * represents p<0.05. 
 
Unlike the data obtained for expression of osteocalcin and ALP, the expression of 
osteopontin is significantly higher in cells grown in ODM than in unsupplemented basal 
media. A notable result from the expression of osteopontin is the relatively high expression 
from cells grown on SF surfaces. While SF supports cell attachment very poorly, for those 
cells that do adhere, the surface appears to be strongly osteogenic. This is not the case for 
gelatin, which shows the lowest level of osteopontin expression of all the materials tested. 
This is consistent with previous results in this work, showing poor rMSC adhesion and 
proliferation on gelatin and SF films (Figures 4.10 and 4.11).  
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For the cells grown in ODM, levels of osteopontin expression are equivalent between the 
various SF/G blends and TCP. This is consistent with the expression of osteocalcin 
detected at day 14, in Figure 4.14. There is a slight trend between increased SF proportion 
and increased osteopontin expression in Figure 4.15 but more replicates would be required 
to establish significance in this case. Taken together, the results for rMSCs differentiated 
on SF/G materials suggest that SF/G blends support osteogenesis at a level equivalent to 
TCP, but the effect of media supplements is unclear. 
There is a small selection of papers reporting the successful osteogenic differentiation of 
both human and rat bone marrow derived MSCs on SF and SF-blended scaffolds which 
strongly suggest SF materials are capable of supporting this process. Examples include 
SF/chitosan nanofibres produced by Lai et al., and gelatin-coated SF porous scaffolds from 
Wongputtaraksa et al. (though in this case it is unclear if the cells themselves interact with 
the SF) [89, 190]. In another example, Vorrapakdee et al. used coatings of Thai silk and 
gelatin to modify decellularised bone samples, resulting in higher levels of calcium 
deposition and ALP activity from differentiating rMSCs. This technique could be useful in 
the optimisation of allografts, but was not compared to the effects of Thai SF or gelatin alone 
[191]. Human nasal inferior turbinate tissue derived MSCs encapsulated in SF/G bio-ink 
were also shown to be capable of osteogenic differentiation, as evidenced by increased 
expression of RUNX2, ALP and osteopontin [192]. A number of reports also claim SF alone 
is capable of supporting osteogenesis, though in the case of Meinel et al. the hMSCs 
themselves were entrapped in Matrigel within a silk sponge, so again the contribution of the 
SF itself is questionable [193]. This report, and others, employed BMP-2 to direct 
osteogenesis, an expensive supplement not used in this work [80, 156, 194, 195]. 
The SF-blended examples cited here are generally in 3D structures, rather than 2D films, 
and this could be a crucial factor in the ability of cells to differentiate on these materials. 
While cells grown in 2D environments are frequently used for quantitative assays, it is 
generally accepted that cells in 3D cultures behave much more like their native counterparts 
in physiological tissues [196, 197]. Cell behaviour is dependent on a number of factors, 
such as mechanical and biochemical cues, tissue-specific architecture, and cell-cell 
interactions. These signals are oversimplified in 2D cultures, and this can affect protein 
expression, cell migration and apoptosis [198, 199]. It therefore seems reasonable to 
suggest that the differentiation of MSCs might also be affected. 
The evidence obtained in this chapter suggests that SF/G materials are capable of 
supporting osteogenic differentiation, in particular the blend of SF/G 25:75, and there is 




In this chapter, the properties of SF and SF/G films have been investigated in a 2D format. 
It has been shown they are capable of becoming mineralised, and in the form of thin films, 
have Young’s moduli equivalent to human bone. While SF alone has poor cell adhesion, 
this is greatly improved in SF/G blends (SF:G 75:25, 50:50 and 25:75), which also support 
cell proliferation over 7 days.  
Blends of rMSCs were successfully isolated from the bone marrow of juvenile Wistar rats 
and shown to be capable of multi-lineage differentiation. Osteogenic differentiation was 
shown to take place on SF/G materials, despite the uncertainty surrounding the efficacy of 
basal media compared to ODM.  
The osteogenic differentiation of bone marrow derived rMSCs on blended Bombyx mori SF 
and gelatin scaffolds has not been previously reported. The results obtained using 2D films 
of the SF/G blends show that the combination of SF and gelatin produces scaffolds with 
improved Young’s moduli and improved abilities to support cell adhesion and proliferation, 
over SF or gelatin alone. The next chapter will therefore investigate the translation of these 






 SF/G microparticles as osteogenic building blocks for tissue engineering 
 Introduction 
SF/G scaffolds for tissue engineering 
Blends of SF and gelatin have been shown to have both mechanical and biological 
properties greater than each material alone, as described in Chapter 4. This is reinforced 
by a number of literature reports of the benefits of combining the two (see Table 4.01). In 
short, it has been shown that incorporating even small percentages of gelatin into a SF 
structure significantly improves cell attachment and proliferation [159, 160]. At the same 
time, the recorded tensile strength of SF/G films, and compressive strength of SF/G discs, 
are increased over SF alone [84, 158]. These results are summarised in Table 4.01. SF/G 
blended scaffolds have been shown to support the osteodifferentiation of mesenchymal 
stem cells, though in the case of reports from Vorrapakdee et al. and Wongputtaraksa et 
al., SF was derived from Thai silk, from the Nangnoi srisaket silkworm rather than the more 
common Bombyx mori [190, 191]. While osteogenic differentiation was observed in human 
mesenchymal progenitor cells encapsulated in sonication-cross-linked SF/G scaffolds, 
these scaffolds were not stable in cell culture media [192]. There is no evidence that bone 
marrow derived MSCs have been cultured on three-dimensional SF/G microparticle 
scaffolds for the purpose of osteodifferentiation, though the two-dimensional results from 
Chapter 4 suggest that these blended materials do support osteogenic differentiation. 
 
Microparticles & three-dimensional tissue constructs  
While most SF-based scaffolds have taken the form of freeze-dried, porous discs, this 
approach is limited. This top down approach to scaffold design can be problematic in terms 
of ensuring even cell distribution through the structure, as cells will naturally settle and 
adhere on the outer edges. Initially this is due to the increased accessibility of the outer 
regions, but even where cells do migrate into internal regions, viability can be compromised 
by lack of oxygen and nutrient supply, and build-up of waste products.  
Instead of starting with a relatively large scaffold, an alternative approach is to seed cells 
onto much smaller units of scaffold material. In this way, cells are provided with a large 
surface area for attachment, increasingly the likelihood of even cell distribution. These cell-
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laden scaffold units can then be built up into larger shapes, utilising cell-cell and cell-scaffold 
interactions to bind the structure together. This promise of this bottom up approach has 
been demonstrated by several groups, frequently starting with microparticles as the initial 
scaffold unit and moulding them together to form macroscopic tissue constructs [30, 57]. 
Their small size means that they can also act as injectable cell delivery systems, for 
example into irregularly sized bone defects. Cells alone may rapidly migrate away from the 
injection site, whereas injected cell-laden microparticles entrap cells and provide structural 
support to the tissue. 
Microparticles have been used extensively for the scale-up of adherent cell lines in stirred 
tank bioreactors, including for the culture of embryonic cell stems [200], and are discussed 
more fully in Section 2.2.5. A number of microparticles are commercially available, such as 
Cultispher and Cytodex beads, but information about the exact constituents and cross-
linking protocols are unknown. Though microparticles of a suitable size have been produced 
from SF alone, the only SF/G microparticles in the literature were investigated for controlled 
release applications and were therefore smaller than would be desired for cell culture 
applications [55, 201]. Microparticles for cell culture are typically 100-300 μm in diameter. It 
is therefore desirable to investigate the potential of creating a homogenous population of 
SF/G microparticles approximately 200 μm in diameter, for use in tissue engineering and 
cell delivery applications. 
 
 Aims & Objectives 
Having shown how SF/G materials can support cell growth and differentiation in two-
dimensional culture, the next stage is to move to a three-dimensional system. The 
objectives of this chapter are therefore: 
 To reproducibly create homogenous populations of microparticles from SF/G 
materials. 
 To seed cells onto SF/G microparticles and culture cells in a three-dimensional 
environment. 
 To mould cell-laden microparticles into a macroscopic tissue construct and 
characterise cell viability, cell distribution and construct strength. 




 Results & Discussion 
 
5.3.1. Development of an axisymmetric flow focussing device for particle production 
Different techniques were investigated for the production of microparticles. The first was the 
use of a homogeniser to create an emulsion of an aqueous protein solution in an immiscible 
solvent such corn oil. However, it became apparent that although homogenisation of the 
two solutions rapidly produced a large number of droplets of protein solution that could be 
processed into solid microparticles, control over the system was limited. The faster the 
homogeniser rate, the smaller the microparticles produced, but the homogeniser itself could 
not be finely tuned to a specific rate, and even when set at a fixed speed (e.g. the lowest 
possible), the size distribution of the droplets produced was very large. While Baimark et al. 
reported some success in preparing SF microparticles from water-in-oil emulsions, the size 
distribution of these particles remained large, and the method required hazardous organic 
solvents such as dichloromethane for the production of spherical microparticles [202].  
Ideally, the microparticles produced for cell culture would have a narrow size distribution 
since the diameter of the microparticles affects the curvature of the particle surface. 
Therefore cells cultured on differently sized microparticles are subject to markedly different 
environments. A technique that would allow for a more homogenous output was therefore 
desirable. Microfluidic approaches have been shown to generate microparticles with a much 
narrower size distribution [203]. Systems of this sort consist of two immiscible co-flowing 
streams, and utilise the predictable break-up of these streams to produce homogenous, 
discrete droplets. Using a polymer or protein solution as the disperse phase allows the 
production of microparticles.  
The system used to produce SF microparticles was based on a design by Terray et al., 
though the design was altered to be composed entirely from unmodified off-the-shelf fittings 
allowing easy, rapid and reproducible assembly [204]. This is a clear advantage over 
systems using custom modified pieces such as those described by a number of groups [30, 
55]. The ability to take the device apart for cleaning and to remove any blockages is also a 
benefit of using component parts over single-piece three-dimensional-printed devices such 
as that described by Morimoto et al. [203]. The final design of the flow focussing device, 
and the parts used in assembling it, are described in Section 3.1.8. 
The solvent system used was based on that reported by Breslauer et al., and consisted of 
73% oleic acid, 2% Span 80 and 25% methanol [55]. The Span 80 surfactant acts to 
stabilise the droplets and prevent them coalescing before they solidify. The inclusion of 
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methanol causes the aqueous SF to undergo a conformational change into its insoluble β-
sheet structure [148]. In this way the droplets produced in the axisymmetric flow focussing 
system are collected as microparticles. While higher proportions of methanol cause more 
rapid solidification of SF, this can lead to blockages within the narrow channels of the flow 
focussing device, whereas lower proportions cause the droplets to solidify too slowly, 
resulting in the coalescence of individual droplets. The inclusion of 25% methanol strikes a 
balance between these competing outcomes. This was not affected by the inclusion of 
gelatin in the disperse protein phase, which utilised the temperature-dependent hydrogel 
formation of gelatin in combination with the phase change of SF to produce solid 
microparticles. The SF/G solutions were maintained at above 35 °C, the approximate 
melting point of gelatin, while in the input syringe, and the output was collected into the oleic 
acid/Span 80/methanol solution on ice, causing the gelatin component of the droplets to 
solidify.  
By altering the flow rates (Qouter (flow rate of the continuous phase) and Qinner (flow rate of 
the disperse phase)) in the axisymmetric flow focussing device, the size of the 
microparticles can be controlled [50, 205]. The higher the ratio between the two flow rates, 
the smaller the microparticles. This is illustrated in Figure 5.01. The degree of control shown 
here is much greater than that which could be achieved using the emulsion method. 
Figure 5.01: Mean diameters of SF/G 75:25 microparticles produced under selected flow rate 
ratios. Q
inner 





5.3.2. Topography & size of SF/G microparticles 
 
The size distribution data and mean microparticle diameters are summarised in Table 5.01. 
Images of the microparticles were processed using ImageJ to determine the mean diameter 
of each microparticle blend. An example image is shown in Figure 5.02. The microparticles 
were produced using a flow rate ratio (Qouter/Qinner) of 20, since this value consistently yielded 
microparticles with diameters in the range of 300-350 μm. The size distributions obtained 
compare favourably with those measured for the commercially available gelatin Cultispher-
S microparticles.  
 
Table 5.01: Mean diameters of SF and SF/G particles produced by axisymmetric flow 
focussing (Qouter/Qinner = 20, Qinner = 0.36 mL/hr), from 3 batches each. Data shown represents 
mean ± standard deviation. Values for Cultispher-S are included for comparison.  
Material Diameter (μm) Range (μm) 
SF/G 75:25 339 ± 59 201-490 (98.6%) 
SF/G 50:50 347 ± 44 213-446 (99.8%) 
SF/G 25:75 308 ± 39 218-428 (98.6%) 
Cultispher-S 237 ± 86 108-565 (98.6%) 
 
 
Figure 5.02: Bright field image of SF/G 25:75 microparticles produced by flow focussing. Scale 
bar represents 200 µm. 
 
The microparticles were examined by SEM and representative images are shown in Figure 
5.03. Microparticles produced from SF/G blends all show a distinctive textured topography. 
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From the images it appears as though the particles have a porous structure, although the 
pores are in the region of 2 μm, and thus too small for cells to migrate into or through. The 
topography observed in Figure 5.03 is typical of that observed for all the SF/G particles. It 




Figure 5.03: SEM images of a SF/G 75:25 microparticle produced by axisymmetric flow 
focusing.  
 
5.3.3. Effect of porogens on SF microparticle structure 
To see if larger pores could be created within the microparticles, the starting SF solution 
was blended with porogens. If the pores in the microparticles were sufficiently large, cells 
could be seeded into them, or migrate into them, thus producing a more homogenous cell 
distribution. Without cell-sized pores, cells will simply settle on the exterior of the particles.  
The particles produced with porogens were examined by SEM and the results are shown in 
Figure 5.04. The particles are very similar to the porogen-free samples in Figure 5.03, and 
the structures do not show any pores of the size described above. This could be expected 
from samples produced using sodium chloride or PEG as a porogen, since at the low 
concentrations used here, they simply dissolve into the silk solution. Examples of porous 
SF scaffolds produced using salt leeching typically use much higher concentrations of 
sodium choride, and cast scaffolds into fixed moulds [190, 207]. Since the SF solution must 
pass through the axisymmetric flow focussing device, these supersaturated slurries are not 
suitable for use here, and the lower concentrations investigated do not make a significant 
difference to the microparticle structure.  
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The use of insoluble, fine calcium carbonate particles was investigated on the basis that the 
calcium carbonate would become encapsulated within the SF structure, and then dissolve 
away in an acidic solution to leave pores throughout. However, this was not observed, even 
at the highest concentration tested (20% w/v). This could be due to the calcium carbonate 
granules not being sufficiently large to leave visible pores, though as mentioned earlier, the 
use of large particles runs the risk of blocking the axisymmetric device, and they would also 
settle within the input syringe, leaving an uneven distribution within the SF solution. The use 
of porogens was not pursued further given these results. 
 
Figure 5.04: SEM images of SF microparticles made with porogens. (A) 10 % w/v PEG; (B) 1% 
w/v NaCl; (C) 10% w/v NaCl; (D) 5% w/v CaCO3; (E) 10% w/v CaCO3; (F) 20% w/v CaCO3. 
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5.3.4. Young’s moduli of SF/G materials  
The Young’s moduli of discs made from SF and SF/G blends were determined by 
compression testing, in order to see if they corresponded to the elasticity range favouring 
osteogenic differentiation, and to see the effect of blending the two primary materials. The 
results are shown in Figure 5.05. As observed for the films in Chapter 4, SF actually had 
the lowest Young’s modulus of the materials measured, at 20 kPa. However, unlike the 
SF/G films, the discs cast from SF/G 50:50 and 25:75 had the highest values, at 183 kPa 
and 162 kPa respectively. The values obtained here are similar to those obtained for freeze-
dried porous SF/G scaffolds in the literature (between approximately 60 and 160 kPa for 
SF/G blends). He et al. attribute the higher value of compressive modulus for SF/G 50:50 
scaffolds to a more homogenous pore structure than is obtained for 25:75 or 75:25 [85]. 
Figure 5.05: Young’s modulus of SF/G gel discs determined by compression testing. Data 
shown represents mean + standard error (n=3). ** p<0.01 w.r.t SF; # p<0.05 w.r.t gelatin. 
 
Engler et al. describe a substrate stiffness of 25-40 kPa as sufficiently rigid to induce 
osteogenic differentiation [33]. This value, much lower than the expected Young’s modulus 
of bone itself, corresponds to the stiffness of the osteoid region of bone, which is the matrix 
on which MSCs transition to pre-osteoblasts [167]. Though SF and SF/G 75:25 materials 
sit at the lower end of this range, the blends of SF/G 50:50 and 25:75 should adequately 
support osteogenic differentiation according to these criteria. 
 79 
 
Measurements were recorded using solid, centimetre-sized discs of SF and SF/G blends, 
since it was not logistically possible to analyse the microparticles themselves due to their 
small size. The discs were in a hydrated state during compression testing, unlike the dry 
films analysed for tensile strength in Chapter 4. This may explain why the values observed 
in Figure 5.05 are much lower than those in Figure 4.04 (for example, 20 kPa for wet SF 
discs compared to 19.8 MPa for dry SF films). Since the materials are hydrated during cell 
culture, the values in Figure 5.05 are likely to be more representative of the environment 
cells would experience. 
To measure the Young’s modulus of the microparticles directly, it would be possible to use 
atomic force microscopy (AFM). Indentation of the AFM tip into microparticles has been 
used to measure the elastic properties of SF microparticles, for example by Breslauer et al. 
who recorded an average Young’s modulus of 1.5 kPa [55]. The discrepancy between this 
value and the value determined here could be due to the differences in structure between 
flow focussing-produced microparticles and moulded discs, or due to a variation in SF 
properties or processing steps. The results in Figure 5.05 again confirm the potential for 
SF/G blends as scaffolds for osteogenic tissue engineering, especially in terms of using a 
blend of the two materials rather than one alone. 
 
5.3.5. Microparticle stability in solution 
As a measure of stability, the mass of protein lost from SF/G 75:25 microparticles was 
calculated over 7 days incubation in PBS at 37°C. The results are shown in Figure 5.06. 
Although particles do gradually lose mass over the time period, this is only equal to 2.3% of 
the total mass of microparticles. The microparticles show an acceptable level of stability, 
and when examined visually appeared robust.  
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Figure 5.06: Percentage of mass lost from SF/G 75:25 microparticles in PBS over 7 days. Data 
shown represents mean ± standard error (n=3). R2 = 0.9871. 
 
This is consistent with results for aqueous-derived SF scaffolds obtained by Kim et al., who 
observed that while protease-treated aqueous-derived scaffolds degraded rapidly, 
untreated scaffolds maintained their structures without significant degradation [207]. The 
same group later reported that aqueous-derived SF scaffolds supported higher levels of 
osteogenesis than HFIP-derived equivalents, attributed to their different degradation rates 
[80]. 
 
5.3.6. Seeding 3T3 fibroblasts onto microparticles  
To confirm the SF/G materials retained their ability to support cell attachment in a 
microparticle format, seeding experiments were carried out, initially using 3T3 fibroblasts as 
a model cell line (described in Section 3.1.1). The results, shown in Figure 5.07, mirror those 
observed for SF/G-coated TCP and for thin films of SF/G materials – in short the cells 
adhered poorly to SF microparticles but adhered at a much higher number to SF/G blends. 
As previously discussed, this is likely due to the presence of RGD residues provided by 





Figure 5.07: Seeding efficiency (percentage of 3T3 fibroblasts seeded adhered to 
microparticles) of SF, SF/G and gelatin microparticles. Data shown represents mean + standard 
error (n=5). *** p<0.001 w.r.t SF alone; # p<0.05 w.r.t gelatin. 
 
Cell viability on SF/G microparticles was confirmed by LIVE/DEAD fluorescent staining, 
visualised by confocal microscopy. Figure 5.08 shows representative images, which all 
show a high level of cell viability on all the SF/G blends and on gelatin, included here as a 
positive control. The images are consistent with the data in Figure 5.07, showing that 3T3 





Figure 5.08: Microparticles seeded with 3T3 fibroblasts, stained with LIVE/DEAD to indicate 
viability after 3 days of culture. Viable cells fluoresce green, while non-viable cells fluoresce red. 
Scale bars represent 200 µm. 
 
Cell adhesion onto SF/G microparticles was also investigated by SEM. In Figure 5.09 (A), 
cells can be seen coating the exterior of the microparticles (though they are somewhat 
damaged by the extensive processing steps required), while in Figure 5.09 (B), a monolayer 





Figure 5.09: SEM images of 3T3 cells on SF/G blended microparticles. (A) SF/G 50:50; (B) SF/G 
25:75. 
 
5.3.7. Seeding rMSCs onto microparticles 
Once cell attachment was confirmed using fibroblasts, the experiments were repeated using 
rMSCs. The seeding efficiencies are shown in Figure 5.10. The results are similar to those 
observed for 3T3 fibroblasts in Figure 5.07, in that cells do not adhere well to the SF 
microparticles and seeding efficiency is improved on SF/G blends. While for fibroblasts, the 
SF/G blends appear equivalent, for rMSCs, seeding efficiencies are higher on the 50:50 
and 25:75 blends (i.e. those with a higher gelatin proportion). Anecdotally it is recognised 
that fibroblasts are relatively unselective in their adhesion to culture substrates, whereas 
MSCs can be more selective. This is reflected in the data shown here, where more rMSCs 
adhere to the substrates with a higher proportion of gelatin.  
The viability of the rMSCs on the microparticles was again examined using LIVE/DEAD 
staining. A representative image of rMSCs seeded on SF/G 25:75 microparticles is shown 




Figure 5.10: Seeding efficiency (percentage of rMSCs seeded that have adhered to 
microparticles) of SF, SF/G and gelatin microparticles. Data shown represents mean + standard 
error (n=3). ### p<0.001 w.r.t. SF; *** p<0.001 w.r.t. SF/G 75:25. 
 
 
Figure 5.11: Fluorescent confocal image of rMSCs cells seeded onto SF/G 25:75 
microparticles after 4 days of culture. Cells were stained with LIVE/DEAD to indicate viability. 




The rMSC adhesion to SF microparticles is higher than anticipated, with 62% of cells 
adhering to the microparticles, only marginally lower than the seeding efficiency observed 
for SF/G 75:25. This is in contrast to the results observed for 3T3 fibroblasts, in Figure 5.07, 
where the seeding efficiency of cells on SF microparticles was 25% and significantly lower 
than that of SF/G 75:25. For the remaining materials, SF/G 50:50, SF/G 25:75 and gelatin 
(Cultispher-S microparticles), rMSC seeding efficiencies were over 80%, as for 3T3 
fibroblasts. It is not clear why the level of rMSC attachment to SF microparticles is relatively 
high here, especially since this was not observed in two-dimensional seeding experiments 
(Figure 4.08). One possibility is that rMSCs form large cell aggregates, adhering to each 
other in preference to the SF microparticles. If these aggregates are sufficiently large 
(greater than 70 μm), they would be filtered out of the solution with the microparticles while 
single cells and smaller aggregates are collected and counted. However, since this is a risk 
for all of the microparticle cultures, the presence of the cells on the microparticles was 
confirmed by fluorescent confocal microscopy images and SEM images for both 3T3s and 
rMSCs (Figures 5.08, 5.09 and 5.11). 
 
5.3.8. Osteodifferentiation of rMSCs on SF/G microparticles 
Once rMSCs had been seeded onto SF/G microparticles, the media they were suspended 
in was switched to osteodifferentiation media (ODM). The cultures were assayed for 
markers of osteogenic differentiation: ALP activity and osteopontin expression. Background 
staining of the SF/G materials rendered typical osteogenic assays such as Alizarin Red and 
Von Kossa unusable, as was the case for two-dimensional films described in Chapter 4. 
Given the results obtained for cell adhesion to SF/G blends, as well as the varied Young’s 
modulus values, the decision was made to progress into osteodifferentiation assays with 
the SF/G 25:75 blend only, using Cultispher-S particles as a positive control for comparison. 
While the rMSCs cultured on Cultispher-S microparticles showed much higher ALP activity 
in ODM than basal media, rMSCs cultured on SF/G 25:75 microparticles appeared to have 
equal levels of ALP activity in both ODM and basal media (Figure 5.12). This is consistent 
with results in Chapter 4, in which levels of osteogenic differentiation appeared equivalent 
for rMSCs on SF/G 25:75 cultured in basal media and ODM, particularly when measured 
by osteocalcin expression, and to a lesser extent, ALP activity. Compared to the results 
observed for the Cultispher-S seeded rMSCs, this may suggest that the SF/G blend 




Figure 5.12: ALP activity in rMSCs cultured for 28 days on SF/G 25:75 or Cultispher-S 
microparticles. (A) SF/G 25:75 with basal media; (B) SF/G 25:75 with ODM; (C) Cultispher-S with 
basal media and (D) Cultispher-S with ODM. Scale bars represent 500 μm.  
 
To confirm this result, osteopontin levels in the cultures were assayed. The results are 
shown in Figure 5.13. In contrast to the results for ALP activity in the SF/G cultures observed 
in Figure 5.12, osteopontin expression is much higher in ODM-cultured rMSCs than in the 
basal media, as would normally be expected. For rMSCs cultured on Cultispher-S 
microparticles, the osteopontin expression mirrors the results for ALP activity, whereby 
rMSCs cultured in ODM show stronger evidence of osteodifferentiation than those cultured 
in basal media. The expression of osteopontin in ODM-SF/G 25:75 cultures appears slightly 
higher than for ODM-Cultispher-S cultures, however this difference was not found to be 
significant. The large error bars (standard error) observed for ODM-SF/G 25:75 osteopontin 
expression reflect the variable results obtained here. This could be a result of the fact that 
osteopontin is a late marker of differentiation, and day 14 is a relatively early time point, 
leading to variation in cell responses. However, this large variation was not observed for the 
Cultispher-S seeded rMSCs, nor for the rMSCs in two-dimensional cultures (Figure 4.13). 
Osteopontin expression should be measured at further time points (perhaps day 21 and 28) 
in addition to day 14 to gain a clearer understanding of the rMSC behaviour on SF/G 25:75 
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microparticles. A further factor may be that the cells have not reached a confluent state by 
day 14. The rMSCs were seeded onto the microparticles at a concentration of 3-5 x 104 
cells/cm2. Successfully differentiated rMSCs have been seeded in static cultures at 
densities of 1-4 x 104 cells/cm2 [141, 208], so the cell density on the particles is within the 
normal range and is unlikely to be a contributing factor here.  
 
Figure 5.13: Expression of osteopontin at day 14 in cultures of rMSCs seeded on SF/G 25:75 
and Cultispher-S microparticles. Data is normalised by cell number. Data shown represents mean 
+ standard error (n=5). No significance was observed. 
 
The observed results are consistent with several reports of osteogenic differentiation of 
MSCs on SF/G scaffolds. Das et al. observed increased expression of the bone markers 
RUNX2, ALP and osteopontin in human nasal inferior turbinate MSCs encapsulated in 
sonication-cross-linked SF/G scaffolds, when cultured in ODM for 14 days. These scaffolds 
were not stable in culture media for prolonged periods however, resulting in much lower 
levels of these markers at day 21 [192]. However, it could be that the faster degradation 
rate encourages cells to deposit their own ECM more rapidly, as was observed by Park et 
al. for pure SF scaffolds [80]. The osteoinductive potential of the SF/G microparticles could 
therefore potentially be improved by decreasing the extent of cross-linking to decrease 
stability. Another alternative could be the inclusion of a third material to improve 
differentiation. SF/G/hydroxyapatite scaffolds have been produced by Moisenovich et al. 
though not yet investigated for their ability to support osteodifferentiation [161]. 
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Vorrapakdee et al. observed increased ALP activity and calcium deposition in rMSCs grown 
on decellularised bone scaffolds modified with SF/G, while Wongputtaraksa et al. had 
similar results using SF scaffolds modified with gelatin, though both these reports used Thai 
Nangnoi srisaket silk rather than Bombyx mori [190, 191]. Together, these reports and the 
data collected here suggest SF is an osteoconductive material. 
 
5.3.9. Moulding 3T3-laden SF/G microparticles into a macroscopic tissue construct 
In order to create a macroscopic solid bone construct it was necessary to mould the cell-
laden SF/G microparticles together. To this end, 3T3 fibroblast-laden SF/G microparticles 
or Cultispher-S microparticles were placed inside small cylindrical moulds within 24 well 
plates (see Section 3.1.2). In theory, within the mould, the cells on adjacent microparticles 
should start to make adhesions to each other and other microparticles, thus effectively 
cross-linking the separate microparticles into one densely populated structure. This has 
been observed and utilised elsewhere, and the ability to mould small building blocks into a 
larger tissue construct is a strong motivator for using microparticles as opposed to a larger 
pre-formed scaffold [30].  
It was possible to form a stable structure from SF/G 25:75 microparticles seeded with 3T3 
fibroblasts. Once the mould was removed the structure held its shape, as evidenced by the 
dense arrangement of microparticles shown in Figure 5.14. A similar construct was also 
produced using 3T3 fibroblasts on Cultispher-S microparticles. H&E staining (described in 
Section 3.2.7) showed that the SF/G construct was held together by relatively large cell 
clumps or aggregates (Figure 5.15). The scaffold material was stained a light pink by eosin, 
and from this it is possible to see that the particles have a homogenous, porous structure 
throughout, though the pores themselves are very small, whereas the Cultispher-S particles 
have much larger pores producing an irregular honeycomb-type structure. The cells, nuclei 
stained blue by haematoxylin, appear much more disperse in the Cultispher-S structure, 
possibly due the greater accessible surface area for cells seeded on these particles. It 
appears that the Cultispher-S structure was held together primarily by individual cell-cell or 





Figure 5.14: SF/G 25:75 microparticles seeded with 3T3 fibroblasts and moulded into a 
cylindrical disc, measuring approximately 5 x 2 mm. Right hand images show the dense structure 
of microparticles held together by cell-cell and cell-scaffold adhesions. Scale bars represent 200 μm. 
 
 
Figure 5.15: Fixed slices through constructs formed from 3T3 fibroblasts on (A) SF/G 25:75 
microparticles and (B) Cultispher-S microparticles. Sections were stained with Haematoxylin and 
Eosin. Dark blue nuclei are indicated with arrow heads. Scale bars represent 100 μm. 
 
Unfortunately this process was not robust enough to be repeatable, with 3T3 fibroblasts nor 
rMSCs, and although it worked as a proof of concept, the lack of reliability means the 
production of a macroscopic tissue construct using SF/G microparticles is not practical. It is 
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possible that further refinement could overcome this problem, by optimising parameters 
such as cell seeding density, microparticles per moulding volume and mould design. 
Similar approaches have been successful elsewhere, frequently using commercially 
available microparticles and using a variety of cell types. Twal et al. coated Cultispher-G 
microparticles with human umbilical vein endothelial cells and human aortic smooth muscle 
cells before successfully moulding them into O-shaped rings, which were stacked together 
to produce a tubular construct [56]. Unlike the Cultispher-S structure observed in Figure 
5.15, a large number of cells were seen to be located in the spaces between particles. This 
could be a factor of the different cell types used and their differing proliferative potential. 
Slower growing cells would not fill the spaces between microparticles as rapidly as quicker 
growing lines. The difference observed is not likely to be due to the different microparticles 
used, as Cultispher-G and Cultispher-S particle are both composed of porcine gelatin and 
differ only in their thermal stabilities. 
The construction of centimetre-scale tissue constructs from Cultispher-S and Cytopore-2 
microparticles in perfusion cultures has been described elsewhere [57, 209]. Although 
perfusion cultures prevent central tissue necrosis and prolong construct viability, they can 
also be responsible for ‘washing out’ any de novo ECM proteins, hindering tissue formation 
[42]. 
Matsunaga et al. were also able to mould cell-laden microparticles into a self-supporting 
structure, using 3T3 fibroblasts. However, the use of a very soft form of collagen 
(atelocollagen) resulted in rapid shrinking of the construct due to the contractive forces of 
the cells and degradation by proteolytic enzymes [30]. Preliminary work undertaken in this 
thesis investigated the preparation of collagen I microparticles using the conditions 
described by Matsunaga et al. However, it was not possible to reproduce microparticles of 
the type described, due to the slow, temperature-dependent gelation of collagen. Droplets 
inevitably coalesced before gelation, producing large clumps rather than discrete droplets, 
even when using surfactants. 
This demonstrates that the development of a tissue construct using a bottom up approach 
depends heavily on the choice of materials and cells. In order to create such a structure 
using SF/G microparticles, it may be necessary to encapsulate the microparticles in a 




The work in this chapter describes how microparticles were reproducibly created from SF/G 
75:25, 50:50 and 25:75 blends using a custom flow focussing device. By adapting systems 
described in the literature, an easily-assembled device was created from unmodified 
commercially available parts. This system is simple to assemble and a significant advantage 
of its design is that, because it requires no custom modification of parts, it can be built by 
any group interested in its application for microparticle production (and this is not limited to 
SF/G materials). 
Both 3T3 fibroblasts and rMSCs were successfully seeded onto SF/G microparticles in 
small dynamic cultures, though there is certainly potential for these systems to be scaled 
up: some preliminary work using stirred flasks was carried out, though not pursued. Future 
work should investigate optimisation of stirred flask microparticle cultures. rMSCs were 
shown to remain viable once seeded on SF/G microparticles and evidence of 
osteodifferentiation was observed, by ALP activity and expression of osteopontin, at levels 
equivalent to Cultispher-S cultured rMSCs. 
A centimetre-scale construct was successfully created from SF/G 25:75 microparticles 
seeded with 3T3 fibroblasts, but unfortunately could not be reproduced using either 3T3s 
or rMSCs. However, SF/G microparticles could still be used for cell expansion in scaled-up 
cultures, or for the injectable delivery of MSCs. Using SF/G microparticles for both the 
expansion of MSCs and as the scaffold for their differentiation would minimise processing 







Rapid production of alginate/ECM microparticles for use in tissue 
engineering applicationsIntroduction 
Alginate as a biomaterial 
Alginate, a brown algae-derived polysaccharide, is a useful material for cell culture because 
it is biocompatible, although not cell adhesive, and rapidly forms hydrogels on exposure to 
divalent cations (see Section 2.3.2). The ratio of guluronic to mannuronic acid residues 
within different types of alginate can vary and this, combined with choice of cross-linking 
cation, can affect the properties of the resultant hydrogel [91]. Cells do not adhere to 
alginate alone, but it can be modified or blended with other materials in order to improve 
this.  
Alginate hydrogels have been used for encapsulating cells, either to act as immune barriers 
in cell transplantations, or for storage purposes [90, 210, 211]. They can also be used as 
wound dressings (e.g. Algicell™ and AlgiSite M™), utilising their high fluid uptake ability to 
absorb wound exudates [212]. Although unmodified alginate degrades slowly and 
unpredictably, oxidation of alginate produces a dialdehyde derivative that is susceptible to 
hydrolysis under physiological conditions [213]. Oxidation can also affect the swelling of the 
alginate gel, with higher levels of oxidation producing softer, less stable gels [95]. 
 
Decellularised extracellular matrix (ECM) materials 
Decellularised whole organ scaffolds have been used successfully to produce functional 
tissue engineered organs, but are dependent on finding donor organs of an appropriate 
size, and face similar issues as synthetic scaffolds designed in a top down manner, such 
as even cell distribution upon re-seeding. However, it is possible to produce solubilised 
solutions of decellularised ECM components which can be used to coat cell culture vessels, 
or formed into hydrogels (see Section 2.3.4) [122, 214]. This provides the flexibility to 
produce scaffolds of a variety of sizes and shapes. The advantage of using decellularised 
materials rather than purified protein samples is that within the original tissue, a mixture of 
proteins exists in the right proportions to support cell growth, attachment, proliferation and 
possibly differentiation. Instead of trying to replicate the ECM artificially, decellularised 
tissue samples can provide an appropriate scaffold for re-population with a low risk of 
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immune rejection. A number of scaffolds of this type have received FDA approval for in vivo 
human applications, including Alloderm®, a collagenous matrix derived from cadaveric skin.  
The specific constituents of an ECM product will depend on the starting material, although 
typically they include a large proportion of collagen, along with glycosaminoglycans, laminin, 
fibronectin, elastin, and possibly small amount of growth factors. Adequate removal of 
cellular material is necessary to prevent adverse host reactions to scaffolds produced from 
decellularised materials upon implantation. Insufficient decellularisation may result in 
cytocompatibility issues when cells are reintroduced to the material, or immunogenic 
reactions in vivo. Decellularisation is commonly evaluated by assaying double-stranded 
DNA rather than other cellular components because DNA content of a decellularised 
scaffold directly relates to adverse in vivo reactions [119]. It is also equivalent in all cell 
types. The criteria for decellularisation are described in Section 2.3.4. 
 
Bottom up tissue engineering  
As previously discussed (see Section 2.2.4) the method of starting with small building blocks 
of scaffold and cells to produce a final larger structure is considered a bottom up approach 
to tissue engineering. This has advantages in that it allows for even cell distribution and 
precise control over a hierarchical structure. Encapsulating cells within small scaffold units, 
such as microparticles, provides a suitable starting point for this. The mild conditions 
required for the rapid gelation of alginate make it ideal for cell encapsulation, without 
compromising viability.  
 
  Aims & Objectives 
While SF/G microparticles have been shown to have some potential as osteogenic scaffolds 
for tissue engineering, the inability to mould these particles into a 3D structure prompted 
investigation into alternative materials for microparticle production. This also provided the 
opportunity to look at improving other characteristics of the microparticles such as 
production time, bioactivity and need for post-production cross-linking. Alginate was chosen 
due to its ease of handing and rapid gelation, while ECM proteins were selected for their 
ability to support cell adhesion and function. 
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The aims of the work in this chapter were therefore to investigate a rapid method of particle 
production using alginate based biomaterials, blended with cell-adhesive and bioactive 
extracellular matrix components. 
The objectives were as follows: 
 Investigate methods of rapidly producing a homogenous population of 
microparticles using oxidised alginate as the primary material. 
 Determine the best method for the removal of cellular material from skeletal muscle 
samples to harvest extracellular matrix proteins. 
 Establish whether the decellularised materials are capable of forming collagenous 
hydrogels. 
 Blend extracellular matrix proteins with oxidised alginate to produce a 
biocompatible, cell-adhesive scaffold and establish cell seeding or cell 
encapsulation protocols. 
 Investigate whether these materials can be moulded into a macroscopic construct.  
  
 Results & Discussion 
 
6.3.1. Periodate oxidation of alginate 
Treating alginate with sodium periodate results in the oxidation of the hydroxyl groups on 
carbons 2 and 3 to aldehyde groups, breaking the carbon-carbon bond in the process. 
Alginate itself degrades very slowly and in an uncontrolled manner, producing high 
molecular weight fragments that are not easily cleared in vivo. Partial oxidation of alginate 
creates the more reactive aldehyde groups (Figure 6.01), which results in higher levels of 
alginate hydrolysis while not significantly affecting the gelation properties of the material 
[143, 215].  
It has been reported previously that microparticles produced from 10%-oxidised alginate 
were too fragile to handle, and thus a range of oxidation levels from 2.5% to 10% were 




Figure 6.01: Oxidation of sodium alginate. Sodium periodate cleaves the bond between carbons 
2 and 3, oxidising the hydroxyl groups to produce alginate dialdehyde [143]. 
 
The oxidation level of the alginate was quantified by measuring the amount of sodium 
periodate remaining in the reaction mixture after 24 hours, with the amount consumed 
directly proportional to the oxidation level of the alginate (Section 3.1.5). This was regularly 
found to be more than 98% of the initial amount, thus it was safe to assume that, for 
example, for a 5%-oxidised alginate, the actual level of oxidation was 4.9 – 5.0%. Gomez 
et al. observed than for low levels of oxidation, a high level of periodate consumption is 
typical of the reaction with alginate [143]. 
 
6.3.2. Measured viscosities of alginate solutions 
The oxidised alginate solutions became progressively less viscous with increasing levels of 
oxidation. This was confirmed by dynamic rheology measurements (Table 6.01). The 
decrease in viscosity of oxidised samples is related to the decrease in molecular mass as 
a result of cleavage of the alginate backbone during oxidation [95, 215]. Gomez et al. 
suggest this is the result of a free radical-independent degradation. Another factor is that 
the stiffness of the alginate chains is decreased upon oxidisation, as the cleavage of the 
bond between C2-C3 produces a more flexible chain (Figure 6.01) [143]. 
The initial viscosity of an alginate is a result of the conditions under which it is extracted 
from seaweed. Extraction is achieved by solubilising the alginate so that it can be separated 
from the bulk of the seaweed. By adjusting the temperature and time of the extraction, the 
viscosity of the final product can be altered. Higher temperatures and longer reaction times 
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result in the breakdown of uronic acid chains within the structure, leading to lower viscosities 
[216].  
The relative viscosities of the alginate solutions were of particular interest because of their 
effect on the production of alginate microparticles through the air flow focussing system 
(see Section 6.4.4.). 
 








Low viscosity 1 - 8.62 x 10-3  
Low viscosity  5 - 1.95 x 10-1 
Low viscosity 10 - 1.23 x 100 
Low viscosity 5 5.0 1.15 x 10-2 
Low viscosity 5 7.5 5.00 x 10-2 
Low viscosity 10 5.0 4.99 x 10-2 
Medium viscosity 1 - 9.04 x 10-2  
Medium viscosity 5 - 2.30 x 101 
Medium viscosity 10 - 2.74 x 103 
Medium viscosity 5 5.0 2.30 x 10-2 
Medium viscosity 10 5.0 1.90 x 10-1 
Medium viscosity 5 2.5 4.45 x 10-1 





6.3.3. Production of alginate microparticles using liquid flow focussing 
The rapid gelation of alginate upon exposure to divalent cations proved unhelpful when the 
production of alginate microparticles was attempted using the liquid-liquid flow focussing 
system described in Chapter 3 (Section 3.1.9). Using alginate as the disperse phase and 
calcium chloride as the continuous phase resulted in rapid gelation of the alginate within 
the device, blocking the tubing and creating misshapen and irregular lumps of gel rather 
than defined spherical microparticles. Increasing concentrations of sodium salts were added 
to the calcium chloride continuous phase in an attempt to delay gelation by means of 
sodium/calcium competition but this did not prove successful.  
Instead, to delay the gelation process, an internal gelation method was used. The alginate 
was mixed with fine, insoluble calcium carbonate particles. To ensure even and 
homogenous gelation, the calcium carbonate particles must be small and evenly dispersed. 
To encourage this, ‘nano’-calcium carbonate was produced, as described by Ueno et al. 
[144]. This created a fine suspension that could be fed through the flow focussing device 
as the disperse phase. The continuous phase was replaced with acidified oil, which acted 
as an immiscible solvent but also reacted with the carbonate to release calcium ions, which 
in turn cross-linked the alginate solution: 
2 CH3CO2H + CaCO3  Ca(CH3CO2)2 + CO2 + H2O  (Equation 6.01) 
Although this method was used to successfully produce microparticles (shown in Figure 
6.02), the microparticles produced were opaque, in contrast to alginate gels produced from 
direct contact with a calcium solution which are typically clear and colourless. This is typical 
of this process of internal gelation [217]. The opacity observed is most likely due to 
unreacted calcium carbonate or to the presence of small bubbles within the alginate from 
the released carbon dioxide. Decreasing the concentration of calcium carbonate did not 
improve the transparency significantly. Opacity is not an ideal characteristic of a scaffold, 
as it makes visualising cells much harder. The use of a processing step involving acid also 
means that it would not be possible to encapsulate cells within microparticles of this type 
without compromising cell viability. Alternative methods of particle production were 
therefore investigated. 
However, alginate-calcium carbonate scaffolds have been investigated for the controlled 
release of ibuprofen, as the drug can be adsorbed to calcium carbonate particles, which act 
as reservoirs within the structure. In this case, release of calcium ions is controlled by the 
gradual hydrolysis of D-glucono-δ-lactone, which causes a decrease in pH [217]. It is 
possible that the alginate-calcium carbonate microparticles could be produced in the same 
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way. In which case, the microparticles described above could also be useful as a method 
of controlled drug delivery, especially with the increased surface area provided over a solid 
scaffold of the same volume. 
 
 
Figure 6.02: 7.5%-oxidised LV calcium alginate microparticles (2% w/v) produced using 2% 
w/v CaCO3. Scale bar represents 200 µm. 
 
6.3.4. Production of alginate microparticles using air flow focussing  
Microparticles were produced using the air flow focussing device shown in Figure 3.04. The 
viscosity of the alginate solution was found to be a crucial parameter. The alginate solution 
needed to be very viscous to ensure a homogenous particle population. With low viscosities, 
the microparticles produced tended to have a very wide size distribution and were often 
more tear-shaped than spherical. In preliminary experiments, spherical, consistently-sized 
microparticles were produced using 10% w/v low viscosity (LV) alginate in the air flow 
focussing system. Examples of these microparticles are shown in Figure 6.03. Unlike the 
microparticles formed using calcium carbonate, the alginate-only microparticles were 
translucent, allowing for the visualisation of cells either on or in the microparticles 
themselves. The gentle processing conditions make this a suitable method for the 
encapsulation of cells, unlike the SF/G microparticles described in Chapter 5 which required 
soaking in methanol. 
However, the unpredictable degradation of unmodified alginate makes it less attractive as 
a scaffold material than oxidised alginate, as previously discussed. Therefore, attempts to 
find an oxidised alginate solution with an equivalently high viscosity were undertaken. The 
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oxidised LV alginates all showed very low viscosities and so a very high concentration would 
have been required to attain the necessary viscosity. Low level oxidation of medium 
viscosity (MV) alginate was therefore considered a more practical approach. To generate a 
solution of 2.5%-oxidised MV alginate, the minimum volume of PBS required to dissolve a 
known mass of the solid was determined, producing a solution at 13% w/v. However, the 
viscosity of this solution was measured at 61.7 Pa∙s, much higher than the 10% w/v LV 
alginate at 1.23 Pa∙s (Table 6.01). The decision was therefore taken to use the 2.5%-
oxidised MV alginate at a concentration of 10% w/v for air flow focussing. This improved its 
ease of handling, and also allowed for the blending of the alginate solution with solutions 
containing extracted ECM proteins without excessive decrease in the viscosity. 
 
 
Figure 6.03: Calcium alginate microparticles produced in the air flow focussing system, from 
10% w/v LV alginate. Scale bar represents 500 μm. 
 
The use of a co-axial air flow to create beads or microparticles is well-reported in the 
literature. Though the equipment and precise set-ups vary, the principal is the same 
throughout [48, 93, 218]. The system used in this work is described in Section 3.1.9. The 
air flow acts to disrupt the flow of alginate to produce small droplets, which are cross-linked 
by collection in a calcium chloride or barium chloride bath. Having defined the concentration 
and oxidation level of the alginate solution, the key parameters that affect the output are: 
 The distance between the end of the alginate nozzle/needle and the collection bath. 
 The air flow rate disrupting the alginate solution. 
 The rate of alginate flow [219]. 
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While electrospraying is a similar, alternative method, air flow focussing holds less risk for 
the operator and requires less specialist equipment. Air flow focussing also provides more 
control over microparticle size than the formation of an emulsion, another alternative 
technique, and is also less damaging to cells. 
 
6.3.5. Analysis of decellularisation techniques and products 
While alginate allows for the rapid production of microparticles, its lack of bioactivity means 
cells do not adhere to it and can become quiescent when entrapped inside it [220]. In order 
to provide ECM proteins and bioactive signals to cells, decellularised skeletal muscle was 
produced for combination with alginate. However, as discussed, decellularisation must be 
carefully quantified to prevent immune rejections in vivo. Removal of cellular material from 
porcine skeletal muscle (PSM) was assessed by investigating levels of DNA within the 
treated samples. Although histological stains are not a quantitative method of examining 
decellularisation, they still prove useful. Sections of untreated PSM, SDS-treated PSM and 
Triton X-100/EDTA-treated PSM were stained with H&E and Hoechst 33342. This technique 
was not suitable for the homogenised sample as it was produced in a liquid form. 
Figure 6.04 shows the stained sections. In 6.04(A), the untreated sample, cell nuclei are 
clearly visible around the outside of muscle bundles, and individual muscle fibres can be 
observed within the bundles. In both 6.04(B), the SDS-treated sample, and 6.04(C), Triton 
X-100/EDTA-treated PSM, the tissue has clearly been degraded by the decellularisation 
treatment. However, it is possible to see some intact nuclei within each section. In Figure 
6.05, the sections have been stained with Hoechst to illuminate cell nuclei. There is clearly 
a large number of nuclei in the untreated sample, and there also appear to be a number of 
intact nuclei within the Triton X-100/EDTA-treated PSM. In the SDS-treated PSM sample, 
it is harder to distinguish any clear nuclei, suggesting a higher level of decellularisation in 





Figure 6.04: H&E stained sections of (A) untreated PSM, (B) SDS-treated PSM and (C) Triton 




Figure 6.05: Hoechst-stained sections of (A) untreated PSM, (B) SDS-treated PSM and (C) 
Triton X-100/EDTA treated PSM. Arrow heads indicate fluorescently stained cell nuclei. Scale bars 
represent 100 μm.  
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The DNA content of samples of untreated PSM, SDS-treated PSM, Triton X-100/EDTA-
treated PSM and homogenised/solubilised PSM was quantified as described in Section 
3.2.7. The results are shown in Figure 6.06. As expected, the SDS-treated PSM contains 
significantly less DNA than the untreated sample. The value of 36.5 ng DNA/mg suggests 
a sufficient level of decellularisation according to the criteria described by Crapo et al. [104]. 
However, the Triton X-100/EDTA-treated sample is shown to still contain a high level of 
DNA (131.54 ng/mg), implying this protocol is not efficiently removing cellular material from 
the sample. The homogenised samples contained on average 48.5 ng of DNA per milligram 
of freeze-dried solution, just under the upper limit for successful decellularisation. It is 
possible that optimising the protocol could reduce this further below the threshold of 50 
ng/mg. The levels of DNA in samples of this type were not reported in the original paper by 
Abberton et al. [145].  
 
Figure 6.06: DNA levels in untreated PSM, SDS-treated PSM, Triton X-100/EDTA-treated PSM 
and homogenised/solubilised PSM, as determined by the PicoGreen assay. The dashed line 
indicates 50 ng/mg, the threshold level for successful decellularisation. Data shown represents mean 
+ standard error (n=3). *p< 0.05 with respect to Untreated, ** p<0.01 w.r.t. Untreated; # p<0.05 w.r.t. 
Triton X-100/EDTA. 
 
From the data shown here, it is apparent that the Triton X-100/EDTA procedure does not 
adequately remove cellular material from samples of PSM. The paper reporting this method 
only assessed DNA removal by H&E staining, and did not use a quantitative method of 
analysis [121]. The results obtained here suggest that H&E staining alone is not sufficient 
to confirm the removal of cellular material, since in Figure 6.04, the effectiveness of the 
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Triton X-100/EDTA method and the SDS method seem equivalent. However, the 
quantitative DNA results in Figure 6.06 strongly counter that. The SDS treatment and the 
homogenisation/solubilisation method appear to remove more cellular material than the 
Triton X-100/EDTA, but to confirm this, gel electrophoresis should be used to investigate 
the length of remaining DNA fragments.  
Three methods were investigated here but there are multiple reports of different protocols, 
with different variations and combinations of decellularising agents [105, 221, 222]. The 
variety of results suggests that the efficacy of a particular method also depends on the 
starting tissue. This emphasises the importance of quantifying DNA remaining within a 
decellularised sample, especially for use in vivo where remaining DNA is likely to promote 
an immunogenic reaction [120]. 
One of the objectives of this work was to determine whether the decellularised muscle 
products would form self-supporting gels, as this would influence the amount and 
concentration of alginate necessary as a supporting matrix. The solubilised SDS-treated 
PSM sample did not form a gel, in contrast to instances described in the literature [214, 223, 
224]. Even after neutralisation and 24 hours incubation at 37°C, the solution remained fluid. 
This could be due to the low protein concentration of the sample, which was determined by 
the BCA assay as 2.25 mg/mL. Though collagen alone would be expected to form a weak 
gel at concentrations of this range, it is likely the sample contained a large proportion of 
other proteins less prone to gelation. The inability of the product to gel could also be due to 
the denaturing effect of SDS on proteins, which results in the loss of tertiary structure [225]. 
The use of this product was therefore not pursued. 
The protein content of the homogenised/solubilised PSM solution ranged between 7.0 and 
11.4 mg/mL in different batches. Aliquots of the solution were found to gel at physiological 
conditions, after approximately 1 hour at 37°C, as reported by Abberton et al. [145] (Figure 
6.07). This is likely to be due to a large proportion of collagen within the extract. However, 
the gels produced were soft and fragile, despite observed syneresis. The product was 
therefore deemed more suitable for blending with a stronger scaffold material such as 




Figure 6.07: Homogenised/solubilised product of decellularisation. The product is initially in a 
liquid form. After 1 hour incubation at 37°C, it forms a gel stable to inversion.  
 
The product was analysed by SDS-PAGE, and the results are summarised in Figure 6.08. 
The results are consistent with those obtained by Abberton et al., showing bands that 
correspond to the masses of collagen I, laminin α4 and α1 chains, as well as entactin [145]. 
 
 
Visible bands (kDa) Possible protein 
~35 Degradation products 
~50 Biglycans 
~100 Collagen I 
~140 Entactin 
180-200 Laminin α1 & α4 
 
Figure 6.08: An SDS-PAGE of homogenised/solubilised samples (#1, #2) with a molecular 
weight ladder (MW) for reference. The most prominent bands are summarised with the proteins 
likely to be responsible. 
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To test the cytocompatibility of the product, 3T3 fibroblasts were seeded on multiwell plates 
coated with either the decellularised product or collagen. After three days, cell metabolism 
was assessed with the MTS assay. The results are shown in Figure 6.09. 3T3 fibroblasts 
showed equivalent levels of metabolic activity between untreated TCP and the 
decellularised product and collagen coated surfaces. This strongly suggests that the 
decellularised product is biocompatible and supports cell attachment and growth. 
Figure 6.09: 3T3 fibroblast metabolism assessed 3 days after seeding expressed as a 
percentage of the signal obtained for the control, untreated TCP. Higher values suggest higher 
cell adhesion to the substrate in question. Data shown represents mean + standard error (n=4). No 
significant differences were observed. 
 
6.3.6. Production of alginate/ECM protein microparticles 
The homogenised/solubilised PSM protein solution was blended 1:1 with 2.5%-oxidised MV 
alginate and fed into the air flow focussing system to produce the microparticles shown in 
Figure 6.10. These microparticles showed some size variation but were generally 
consistently sized with a mean diameter of 321 ± 82 μm (mean ± standard deviation). 
However, the microparticles had a mottled appearance, suggesting that the 
homogenised/solubilised proteins might have precipitated out of solution and were not 
consistently mixed with the alginate solution. These microparticles look very similar to 
examples of alginate microparticles encapsulating decellularised ECM powders, produced 
by Mazzitelli et al., who showed the inclusion of the ECM powders in the (un-oxidised) 
alginate microparticles resulted in improved encapsulated Sertoli cell viability compared to 
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cells encapsulated in alginate alone [115]. The fact the ECM extract was in powdered form 
rather than solubilised did not seem to have any effect, although it is still the case that the 
ECM constituents are not evenly distributed which could lead to uneven cell distribution and 
viabilities within the microparticles. 
 
 
Figure 6.10: Microparticles produced from 2.5%-oxidised calcium alginate and 
homogenised/solubilised PSM solution. The final oxidised alginate concentration was 5% w/v; the 
final protein concentration was 0.35% w/v. Scale bar represents 500 μm.  
 
6.3.7. Cell encapsulation within alginate-blended microparticles 
As previously discussed, alginate alone does not interact with cells to support adhesion or 
proliferation and simply acts as an inert scaffold. An aim of the work in this chapter was to 
combine alginate with decellularised ECM extracts, but as shown above, the 
homogenised/solubilised ECM solution appeared to precipitate in the oxidised alginate 
particles. In order to provide cells with a homogenous environment, with protein evenly 
distributed throughout, commercially available collagen was adopted as a model protein. 
As collagen is the major structural protein in mammalian tissues, it is also likely to be the 
major constituent of any ECM extract. 2.5%-oxidised MV alginate (10% w/v) was therefore 
blended in a 1:1 ratio with a commercially available collagen solution, producing the 
microparticles shown in Figure 6.11. Blending oxidised alginate with lysine residue-
containing proteins such as gelatin or collagen can lead to the cross-linking of the two 
components by formation of a Schiff base, between the amine group provided by the protein 




Figure 6.11: Microparticles produced from 2.5%-oxidised calcium alginate (final 
concentration 5% w/v) and collagen (final concentration 0.15 % w/v). Scale bar represents 500 
μm. 
 
To establish the feasibility of encapsulating cells within oxidised alginate/ECM 
microparticles, rMSCs were re-suspended in collagen solution and then blended with 
oxidised alginate. The resultant solution was used to produce microparticles, shown in 
Figure 6.12. The translucent nature of the microparticles makes it possible to see the cells 
without the need for fluorescent staining. This is a strong advantage over commercially 
available microparticles like Cultispher-S. Unlike the microparticles blended with the 
decellularised ECM extract, the oxidised alginate/collagen microparticles show no evidence 
of precipitated proteins. 
 
Figure 6.12: rMSCs encapsulated in oxidised calcium alginate/collagen microparticles. Scale 
bar represents 200 μm. 
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However, in calcium chloride solution these oxidised alginate/collagen microparticles had a 
mean diameter of 329 μm, but expanded upon transfer into DMEM, swelling to an average 
of 529 μm, a 60% increase. This swelling is possibly due to exchanges between the calcium 
ions in the alginate with other cations in the cell media, such as sodium. This weakens the 
structure of the cross-linked alginate and allows swelling to occur. Oxidised alginates are 
also recognised to be more highly hydrated than their unmodified components, possibly 
contributing to this effect [95]. 
To improve the stability of alginate-based microparticles in cell culture media, the use of 
barium chloride as a divalent cation source was investigated. It has been reported that the 
use of Ba2+ to cross-link alginate gels can increase the resultant stability, as barium ions 
have a higher affinity for alginate than calcium ions [91]. However, barium can act as an 
inhibitor of potassium ion channels above 10 mM and so should be used at low 
concentrations to avoid this toxicity [227]. Though the benefit of using Ba2+ in place of Ca2+ 
can depend on the ratio of guluronic acid to mannuronic acid within the alginate (not defined 
for the alginate used), an increase in stability was observed for barium alginate 
microparticles in DMEM, suggesting the alginate used here had a high proportion of 
guluronic acid residues. The mean diameter of the barium alginate/collagen microparticles 
increased upon the transfer of the microparticles into DMEM but this was limited to a 13% 
increase.  
Cardiomyocyte cells have been encapsulated within barium alginate/collagen 
microparticles, cross-linked by an initial exposure to 50 mM barium chloride with no 
detrimental effects on cell viability [228]. However, to stay well below toxicity limits, in this 
work a solution of 10 mM barium chloride was used.  
Maintenance of cell viability in the oxidised alginate/collagen microparticles was assessed 
by fluorescent staining (Section 3.2.2). The results are shown in Figure 6.13. At both days 
3 and 7 post-encapsulation, the rMSCs remain predominately viable. A higher proportion of 
rMSCs appear viable at day 7, which could be a result of the individual particles measured, 
though representative samples were chosen. It is more likely that by day 7, viable cells have 
proliferated, resulting in a higher proportion of viable cells. Measuring total cell number at 
these time points would help establish whether this was the case.  
High cell viability is consistent with reports suggesting alginate and alginate/protein blends 
can adequately support cell growth and proliferation. Bai et al. cultured cardiomyocytes in 
electrosprayed alginate/collagen microparticles for periods of up to 180 days, and observed 
high cell viability, along with the development of a contractile phenotype [228]. It has also 
been shown that oxidised alginate/gelatin scaffolds can help maintain the function of 
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hepatocytes, avoiding de-differentiation while supporting proliferation for a period of four 
weeks [92]. Wright et al. also observed that the inclusion of collagen IV in oxidised alginate 
gels increased the viability of encapsulated limbal epithelial cells, while Sang et al. found 
that the use of alginate/collagen gels resulted in increased proliferation over collagen gels 
alone [95, 229]. Generally, the inclusion of gelatin, collagen or other ECM proteins in 
alginate gels improves cell adhesion, viability and proliferation [115, 230]. 
A number of groups also used alginate to improve the mechanical properties of collagen 
gels, either increasing the Young’s modulus of the combined alginate/collagen gels, making 
the gels more resistant to plastic deformation, or using alginate to allow more rapid gelation 
and control over the final gel shape [226, 231, 232]. 
 
Figure 6.13: Confocal images of encapsulated rMSCs in oxidised alginate/collagen 
microparticles. Microparticles are shown at 3 days (A and B) and 7 days (C and D). Cells are stained 
with LIVE/DEAD to indicate viability. Viable cells fluoresce green, while non-viable cells fluoresce 
red. Graphs represent the proportion of viable to non-viable cells at each time point (n=1). Scale bars 
represent 100 μm. 
 
6.3.8. Osteodifferentiation of encapsulated cells 
Osteodifferentiation of rMSCs encapsulated within oxidised alginate/collagen microparticles 
was assessed to determine whether this scaffold type was suitable for bone tissue 
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engineering. Differentiation was assessed by ALP activity and osteopontin expression 
(Section 3.2.3). ALP activity is indicated by the purple deposits within the microparticles as 
shown in Figure 6.14. There does not appear to be a large difference in ALP activity 
between rMSCs cultured in either basal media or ODM. However from these results it would 
appear the oxidised alginate/collagen microparticles do support osteodifferentiation. 
 
Figure 6.14: rMSCs encapsulated in alginate/collagen microparticles. Cells were cultured for 14 
days in A) basal media; or B) ODM. The samples were assayed for ALP activity, indicated by purple 
deposits within the microparticles. Scale bars represent 500 μm. 
 
The levels of secreted osteopontin were assessed to confirm these results (Section 3.2.3) 
and can be seen in Figure 6.15. Very small quantities of osteopontin were expressed by 
both rMSCs in ODM and basal media. The low values observed (compared to expression 
from rMSCs culture on SF/G 25:75 microparticles, Figure 5.15), could be due to expressed 
protein remaining encapsulated within the alginate/collagen microparticles rather than freely 
diluted in the culture media.  
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Figure 6.15: Expression of osteopontin at day 14 in cultures of rMSCs encapsulated in 
oxidised alginate/collagen microparticles. Data was normalised by cell number. Data shown 
represents mean + standard error (n=3). No significance was observed. 
 
Future experiments should investigate dissolving the oxidised alginate/collagen 
microparticles, for example by use of a chelation agent such as EDTA, before assaying the 
sample for protein expression. It would also be desirable to assay samples for other 
osteogenic bone markers, such as calcium deposition or osteocalcin expression, and 
examining the cultures at later time points, up to 28 days. 
The ability of oxidised alginate/collagen materials to support osteodifferentiation has not 
been widely reported, though cardiogenesis and chondrogenesis on these blends have 
been separately reported [228, 233, 234]. However, the results here suggest oxidised 
alginate/collagen materials can adequately support osteogenic differentiation, though 
further analysis and investigation is required. 
 
 Conclusions 
Having established that the method for microparticle production described in Chapter 5, 
axisymmetric flow focussing, was not suitable for alginate, oxidised alginate and alginate-
blended materials, an alternative system was developed. An air flow focussing system was 
constructed to rapidly produce oxidised alginate microparticles. This system was found to 
be highly dependent on the viscosity of the alginate solution used. As with the axisymmetric 
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flow focussing device, the air flow focussing device was constructed using unmodified 
commercially available fittings, and so can be reproduced by any interested party.  
Collecting alginate droplets directly into a gelling bath of calcium or barium chloride allowed 
for rapid gelation of the resulting beads. It was observed that the use of barium chloride 
provided improved stability of the gels in culture medium over calcium chloride for the 
alginate used here. 
The decellularisation of skeletal muscle samples was investigated as a method of producing 
an alternative scaffold material, and although a number of methods were considered, only 
one (homogenisation and solubilisation of skeletal muscle) proved suitable for the 
production of a gel-forming material. However, the softness of the resultant gel meant it was 
impractical for use alone, but may yet prove useful as a supplement to blended scaffolds. 
The gel product of the homogenisation/solubilisation process described was composed of 
a high proportion of collagen, and thus, oxidised alginate/collagen blended gels were 
investigated for their ability to support the proliferation and differentiation of encapsulated 
cells. The use of an oxidised alginate/collagen blend for osteogenic differentiation of MSCs 
has not been previously described. It was shown that the oxidised alginate/collagen 
materials supported cell viability and the osteogenic differentiation of rMSCs. Future work 
should look into the potential benefits of using decellularised ECM proteins compared to 
collagen alone, and whether cell-laden oxidised alginate/collagen or alginate/decellularised 
ECM microparticles can be seeded externally with cells to allow moulding into a 




Chapter 7  
Design of a hollow fibre perfused bioreactor for the development of pseudo-
vascularised tissue constructs 
  Introduction 
Bioreactors for tissue engineering 
Bioreactors are used to support cell growth and proliferation in three-dimensional cultures, 
by providing oxygen, nutrients, and appropriate stimuli to cell-seeded scaffolds. The use of 
microparticles, or even porous sponge-like scaffolds, provides much higher surface areas 
in smaller volumes than the equivalent two-dimensional culture systems, therefore making 
the expansion of cells in these systems much more efficient.  
For the culture of tissue constructs, there are a number of bioreactor types that can be used, 
of varying levels of complexity. The properties of some of these are summarised in Table 
7.01. For a fuller description of various bioreactor types, refer to Section 2.4. 
 
Table 7.01: Advantages and disadvantages of selected bioreactor design types for the culture 
of cell/scaffold tissue constructs. 
Bioreactor type Advantages Disadvantages 
Stirred tank/spinner 
flask 
Simple to assemble and use; 
shear stress may positively 
affect osteogenesis of MSCs 
[127]. 
Construct size limited, as 
shear stresses increase with 
the increased stir rate required 
for larger constructs [125]. 
Perfusion chamber 
Can be used to seed cells 
through scaffold initially 
[129]; shear stress may 
increase osteogenesis of 
MSCs. 
Media flow may wash out 
newly formed ECM; sample 
must fit chamber exactly to 
ensure media flows through 
and not around the construct 
[42]. 
Hollow fibre bioreactor 
Very large surface area 
available; cells can be 
seeded on or in fibres; cells 
on fibre exterior are 
decoupled from shear stress 
[132]. 
Not generally integrated with 
scaffolds; cell harvest can be 
difficult to achieve efficiently 
[235]. 
Rotating wall bioreactor 
Low shear stress and low 
turbulence environment 
[125]. 
Oxygen delivery to cell 
aggregates and constructs is 
by diffusion only, limiting scale 
up [125].  
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Tissue constructs and the importance of vascularisation 
Tissue constructs have been built, from cell-laden microparticles in a bottom up approach, 
using perfusion chamber bioreactors [57, 58]. Perfusion chambers prevent necrosis by 
providing media flow through the scaffold, but may wash out de novo ECM components 
[42]. The use of a hollow fibre to perfuse the culture, isolating shear stress from oxygen and 
nutrient delivery, could prevent this whilst maintaining viability.  
Construct viability can be improved and maintained for longer periods of time using the 
bioreactors discussed, by preventing necrosis of central regions and therefore allowing 
larger construct sizes to be grown. However, on implantation in vivo, unless nutrient flow is 
maintained the construct may become necrotic as angiogenesis and vasculogenesis may 
not occur rapidly. If a construct is designed with an in-built pseudo-vasculature system, this 
would allow for anastomosis upon implantation and therefore rapid integration with the host 
vasculature. 
While some groups have taken the somewhat laborious approach of building microchannels 
by the piece-by-piece assembly of individual hollow rings, others have utilised more elegant 
approaches [236-238]. Miller et al. printed 3D grids from carbohydrate glass (i.e. sugars), 
then moulded cell-laden gels around the structure which began to dissolve on exposure to 
cell culture media, leaving behind a hollow, interconnected network through which media 
was perfused [239]. A similar approach has been used to create collagen scaffolds with 
capillary-like networks, by moulding collagen around gelatin hydrogel rods – the gelatin 
dissolves as the collagen solidifies at 37 °C [240]. A simpler approach is to mould scaffolds 
around biodegradable hollow fibres, which reduces the processing steps as the fibres do 
not need to be removed. They could also be seeded internally and externally with 
endothelial and smooth muscle cells, respectively, before encasing in a scaffold structure, 
in order to replicate the vascular phenotype. Highly permeable, biodegradable PLA hollow 
fibres have been designed with this application in mind [241]. 
 
 Aims & Objectives 
Previous chapters have shown that microparticles can be produced from both silk 
fibroin/gelatin (SF/G) and alginate/extracellular matrix protein blends. The SF/G 
microparticles were shown to support cell adhesion on their exterior, and evidence of the 
osteodifferentiation of rMSCs was observed. Meanwhile, the gentle conditions necessary 
for the production of alginate/ECM microparticles allowed for the encapsulation of cells 
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within the microparticles, also supporting osteodifferentiation of rMSCs. The original aim of 
using microparticles as a scaffold type was the ability to rapidly mould them together to 
produce a relatively large tissue construct (as in Figure 2.02). Preliminary results suggested 
that the SF/G microparticles had some potential for building up structures in this way. 
However, as previously discussed (Section 2.2.4), larger constructs are hindered by lack of 
vasculature and central areas will become necrotic if cells are further than 200 μm from a 
source of oxygen [242].  
The aim of the work in this chapter is therefore to create a bioreactor system to allow the 
generation of a macroscopic construct from cell-laden microparticles with a pseudo-
vascular structure. The objectives were defined as follows: 
 Design a hollow fibre bioreactor system for moulding cell-laden microparticles into a 
three-dimensional construct. 
 Examine whether the use of the hollow fibre system can improve construct viability 
over a non-perfused control. 
 Create and characterise a centimetre-scale bone tissue construct using rMSC-laden 
microparticles moulded within the bioreactor. 
 
  Results & Discussion  
 
7.3.1. Design of a hollow fibre/microparticle bioreactor 
To investigate whether cell-laden microparticles could be moulded around a perfused 
hollow fibre, a prototype bioreactor was developed. It was designed so that a permeable 
hollow fibre would pass through a chamber or mould containing the microparticles, and thus 
support cell growth and proliferation (and therefore the formation of a cell linked construct). 





Figure 7.01: Schematic of bioreactor set up for cell culture experiments. The dashed box shows 
the alternative fittings to allow sampling from within the chamber. Arrows indicate the direction of 
media flow. A photograph of the set-up is shown on the right. 
 
Since these experiments were preliminary investigations, it was deemed practical to design 
the hollow fibre bioreactor on a small scale. Protein extraction spin columns were chosen 
for the outer body of the hollow fibre chamber due to their size (approximate volume of 1 
mL) and convenient design – open at both ends with a Luer lock fitting cap. This allowed 
for a hollow fibre to be threaded through the column easily, and the whole chamber can 
easily be connected onwards using a Luer-barb connector.  
To ensure consistency in the permeability of the fibre, commercially available KrosFlo® 
Implant Membranes were used. These are PVDF hollow fibres, designed for the 
implantation of cells within animal models. The fibres can be sterilised by autoclaving, and 
resist cell adhesion. This would prevent cells coating the fibre and creating a monolayer 
which would hinder diffusion to the rest of the chamber. The molecular weight cut off of the 
tubing is 500 kDa, high enough to readily allow the diffusion of BSA (approximately 70 kDa), 
a major component of foetal bovine serum (FBS) in cell culture media. However, this cut off 
is low enough to isolate mycoplasma, viruses and bacteria, protecting cells from any 
potential contaminants in the media (though aseptic cell culture techniques should prevent 
this occurring in the first place). 
The fibres were threaded through the spin columns and fixed at both ends to ensure that 
media flow into the hollow fibre chamber was only through the hollow fibre wall. Flow 
 118 
 
through the fibre was against the direction of gravity so that the fibre was entirely full of 
media with no bubbles (which would minimise the contact of the media with the wall and 
therefore minimise the potential surface area for media diffusion). 
The chamber was connected to platinum-cured silicone tubing at each end to allow for gas 
exchange between the media and the atmosphere. Silicone tubing is low protein binding, 
and platinum curing reduces the amount of chemicals that can be leeched from it [128]. 
However, it has relatively low mechanical durability, so PharMed® BPT peristaltic tubing 
was connected in line, via the pump and the cell culture media reservoir, to create a closed 
circuit around the hollow fibre bioreactor chamber. The PharMed tubing was chosen for its 
ability to withstand the stress of the peristaltic pump over a week. The use of a peristaltic 
pump allowed for the continuous circulation of media through the system. 
Due to the size of the equipment, the hollow fibre system could not be assembled within the 
atmosphere-controlled incubators available for use. The cells grown for culture in the hollow 
fibre bioreactor were therefore adapted to grow in carbon dioxide-independent media. This 
media uses a buffering system of mono- and dibasic sodium phosphate and glycerol 2-
phosphate (instead of sodium bicarbonate), so that carbon dioxide is not required for 
buffering and cells can be grown under atmospheric conditions. 
Each bioreactor chamber with hollow fibre was discarded after a single use, as the 
component parts were relatively cheap and easily replaced. This also removed the need to 
thoroughly clean and sterilise the chambers between uses, minimising the risks of cross-
culture contamination. The small size of the bioreactor chamber meant that the inclusion of 
inline monitoring for pH and dissolved oxygen was not practical, although further refinement 
of the design should look to include a mechanism for this.  
At this stage, scale-up of the system was not a priority for design, but it would be 
theoretically possible to run a number of the bioreactor chambers in parallel. Alternatively, 
the chamber itself could be expanded, and with the inclusion of additional fibres, larger 
constructs could potentially be formed. 
 
7.3.2. Diffusion of protein through the hollow fibre bioreactor 
The purpose of moulding microparticles around a hollow fibre was to improve delivery of 
nutrients and oxygen to central regions of the final construct, with the aim of improving cell 
viability. To test whether cell culture components, including large molecules such as serum 
proteins, would diffuse across the hollow fibre wall into the cell chamber, preliminary 
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experiments were carried out using BSA. As mentioned above, BSA is a major component 
of FBS (accounting for over 60% of the protein content) [243]. A solution of BSA was 
pumped through the bioreactor and samples were taken from within the chamber at hourly 
time points during the day (Section 3.1.3). The results are shown in Figure 7.02.  
 
 
Figure 7.02: Diffusion of BSA through hollow fibre into bioreactor chamber.  Data shown 
represents mean values (n=2). 
 
Initially, BSA diffused into the chamber rapidly, though this rate slowly plateaued. The 
highest measurement was obtained at 48 hours, thought at 97.1 μg/mL, this is only 24% of 
the concentration within the fibre. The slowing rate of diffusion could be a result of the build-
up of protein on the inside of the fibre and through the pores. This process, of the reversible 
accumulation of solutes at a membrane, is known as concentration polarisation, and over 
longer periods of time can lead to irreversible adsorption and fouling of the membrane [244]. 
This would significantly decrease diffusion through the hollow fibre membrane, and in this 
scenario, deprive cells of their nutrient supply. It is possible this effect could be minimised 




7.3.3. Cell viability with the hollow fibre bioreactor 
3T3 fibroblasts were seeded onto Cultispher-S microparticles before transferral into the 
hollow fibre chamber, or a sealed Eppendorf of approximately the same size, which 
functioned as a control system. After 7 days of culture, the cell viability within the samples 
was assessed using fluorescent LIVE/DEAD staining and a metabolic activity assay. The 
results are shown in Figures 7.03 and 7.04. It is immediately apparent that the 3T3 
fibroblasts grown around the hollow fibre have maintained a higher level of viability. In 
Figure 7.03, 72.4% of visible cells cultured in the hollow fibre bioreactor are viable, 
compared to only 34.3% of cells grown in the control system.  
 
Figure 7.03: 3T3 fibroblasts on Cultispher-S microparticles, stained fluorescently for viability 
after 7 days of culture. Cells were cultured in (A, B) the hollow fibre bioreactor or (C, D) the non-
perfused control system (n=1). Live cells fluoresce green while red cells are dead. Scale bars 
represents 200 μm. The graphs show proportions of visible cells in representative images. 
 
This is reflected also in Figure 7.04, in which 3T3 fibroblast metabolism is shown to be much 
higher than in the hollow fibre bioreactor than in the non-perfused control. This is likely due 
to the reduced number of viable cells in the control system, but nonetheless strongly 
suggests the hollow fibre bioreactor is a useful and functional system for maintaining the 





Figure 7.04: Relative metabolic activity of Cultispher-S seeded 3T3 fibroblasts in the hollow 
fibre bioreactor and non-perfused control system. Metabolism was measure by reduction of 
resazurin after 7 days of culture. Data shown represents one individual experiment. 
 
The results using 3T3 fibroblasts were confirmed using the cells of interest here, rMSCs. 
The proportion of viable cells is shown in Figure 7.05. Again the population from the hollow 
fibre bioreactor shows a higher proportion of viable cells than the control system, at 78.8% 
and 63.1% viabilities respectively. This difference is less pronounced than that which was 
observed in Figure 7.03 for 3T3 fibroblasts (1.25 times more viable cells in the hollow fibre 
bioreactor than in the control using rMSCs, compared to 2.11 times using 3T3 fibroblasts). 
3T3 fibroblasts are faster growing cells, and as such have higher energy requirements and 
oxygen consumption rates. While the specific oxygen consumption rate of 3T3 fibroblasts 
has been reported to be in the region 0.22 picomoles O2/cell/hour, MSCs have shown much 
lower rates of 8.1 femtomoles O2/cell/hour [245, 246]. It is therefore likely that the 3T3 
fibroblasts were more affected by the lack of oxygen and nutrients in the control system 
than the rMSCs. rMSCs also exhibited very slow growth in two-dimensional culture in the 
carbon dioxide-independent media required for growth in the bioreactor, further 
emphasising this effect.  
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Figure 7.05: Proportion of viable rMSCs in the hollow fibre bioreactor and non-perfused 
control system after 7 days. Viability was determined by fluorescent staining and quantified. Data 
shown represents one individual experiment. 
   
7.3.4. Cell expansion within the bioreactor 
Equal numbers of cells were seeded within the hollow fibre and non-perfused control 
systems. After 7 days of culture within the systems, the cultures were extracted, washed, 
and analysed for DNA content to establish cell number. For both 3T3 fibroblasts (Figure 
7.06) and rMSCs (Figure 7.07), higher cell numbers were obtained from the hollow fibre 
bioreactor, strongly suggesting again that this system supports cell proliferation compared 
to the control system. As discussed in the previous section, the difference is more 
pronounced in the 3T3 fibroblast cultures, likely due to their more rapid growth. The overall 
number of cells is also higher in the 3T3 fibroblast cultures, possibly also a reflection of the 
higher growth rate in these cells. It could be a reflection of the difference in initial cell 
adhesion to the microparticles (though this was shown in Chapter 5 to be 93% for 3T3 




Figure 7.06: Number of 3T3 fibroblasts harvested from the hollow fibre bioreactor and non-
perfused control system after 7 days. Cell number was determined by Hoechst staining of cell 
lysate. The initial cell number was 1.88 x 105 cells. Data shown represents one individual experiment. 
 
 
Figure 7.07: Number of rMSCs harvested from the hollow fibre bioreactor and non-perfused 
control system after 7 days. Cell number was determined by Hoechst staining of cell lysate. The 





7.3.5. Formation of tissue construct within the bioreactor 
Literature reports of cell-Cultispher-S constructs suggest that culturing the microparticles 
within a small mould, with microparticles in close proximity to each other, is sufficient to 
induce the formation of a stable structure by means of cell-bridging [56, 57]. This was not 
observed in this thesis despite the promising preliminary results described in Chapter 5. No 
stable construct was formed using the hollow fibre bioreactor, though on occasion loose 
structures were formed, as shown in Figure 7.08. These were not stable to manipulation, 
and disintegrated upon contact with buffer solution. This is in contrast to literature reports 
of constructs formed by cell-cell bridging, which were stable to manipulation and handling 
[56, 57]. However, in both of these reports, cells were cultured on microparticles for up to 
28 days before moulding, allowing a high cell density to develop. Comparing results, it 
seems likely that the cell densities achieved in this work were not high enough to support 
the formation of a stable cell-bridged structure and future work should look to address this. 
 
 
Figure 7.08: rMSC-laden Cultispher-S microparticles loosely adhered together immediately 
following removal from the hollow fibre bioreactor. The microparticles are resting on the filter frit 
and surrounding the hollow fibre. Scale bar represents 10 mm. 
 
Unfortunately the lack of structure of the product meant that information about cell viability 
within different regions of the hollow fibre bioreactor could not be obtained. Future work 
could investigate the possibility of fixing the particles into a structure through use of a 
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hydrogel such as collagen, or fibrin glue, though this would change diffusion through the 
structure itself. MSCs have been encapsulated within Matrigel® in hollow fibre bioreactors 
with some success, and the incorporation of microparticles could reinforce the structure to 
produce a stronger construct [247]. 
It would be expected that areas close to the fibre, and on the top of the microparticle layer, 
would contain more viable cells, due to their close or direct contact with media. However, 
the proliferation of cells close to a nutrient or oxygen source can itself create a barrier to 
diffusion [241]. Information about cell distribution within the chamber would therefore prove 
useful to understand whether this is occurring in this system. Scaling up the size of the 
chamber to theoretically produce larger constructs could be coupled with the introduction of 
more fibres, and so to see patterns of cell distribution within a more complex system would 
also be valuable. 
 
7.3.6. Evidence of osteodifferentiation within the bioreactor  
To examine whether the rMSCs cultured within the bioreactor underwent osteogenic 
differentiation, expression of osteopontin in the media was measured from within the cell 
chamber, rather than from the media reservoir. The results are shown in Figure 7.09. The 
expression of osteopontin appears to be slightly higher in the non-perfused control system 
than in the hollow fibre bioreactor, though no statistical tests can be performed until the 
experiment is repeated. The slight difference in expression could be due to the fact that only 
media from the inner chamber of the hollow fibre bioreactor was assayed. Potentially, 
osteopontin may have diffused out of the chamber through the hollow fibre and into the 
media reservoir, and was thus not measured in this experiment. Repeats of this experiment 
should assay the bulk media in addition to the sample from the hollow fibre chamber sample 
to rectify this. 
The non-perfused control would be expected to have a much lower oxygen concentration 
than the hollow fibre bioreactor, though this was not measured directly. Hypoxia has been 
reported to increase the osteogenic differentiation of rMSCs and human periodontal 
ligament stem cells, and this effect could be responsible for the unexpectedly high level of 
osteopontin expression in the control system [248, 249]. The oxygen concentrations in 
these experiments were reported as 5% and 2% respectively. Defining this as a hypoxic 
environment may be inaccurate however, as the percentage of oxygen within the MSC bone 
marrow niche has been estimated at between 2 and 9%. Oxygen levels in this range may 
be better described as providing physiological normoxia [250].  
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However, where the oxygen concentration is set at less than 1%, in what is a truly hypoxic 
environment, the osteogenic potential of human MSCs is decreased [251, 252]. The ability 
to measure the oxygen concentration within the bioreactor chamber would therefore be 
highly desirable for bone tissue engineering applications, though use of a probe sensor at 
this small scale would be impractical. Small LED sensors, colorimetric methods such as the 
indigo carmine reaction, or titration using the Winkler method, could prove useful for 
measuring the dissolved oxygen concentration in the media at defined time points. 
 
Figure 7.09: Osteopontin expression from rMSCs cultured in either the hollow fibre bioreactor 
or control system for 7 days. Data shown represents one individual experiment. 
 
The osteopontin expression levels for both samples are much higher than those observed 
for rMSCs in previous experiments, for example in Figure 5.15, where osteopontin 
expression (by rMSCs on SF/G or Cultispher-S microparticles) is in the range of 0.02 pg/cell, 
compared to 1.0 pg/cell here, shown in Figure 7.09. This higher value could be due to the 
fact that the media in the hollow fibre chamber and the control system was not changed 
directly, causing osteopontin to accumulate over the 7 days of culture, whereas in the SF/G 
microparticle experiments, media was changed completely 4 days before assaying.  
Despite the fact the media used was not supplemented with osteogenic additives, the 
carbon dioxide-independent media already contained one of the ODM supplements, 
glycerol 2-phosphate, as part of its buffering system. Though the concentration in the media 
is unknown, it is possible this could have had an osteogenic effect on the rMSCs. Further 
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experiments should investigate other markers of differentiation such as expression of bone 
sialoprotein, alkaline phosphatase, osteocalcin and deposition of calcium over a range of 
time points to confirm these preliminary results. The effect of using supplemented ODM 
instead of basal media should also be investigated, as this would be expected to increase 
the rate of osteogenic differentiation.  
Osteocytes in vivo exist in fluid cavities, where loading of the joints and bones causes 
increases in pressure as well as shear flow over the cells. There is some evidence that 
mimicking this hydrostatic pressure by compression can increase osteogenic differentiation 
[125, 253, 254]. Future refinement of the bioreactor described here should consider the 
application of mechanical loading as a means to better replicate the native bone cell niche 
and improve cellular outcomes, such as proliferation and matrix deposition. 
 
 Future work 
As a proof of principle design, the bioreactor described here worked to show that cell viability 
within a dense arrangement of microparticles was increased by the inclusion of a central 
hollow fibre. This was observed for both 3T3 fibroblasts and rMSCs. However, neither cell 
type promoted the formation of a stable tissue construct. The design of the system could be 
altered to promote this, for example by surrounding the cell-laden microparticles in a 
hydrogel (for example, gelatin or alginate) to fix the structure together. In terms of the 
bioreactor itself, a number of adjustments to the design could be made to enhance its 
function.  
As a first step, it would be desirable to situate the bioreactor system in an atmosphere-
controlled incubator. This would allow cells to be grown in their preferred media, which 
should positively impact on viability and proliferation. In order to measure the cell behaviour 
within the reactor during culture, it would be useful to have an accessible port to the main 
bioreactor chamber to allow for media sampling. Media samples could be analysed for 
glucose and lactate concentration as a proxy for cell number. As previously discussed, it 
would be very useful to measure oxygen concentrations within the bioreactor chamber, and 
so future designs of the bioreactor should include either inline oxygen sensors on the input 
and output tubing of the reactor, or a small probe within the chamber itself. Though the 
current bioreactor design used only off-the-shelf parts and fittings, the design would benefit 
from a custom chamber part in order to facilitate the changes suggested here. Optimising 
the design to allow for the easy removal of the chamber contents would also be beneficial, 
especially for the removal of a solid construct. 
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As hydrostatic pressure has been shown to positively influence osteogenic differentiation, 
a mechanism to provide this stimuli could be considered for the bioreactor. One possibility 
would be mimicking a syringe, using a plunger as the top of the reactor that could be slightly 
compressed to create small pressure increases. The frequency and size of these stimuli 
would need careful consideration. Co-cultures of different cell types could also be 
investigated to improve the physiological relevance of the resultant product. The use of 
microparticles would allow for the spatial arrangement of different cell types, for example in 
defined layers. 
Further characterisation of the bioreactor and fibre, such as permeation rate of media 
through the fibre or a mass balance of the system, would be valuable to determine how 
efficiently cells are fed by the system and allow for optimisation of flow rates. 
 
 Conclusions 
In this chapter, a bioreactor system was designed for the culture of cell-laden microparticles, 
utilising a hollow fibre to act as pseudo-vasculature while protecting cells from the shear 
stress of media flow. The bioreactor was shown to successfully maintain increased cell 
viability and function over a 7 day period, compared to a control system without a perfused 
fibre. Future work should include the culture of cells within the bioreactor for longer periods 
of time, as well as further refinement of the design as discussed above. While the initial 
experiments described here used Cultispher-S microparticles, results obtained in Chapter 
5 suggested that osteodifferentiation of rMSCs could be improved by the use of SF/G 
microparticles, and so their use within the bioreactor should be investigated. Equally, the 
use of alginate/ECM-encapsulated cells may provide a more homogenous cell distribution 
valuable in creating a bone tissue construct.  
Though microparticles were cultured within the bioreactor successfully, evidence of the 
formation of a stable construct was lacking, and so this aim was not achieved. However, 
the system could be used with alternative scaffold types, or gels moulded within the 
chamber, to investigate whether they would be more successful. It is possible that 
optimisation of cell seeding and culture time before moulding could positively influence this 
outcome. The simple design of the bioreactor is such that it would allow for a variety of 
scaffold types to be cultured within the perfused chamber, in the form of microparticles or 





Conclusions & future work 
 Conclusions 
The use of SF and SF/G blends as biomaterials was studied by assessing biocompatibility 
and cell response to two-dimensional films. It became apparent that while cell adhesion to 
SF films alone was generally poor, blending with gelatin significantly improved cell 
adhesion, and also increased the Young’s moduli of the dry films. The poor cell adhesion 
to SF-only films was in contrast to many literature reports, though the source of silk could 
be an important factor here and should be taken into account in future work. MSCs were 
successfully extracted from rat bone marrow and shown to be capable of osteogenic, 
adipogenic and (sparingly) chondrogenic differentiation. SF/G films supported the 
osteogenic differentiation of these rMSCs, and were shown to be capable of undergoing 
mineralisation under physiological conditions, confirming the suitability of SF/G blended 
materials as osteogenic scaffolds for tissue engineering.  
SF/G materials were translated from two to three dimensions by the production of porous 
microparticles. A flow focussing device was used to produce these microparticles, utilising 
two co-flowing immiscible streams to generate consistently sized microparticles. The device 
described here did not require the customisation of any parts or fittings and therefore it 
should be easily assembled by any research group interested in producing microparticles, 
without requiring custom modifications. This is a clear advantage over many such devices 
described in the literature which are built from custom pieces or 3D-printed in-house. 
Though the solvent system was optimised here for use with SF and SF/G blends, it could 
equally be adapted for use with different polymers and solvents. 
The cell behaviour on SF/G microparticles mimicked the behaviour previously observed on 
two-dimensional films. Cell adhesion increased with the addition of gelatin. Unlike the films, 
however, the blending of SF and gelatin increased the Young’s modulus of hydrated discs 
to values greater than either SF or gelatin alone. Osteogenic differentiation of rMSCs was 
supported on SF/G 25:75 microparticles, evidenced by expression of active ALP and 
osteopontin. The moulding of cell-laden microparticles into a centimetre-scale structure was 
observed, though not repeated.  
The use of oxidised alginate as a supporting matrix for less mechanically stable ECM 
extracts was investigated in Chapter 6. While the liquid-liquid flow focussing device 
described in Chapter 5 was adapted to work with alginate solutions, a more rapid production 
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method was developed using an air flow to disrupt the stream of alginate, propelling droplets 
directly into a gelling bath. This system provided a more rapid, simpler means of producing 
alginate microparticles, and should be translatable for any solution that can be rapidly cross-
linked in this way. 
ECM proteins were extracted from skeletal muscle samples using three alternative 
methods. Homogenising and solubilising the skeletal muscle produced a gel-forming 
solution with sufficiently low DNA levels to confirm decellularisation. SDS treatment also 
adequately removed cellular material from the samples but the products did not form 
hydrogels, likely due to protein denaturation by the detergent itself. The use of SDS in 
decellularisation methods should be minimised to avoid damaging the ECM proteins. The 
third method investigated, using Triton X-100/EDTA did not adequately remove cellular 
components from the samples. Oxidised alginate and the gel-forming ECM extract were 
mixed and processed into microparticles but the protein component appeared to precipitate 
rather than blending uniformly through the microparticles. Oxidised alginate/collagen 
microparticles were therefore produced as a model of alginate/ECM blends and were shown 
to support encapsulated cell viability and osteogenic differentiation. 
Finally, in Chapter 7, a prototype bioreactor was designed to culture microparticles around 
a media-perfused hollow fibre in order to maintain cell viability in a centimetre scale 
construct. Cell viability in the hollow fibre bioreactor was much improved over the non-
perfused control. More cells were harvested from the hollow fibre bioreactors than from the 
control systems, but no stable construct was formed in the bioreactor chamber. However, 
these preliminary results demonstrate the potential of hollow fibre bioreactors to support the 
maintenance and growth of microparticle-seeded cells. 
 
 Future work 
The initial aims of this work were to investigate the use of silk fibroin, alginate, and ECM 
derived proteins as scaffold materials - in particular, for the production of microparticles. 
The motivation for this was the potential to mould cell-laden microparticles into a larger 
construct, around hollow fibres, to create a viable, macroscopic bone tissue construct. While 
microparticles were successfully produced, moulding the particles together was not 
achieved and thus a solid tissue construct was not generated in this work. However, the cell 
behaviour on the materials was promising and thus optimising cell densities or using an 
alternative cell type might allow for the formation of a cell-bridged construct.  
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8.2.1. Short-term targets  
In the short term, it would be valuable to look at optimising cell seeding densities and mould 
design in order to achieve the formation of a cell-bridged construct, as described in the 
literature. As discussed in Chapter 7, the application of hydrostatic pressure may be useful 
to increase the osteogenic differentiation of rMSCs within the bioreactor, and this may also 
have the effect of encouraging cell-cell and cell-scaffold adhesions by pushing cell-laden 
microparticles into closer contact within the bioreactor chamber. Alternatively, it might be 
the case that the scaffolds created here are more appropriate for non-osteogenic 
applications and this should be considered. The length of time the cells are cultured on 
microparticles may also be a crucial factor in promoting aggregation, as the production of 
new ECM by the cells would allow for ECM-cell adhesions across neighbouring particles. 
Time-dependent aggregation should be investigated, as should the production of new ECM 
by rMSCs (for example type 1 collagen and fibronectin). 
If moulding the microparticles together through cell bridging is not achievable, it may be 
valuable to investigate using hydrogels to act as a glue to fix particles together. Hydrogels 
which rapidly solidify, such as gelatin or alginate, could be added to a mould after the 
microparticles to create a solid structure. This would still allow for the formation of layered, 
or hierarchical structures, though diffusion of media through the structure would be 
impeded. 
While rMSCs have been a useful model, in order to produce a clinically relevant model, 
efforts should be made to make the switch to using human cells. Human MSCs have been 
isolated from bone marrow, umbilical cord blood and adipose tissue. Umbilical cord blood 
can be obtained without harm to the mother or new-born, and MSCs harvested from it have 
been shown to possess a high proliferative capacity, though some groups have found that 
MSCs cannot be isolated from cord blood reliably [14, 255]. Adipose tissue, usually 
collected in non-invasive liposuction procedures, is an attractive alternative source of MSCs 
as it provides an abundant source of multipotent MSCs. Where liposuction is performed 
cosmetically, the aspirate would usually be discarded and thus harvest of MSCs from this 
material would make effective use of this waste material. 
Once a source of human MSCs had been determined, osteogenic differentiation of the 
human MSCs on three-dimensional SF/G materials should be fully confirmed, by ALP 
activity, expression of osteopontin, osteocalcin, or bone sialoprotein. These could be 
quantified through the use of ELISAs, Western blotting or PCR. Since the common stains 
for mineralisation were found to stain the SF/G scaffolds under control conditions, 
mineralisation could be examined by EDX. 
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In reference to the work investigating the use of alginate/ECM microparticles, the results 
obtained using alginate/collagen materials should be compared to alginate blended with the 
ECM extracted from skeletal muscle. This ECM extract should first be subjected to gel 
electrophoresis to confirm that any remaining DNA fragments are less than 200 base pairs 
in length, to fulfil the final condition of the decellularisation criteria. As discussed, human 
lipoaspirate material is a waste product but in addition to the extraction of MSCs, the ECM 
itself has been used to produce scaffolds for tissue engineering [105, 113]. This approach 
could be investigated as it provides a potentially autologous source of ECM proteins as well 
as making full use of the lipoaspirate. 
Following encapsulation of MSCs within the alginate/ECM microparticles, external seeding 
of cells should be investigated. Use of an endothelial cell line, such as HUVECs, on the 
exterior of the particles could allow for the formation of connected vascular structures 
between adjacent microparticles once moulded or fixed together. This could begin the 
process of creating a vascularised structure, especially when used in conjunction with a 
perfused flow bioreactor.  
 
8.2.2. Medium to long term targets 
In the medium to long term, the bioreactor designed in Chapter 7 should be optimised for 
the long term culture of tissue constructs. This may include a method of inducing hydrostatic 
pressure to optimise osteogenic differentiation, as well as the inclusion of in-line oxygen 
sensors to ensure cells are maintained in a physiological normoxic environment. Adjustment 
of the design to allow easier removal of the final construct would also be beneficial. The 
bioreactor could be expanded in size, with the inclusion of additional hollow fibres, to 
produce larger constructs. Flow rates should be more carefully optimised to ensure oxygen 
delivery throughout the entire chamber. 
The resultant constructs, whether formed from cell-bridged microparticles or hydrogel-
encapsulated microparticles, should be characterised by cell distribution, cell viability, 
differentiation characteristics and mechanical properties. To investigate whether the 
inclusion of a hollow fibre in the structure hastens anastomosis, preliminary in vivo studies 
could study the integration of constructs with host vasculature.  
Alternatively, the un-moulded microparticles could be utilised as an injectable therapy for 
filling irregularly shaped bone defects. The culture of cell-laden microparticles should be 
scaled up to more efficiently produce larger cultures. This could be achieved through the 
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use of spinner flasks, or even bench top stirred tank bioreactors, though alternative systems 
such as the rotating wall vessel bioreactor should also be considered. 
Although the primary focus of the work in this thesis has been the differentiation of MSCs 
down an osteogenic pathway, it may also be worth considering other cell lineages. For 
example, the proposed alginate/adipose ECM scaffolds may prove more useful for soft 
tissue engineering, with applications as cosmetic fillers or in volumetric tissue loss. 
There is also potential for the scaffolds to act as drug delivery reservoirs. By incorporating 
drugs, growth factors, or therapeutic proteins in the scaffold, gradual release over time could 
be achieved. Depending on the choice of drug or protein, this could provide an antibacterial 
effect to prevent infections, a chemotactic effect to recruit particular cells, or a proliferative 
effect to encourage cell growth. The ability to precisely control the location and 3D 
relationship between different microparticles, laden with different biomolecules or cell types, 
would be very useful, and the use of such microparticles in a 3D printing approach could 
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